Document And Entity Information
Document And Entity Information - shares | 6 Months Ended | |
Jun. 30, 2023 | Aug. 01, 2023 | |
Document Information [Line Items] | ||
Entity Central Index Key | 0001487428 | |
Entity Registrant Name | Horizon Technology Finance Corp | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Document Fiscal Period Focus | Q2 | |
Document Fiscal Year Focus | 2023 | |
Document Type | 10-Q | |
Document Quarterly Report | true | |
Document Period End Date | Jun. 30, 2023 | |
Document Transition Report | false | |
Entity File Number | 814-00802 | |
Entity Incorporation, State or Country Code | DE | |
Entity Tax Identification Number | 27-2114934 | |
Entity Address, Address Line One | 312 Farmington Avenue | |
Entity Address, City or Town | Farmington | |
Entity Address, State or Province | CT | |
Entity Address, Postal Zip Code | 06032 | |
City Area Code | 860 | |
Local Phone Number | 676‑8654 | |
Entity Current Reporting Status | Yes | |
Entity Interactive Data Current | Yes | |
Entity Filer Category | Non-accelerated Filer | |
Entity Small Business | false | |
Entity Emerging Growth Company | false | |
Entity Shell Company | false | |
Entity Common Stock, Shares Outstanding | 32,103,683 | |
The 6.25% Notes due 2027 [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 6.25% Notes due 2027 | |
Trading Symbol | HTFC | |
Security Exchange Name | NYSE | |
The 4.875% Notes due 2026 [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | 4.875% Notes due 2026 | |
Trading Symbol | HTFB | |
Security Exchange Name | NYSE | |
Common Stock [Member] | ||
Document Information [Line Items] | ||
Title of 12(b) Security | Common Stock, par value $0.001 per share | |
Trading Symbol | HRZN | |
Security Exchange Name | NASDAQ |
Consolidated Statements of Asse
Consolidated Statements of Assets and Liabilities (Current Period Unaudited) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Assets | ||
Investments at fair value | $ 715,391 | $ 720,026 |
Cash | 24,395 | 20,612 |
Investments in money market funds | 25,865 | 7,066 |
Restricted investments in money market funds | 2,904 | 2,788 |
Interest receivable | 14,893 | 13,573 |
Other assets | 3,960 | 2,761 |
Total assets | 787,408 | 766,826 |
Liabilities | ||
Borrowings (Note 7) | 418,016 | 434,078 |
Distributions payable | 10,592 | 9,159 |
Base management fee payable (Note 3) | 1,063 | 1,065 |
Incentive fee payable (Note 3) | 118 | 1,392 |
Other accrued expenses | 2,200 | 2,684 |
Total liabilities | 431,989 | 448,378 |
Commitments and contingencies (Notes 3 and 8) | ||
Net assets | ||
Preferred stock, par value $0.001 per share, 1,000,000 shares authorized, zero shares issued and outstanding as of June 30, 2023 and December 31, 2022 | 0 | 0 |
Common stock, par value $0.001 per share, 100,000,000 shares authorized, 32,263,724 and 27,920,838 shares issued and 32,096,259 and 27,753,373 shares outstanding as of June 30, 2023 and December 31, 2022, respectively | 34 | 29 |
Paid-in capital in excess of par | 437,561 | 385,921 |
Distributable loss | (82,176) | (67,502) |
Total net assets | 355,419 | 318,448 |
Total liabilities and net assets | $ 787,408 | $ 766,826 |
Net asset value per common share (in dollars per share) | $ 11.07 | $ 11.47 |
Investment, Unaffiliated Issuer [Member] | ||
Assets | ||
Investments at fair value | $ 714,485 | $ 720,026 |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
Assets | ||
Investments at fair value | $ 906 | $ 0 |
Consolidated Statements of As_2
Consolidated Statements of Assets and Liabilities (Current Period Unaudited) (Parentheticals) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Investments at cost | $ 723,633 | $ 721,248 |
Preferred stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 1,000,000 | 1,000,000 |
Preferred stock, shares issued (in shares) | 0 | 0 |
Preferred stock, shares oustanding (in shares) | 0 | 0 |
Common stock, par value (in dollars per share) | $ 0.001 | $ 0.001 |
Common stock, shares authorized (in shares) | 100,000,000 | 100,000,000 |
Common stock, shares issued (in shares) | 32,263,724 | 27,920,838 |
Common stock, shares outstanding (in shares) | 32,096,259 | 27,753,373 |
Investment, Unaffiliated Issuer [Member] | ||
Investments at cost | $ 723,633 | $ 721,248 |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
Investments at cost | $ 0 | $ 0 |
Consolidated Statements of Oper
Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Investment income | ||||
Total investment income | $ 28,117 | $ 18,588 | $ 56,154 | $ 32,792 |
Expenses | ||||
Interest expense | 7,179 | 4,225 | 14,299 | 7,649 |
Base management fee (Note 3) | 3,207 | 2,523 | 6,408 | 4,767 |
Performance based incentive fee (Note 3) | 118 | 2,145 | 3,094 | 3,570 |
Administrative fee (Note 3) | 368 | 374 | 808 | 735 |
Professional fees | 447 | 271 | 1,106 | 848 |
General and administrative | 546 | 362 | 992 | 706 |
Total expenses | 11,865 | 9,900 | 26,707 | 18,275 |
Net investment income before excise tax | 16,252 | 8,688 | 29,447 | 14,517 |
Provision for excise tax | 179 | 106 | 363 | 206 |
Net investment income | 16,073 | 8,582 | 29,084 | 14,311 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Net unrealized appreciation (depreciation) on investments | 608 | (36) | (6,929) | (2,273) |
Net realized and unrealized loss | (15,921) | (965) | (23,626) | (3,172) |
Net increase in net assets resulting from operations | $ 152 | $ 7,617 | $ 5,458 | $ 11,139 |
Net investment income per common share (in dollars per share) | $ 0.54 | $ 0.35 | $ 1 | $ 0.62 |
Net increase in net assets resulting from operations per common share (in dollars per share) | 0.01 | 0.31 | 0.19 | 0.48 |
Distributions declared per share (in dollars per share) | $ 0.33 | $ 0.30 | $ 0.66 | $ 0.60 |
Weighted average shares outstanding (in shares) | 29,747,290 | 24,301,762 | 28,987,948 | 23,109,584 |
Investment, Unaffiliated Issuer [Member] | ||||
Investment income | ||||
Interest income on non-affiliate investments | $ 26,624 | $ 17,720 | $ 54,023 | $ 31,573 |
Fee income on non-affiliate investments | 1,493 | 868 | 2,131 | 1,219 |
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | (16,529) | 271 | (16,697) | 301 |
Net unrealized appreciation (depreciation) on investments | 548 | (1,436) | (7,835) | (3,723) |
Investment, Affiliated Issuer, Controlled [Member] | ||||
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | 0 | (1,200) | 0 | (1,200) |
Net unrealized appreciation (depreciation) on investments | 0 | 1,400 | 0 | 1,450 |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||||
Net realized and unrealized loss | ||||
Net realized gain (loss) on investments | 0 | 0 | ||
Net unrealized appreciation (depreciation) on investments | $ 60 | $ 0 | $ 906 | $ 0 |
Consolidated Statements of Chan
Consolidated Statements of Changes in Net Assets (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Common Stock Outstanding [Member] | ||||
Balance (in shares) | 28,377,357 | 23,977,137 | 27,753,373 | 21,217,460 |
Issuance of common stock, net of offering costs (in shares) | 3,698,175 | 868,230 | 4,304,023 | 3,618,401 |
Issuance of common stock under dividend reinvestment plan (in shares) | 20,727 | 11,737 | 38,863 | 21,243 |
Balance (in shares) | 32,096,259 | 24,857,104 | 32,096,259 | 24,857,104 |
Common Stock [Member] | ||||
Balance | $ 30 | $ 25 | $ 29 | $ 22 |
Issuance of common stock, net of offering costs | 4 | 1 | 5 | 4 |
Net investment income, net of excise tax | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Net unrealized appreciation (depreciation) on investments | 0 | 0 | 0 | 0 |
Issuance of common stock under dividend reinvestment plan | 0 | 0 | 0 | 0 |
Distributions declared | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Balance | 34 | 26 | 34 | 26 |
Additional Paid-in Capital [Member] | ||||
Balance | 393,312 | 339,688 | 385,921 | 301,359 |
Issuance of common stock, net of offering costs | 43,998 | 10,340 | 51,171 | 48,524 |
Net investment income, net of excise tax | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Net unrealized appreciation (depreciation) on investments | 0 | 0 | 0 | 0 |
Issuance of common stock under dividend reinvestment plan | 251 | 145 | 469 | 290 |
Distributions declared | 0 | 0 | 0 | 0 |
Net realized gain (loss) on investments | 0 | 0 | 0 | 0 |
Balance | 437,561 | 350,173 | 437,561 | 350,173 |
Retained Earnings [Member] | ||||
Balance | (71,659) | (59,724) | (67,502) | (56,046) |
Issuance of common stock, net of offering costs | 0 | 0 | 0 | 0 |
Net investment income, net of excise tax | 16,073 | 8,582 | 29,084 | 14,311 |
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Net unrealized appreciation (depreciation) on investments | 608 | (36) | (6,929) | (2,273) |
Issuance of common stock under dividend reinvestment plan | 0 | 0 | 0 | 0 |
Distributions declared | (10,669) | (7,487) | (20,132) | (14,687) |
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Balance | (82,176) | (59,594) | (82,176) | (59,594) |
Balance | 321,683 | 279,989 | 318,448 | 245,335 |
Issuance of common stock, net of offering costs | 44,002 | 10,341 | 51,176 | 48,528 |
Net investment income, net of excise tax | 16,073 | 8,582 | 29,084 | 14,311 |
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Net unrealized appreciation (depreciation) on investments | 608 | (36) | (6,929) | (2,273) |
Issuance of common stock under dividend reinvestment plan | 251 | 145 | 469 | 290 |
Distributions declared | (10,669) | (7,487) | (20,132) | (14,687) |
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Balance | $ 355,419 | $ 290,605 | $ 355,419 | $ 290,605 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Cash flows from operating activities: | ||||
Net increase in net assets resulting from operations | $ 152 | $ 7,617 | $ 5,458 | $ 11,139 |
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities: | ||||
Amortization of debt issuance costs | 500 | 400 | 950 | 705 |
Net realized loss on investments | 16,697 | 899 | ||
Net unrealized depreciation on investments | (608) | 36 | 6,929 | 2,273 |
Purchase of investments | (87,553) | (253,720) | ||
Principal payments received on investments | 64,496 | 87,473 | ||
Payment-in-kind interest on investments | (1,000) | 0 | (2,154) | 0 |
Proceeds from sale of investments | 8,506 | 43,426 | ||
Equity received in settlement of fee income | (89) | 0 | ||
Changes in assets and liabilities: | ||||
Decrease (increase) in interest receivable | 65 | (1,019) | ||
Increase in end-of-term payments | (1,291) | (1,911) | ||
(Decrease) increase in unearned income | (2,291) | 232 | ||
Decrease in other assets | (717) | (620) | ||
(Decrease) increase in other accrued expenses | (484) | 91 | ||
(Decrease) increase in base management fee payable | (2) | 165 | ||
(Decrease) increase in incentive fee payable | (1,274) | 130 | ||
Net cash provided by (used in) operating activities | 7,246 | (110,737) | ||
Cash flows from financing activities: | ||||
Proceeds from issuance of 2027 Notes | 0 | 50,000 | ||
Proceeds from issuance of common stock, net of offering costs | 51,175 | 48,529 | ||
Advances on Credit Facilities | 30,000 | 119,000 | ||
Repayment of Credit Facilities | (35,000) | (40,000) | ||
Debt issuance costs | (729) | (2,170) | ||
Distributions paid | (18,229) | (13,306) | ||
Net cash provided by financing activities | 15,452 | 141,351 | ||
Net increase in cash, cash equivalents and restricted cash | 22,698 | 30,614 | ||
Cash, cash equivalents and restricted cash: | ||||
Beginning of period | 30,466 | 47,281 | ||
End of period | 53,164 | 77,895 | 53,164 | 77,895 |
Supplemental disclosure of cash flow information: | ||||
Cash paid for interest | 13,409 | 6,535 | ||
Supplemental non-cash investing and financing activities: | ||||
Warrant investments received and recorded as unearned income | 656 | 1,845 | ||
Distributions payable | 10,592 | 7,457 | 10,592 | 7,457 |
End-of-term payments receivable | 11,074 | 7,149 | ||
Non-cash income | 7,182 | 2,378 | ||
Cash | 24,395 | 54,353 | 24,395 | 54,353 |
Investments in money market funds | 25,865 | 21,959 | 25,865 | 21,959 |
Restricted investments in money market funds | 2,904 | 1,583 | 2,904 | 1,583 |
Total cash, cash equivalents and restricted cash | $ 53,164 | $ 77,895 | 53,164 | 77,895 |
Asset-backed Notes 2019 [Member] | ||||
Cash flows from financing activities: | ||||
Repayment of notes | $ (11,765) | $ (20,702) |
Consolidated Schedule of Invest
Consolidated Schedule of Investments (Unaudited) | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Schedule of Investments [Text Block] | June 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 201.1% Non-Affiliate Debt Investments — 192.3% Non-Affiliate Debt Investments — Life Science — 82.9% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,055 $ 2,011 $ 1,938 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,028 1,982 1,910 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,014 991 955 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,028 1,980 1,907 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,028 1,980 1,907 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,014 987 951 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,014 987 951 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,899 4,899 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,982 2,982 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,982 2,982 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,968 1,968 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,969 1,969 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,936 4,936 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,930 4,930 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 10,000 9,887 9,887 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 15,000 14,830 14,830 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,932 5,932 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,932 5,932 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,955 3,955 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,955 3,955 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 4,000 3,886 3,859 Term Loan 14.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,000 1,944 1,931 IMV Inc. (5)(12)(13)(15) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,035 4,988 2,814 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,476 1,397 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 2,795 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 2,794 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,188 6,188 Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,188 6,188 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,711 3,711 Term Loan 13.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,475 2,475 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,727 9,727 Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,707 3,707 Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,707 3,707 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,605 4,605 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,605 4,605 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,289 2,289 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,289 2,289 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,284 2,284 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,284 2,284 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,750 4,680 4,680 Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,375 2,338 2,338 Aerobiotix, LLC (2)(12) Medical Device Term Loan 14.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,471 2,358 Term Loan 14.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,471 2,358 Ceribell, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,981 4,981 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,981 4,981 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,485 2,485 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,485 2,485 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,948 4,948 Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,474 2,474 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.07 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,910 3,910 Term Loan 13.07 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,910 3,910 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 875 867 867 Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 58 58 58 Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,200 1,191 1,191 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,724 2,724 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 979 979 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,953 4,953 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,953 4,953 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,948 4,948 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,949 4,949 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,927 4,927 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,927 4,927 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,417 3,417 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,467 3,467 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,659 3,659 Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,714 3,714 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,928 4,928 Sonex Health, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,463 2,463 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,462 2,462 Spineology, Inc. (2)(12) Medical Device Term Loan 15.25 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,972 4,972 Term Loan 15.25 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,485 2,485 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,460 3,460 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,460 3,460 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,450 3,450 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,450 3,450 Total Non-Affiliate Debt Investments — Life Science 302,687 294,452 Non-Affiliate Debt Investments — Sustainability — 23.4% Aerofarms, Inc. (12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,710 3,585 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,710 3,585 Nexii Building Solutions, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % June 8, 2026 5,000 4,922 4,675 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % June 8, 2026 5,000 4,922 4,675 Term Loan 15.25 % (11) Prime 7.00 % 10.25 % - - September 30, 2023 680 680 646 Term Loan 15.25 % (11) Prime 7.00 % 10.25 % - - September 30, 2023 542 542 515 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,942 4,942 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,471 2,471 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,940 4,940 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,470 2,470 Term Loan 13.75 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,917 4,917 Term Loan 13.75 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,458 2,458 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2026 3,750 3,709 3,709 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2026 3,750 3,723 3,723 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 7,500 7,436 7,436 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 3,750 3,718 3,718 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 3,750 3,718 3,718 Total Non-Affiliate Debt Investments — Sustainability 85,173 83,255 Non-Affiliate Debt Investments — Technology — 75.9% Axiom Space, Inc. (2)(12) Communications Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Better Place Forests Co. (12)(13) Consumer-related Technologies Term Loan 14.50 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,104 5,056 3,426 Term Loan 14.50 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,677 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 150 150 102 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 250 250 169 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 250 250 169 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,467 3,467 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,083 2,069 2,069 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,083 2,069 2,069 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,602 3,602 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,720 3,720 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,720 3,720 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,700 3,700 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,698 3,698 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,698 3,698 Term Loan (14) 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 1,250 1,250 1,250 Term Loan (14) 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 1,250 1,250 1,250 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.25 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,250 1,250 Term Loan 13.25 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,875 1,875 Term Loan 11.75 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.75 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.75 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,330 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,667 4,635 4,635 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,333 2,317 2,317 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,352 5,304 4,630 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,141 2,124 1,854 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,658 2,320 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,211 3,189 2,784 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,644 2,308 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,644 2,308 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,351 5,287 4,614 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,642 2,306 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,400 2,400 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,779 1,779 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,000 1,980 1,980 Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,000 1,980 1,980 Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,600 2,573 2,573 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 868 Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 434 Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 434 Liqid, Inc. (2)(12) Networking Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,333 2,300 2,300 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,333 2,300 2,300 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,149 1,149 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,149 1,149 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,129 1,129 BriteCore Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,489 2,489 Term Loan 15.00 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,489 2,489 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,469 2,469 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,469 2,469 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,370 6,370 Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,880 5,880 Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,447 2,447 Engage3, LLC (2)(12) Software Term Loan 14.50 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,723 3,723 Term Loan 14.50 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,723 3,723 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,860 9,860 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,860 9,860 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,930 4,930 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,930 4,930 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,959 4,959 Term Loan 14.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,480 2,480 Lytics, Inc. (2)(12) Software Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % November 1, 2026 2,500 2,414 2,414 Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,234 1,234 Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % April 1, 2027 1,000 985 985 Noodle Partners, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,741 9,741 Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,932 4,932 Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,933 4,933 Reputation Institute, Inc. (2)(12) Software Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 4,333 4,278 4,278 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,882 4,882 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,456 2,456 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,488 3,488 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,491 2,491 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,762 4,762 Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,461 2,461 Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,461 2,461 Total Non-Affiliate Debt Investments — Technology 276,563 269,863 Non-Affiliate Debt Investments — Healthcare information and services — 10.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,957 4,957 BrightInsight, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,670 6,670 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,455 3,455 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,455 3,455 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,706 2,706 SafelyYou, Inc. (2)(12) Software Term Loan 11.50 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,635 4,635 Term Loan 11.50 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,905 4,905 Total Non-Affiliate Debt Investments — Healthcare information and services 35,739 35,739 Total Non- Affiliate Debt Investments 700,162 683,309 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.2% Non-Affiliate Warrants — Life Science — 1.8% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 212 338 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 175 264 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 23,196 126 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 66 — IMV Inc. (2)(5)(12)(15) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 58 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 163 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 651 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 293,488 442 173 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 125 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 58 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,204 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 32 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,319 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 211 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 145 178 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 229 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 150 154 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 278 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 52 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 390 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 101 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 16 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 57 64 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,098,805 98 125 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 84 Total Non-Affiliate Warrants — Life Science 4,199 6,268 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 — LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 36 56 Nexii Building Solutions, Inc. (2)(12)(15) Other Sustainability Common Stock Warrant 213,746 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 365 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 34,604 121 266 Total Non-Affiliate Warrants — Sustainability 922 687 Non-Affiliate Warrants — Technology — 4.6% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 45 67 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,272 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (12) Consumer-related Technologies Preferred Stock Warrant 10,690 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 67 1,058 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 126 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 95 276 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,947 2,677 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 61 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 595 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 536 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 11 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 912 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 148 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 360 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,211 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 247 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,898 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 57 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 70 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 169 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 121 Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 70 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 299 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 41 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 21 57 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 46 18 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 116 120 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 50 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 101 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 140 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 120 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,401 16,392 See Notes to Consolidated Financial Statements Consolidated Schedule of Investments (Unaudited) June 30, 2023 (Dollars in thousands) Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 56 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 101 1,374 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 181 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 362 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 163 Total Non-Affiliate Warrants — Healthcare information and services 539 2,136 Total Non-Affiliate Warrants 15,061 25,483 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 1.2% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5)(12) Other Sustainability Common Stock 5,205 111 97 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 8 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 2 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,210 4,393 Total Non-Affiliate Portfolio Investment Assets $ 723,633 $ 714,485 Non-controlled Affiliate Investments — 0.3% Non-controlled Affiliate Equity — Life Science — 0.3% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 906 Total Non-Controlled Affiliate Equity $ — 906 Total Non-Controlled Affiliate Portfolio Investment Assets $ — 906 Total Portfolio Investment Assets — 201.4% $ 723,633 $ 715,391 ( 1 All investments of the Company are in entities which are organized under the laws of the United States and have a principal place of business in the United States, unless otherwise noted. ( 2 Has been pledged as collateral under the revolving credit facility (the “Key Facility”) with KeyBank National Association (“Key”), the Note Funding Agreement (the “NYL Facility”, together with the Key Facility, the "Credit Facilities") with several entities owned or affiliated with New York Life Insurance Company (“NYL Noteholders”), the term debt securitization in connection with which an affiliate of the Company made an offering of $100.0 million in aggregate principal amount of fixed rate asset-backed notes that were issued in conjunction with the $160.0 million securitization of secured loans the Company completed on August 13, 2019 ( “2019 November 9, 2022 ( “2022 ( 3 All non-affiliate investments are investments in which the Company owns less than 5% 5% not 25% 25% ( 4 All interest is payable in cash due monthly in arrears, unless otherwise indicated, and applies only to the Company’s debt investments. Interest rate is the annual interest rate on the debt investment and does not June 30, 2023 ( 5 Portfolio company is a public company. ( 6 For debt investments, represents principal balance less unearned income. ( 7 Warrants, Equity and Other Investments are non-income producing. ( 8 Value as a percent of net assets. ( 9 As of June 30, 2023 1940 may not 70% ( 10 ETPs are contractual fixed-interest payments due in cash at the maturity date of the applicable debt investment, including upon any prepayment, and are a fixed percentage of the original principal balance of the debt investments unless otherwise noted. Interest will accrue during the life of the debt investment on each ETP and will be recognized as non-cash income until it is actually paid. Therefore, a portion of the incentive fee the Company may not ( 11 Debt investment has a payment-in-kind (“PIK”) feature. PIK interest is accrued, added to the principal balance of the debt investment, and payable at maturity. ( 12 The fair value of the investment was valued using significant unobservable inputs. ( 13 Debt investment is on non-accrual status as of June 30, 2023 ( 14 Debt investment sold to third July 3, 2023. ( 15 Entity is organized under the laws of Canada and has a principal place of business in Canada. See Notes to Consolidated Financial Statements Consolidated Schedule of Investmen |
Note 1 - Organization
Note 1 - Organization | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block] | 1. Horizon Technology Finance Corporation (the “Company”) was organized as a Delaware corporation on March 16, 2010 1940 1986, not On October 28, 2010, Horizon Credit II LLC (“Credit II”) was formed as a Delaware limited liability company on June 28, 2011, not The Company formed Horizon Funding 2019‑1 “2019‑1 May 2, 2019 2019‑1 May 15, 2019 “2019‑1 2019‑1 “2019‑1 2019‑1 2019‑1 2019 Horizon Funding I, LLC (“HFI”) was formed as a Delaware limited liability company on May 9, 2018, not April 21, 2020, The Company formed Horizon Funding 2022‑1 “2022‑1 September 30, 2022 2022‑1 October 18, 2022 ( “2022‑1 2022‑1 “2022‑1 2022‑1 2022‑1 2022 The Company has established wholly owned subsidiaries, which are structured as Delaware limited liability companies, either to hold assets of portfolio companies acquired in connection with a foreclosure or bankruptcy or to hold equity in portfolio companies which the Company may The Company’s investment strategy is to maximize the investment portfolio’s return by generating current income from the debt investments the Company makes and capital appreciation from the warrants the Company receives when making such debt investments. The Company has entered into an investment management agreement (the “Investment Management Agreement”) with Horizon Technology Finance Management LLC (the “Advisor”) under which the Advisor manages the day-to-day operations of, and provides investment advisory services to, the Company. |
Note 2 - Basis of Presentation
Note 2 - Basis of Presentation and Significant Accounting Policies | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Basis of Presentation and Significant Accounting Policies [Text Block] | Note 2. The consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and pursuant to the requirements for reporting on Form 10‑Q 6 10 X X” 1933, not may December 31, 2022 Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may June 30, 2023 two December 31, 2022 three three six June 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three six June 30, 2023 three six June 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three June 30, 2023 2022 not six June 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 three June 30, 2023 2022 six June 30, 2023 2022 Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three June 30, 2023 2022, six June 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no June 30, 2023 December 31, 2022 2021, 2020 2019 Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may Stockholders Equity On August 2, 2021, “2021 2021 may may 415 During the three June 30, 2023 2021 During the three June 30, 2022 2021 During the six June 30, 2023 2021 During the six June 30, 2022, 2021 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of June 30, 2023 2021 On March 14, 2022, On June 2, 2023, Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three six June 30, 2023 2022 not June 30, 2023 Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03 |
Note 3 - Related Party Transact
Note 3 - Related Party Transactions | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Related Party Transactions Disclosure [Text Block] | Note 3. Investment Management Agreement On October 28, 2022, March 7, 2019 ( “2019 May 25, 2023 June 28, 2023, June 30, 2023 ( 2019 2019 2019 The Advisor’s services under the Investment Management Agreement are not not two The base management is calculated at an annual rate of 2.00% of the Company’s gross assets (less cash and cash equivalents) including any assets acquired with the proceeds of leverage; provided, that, to the extent the Company’s gross assets (less cash and cash equivalents) exceed $250 $250 The base management fee payable at June 30, 2023 December 31, 2022 three June 30, 2023 2022 six June 30, 2023 2022 The incentive fee has two The first zero not no 1.75%, 2.1875% 20.00% not Pre-Incentive Fee Net Investment Income does not may 2.00% three The incentive fee on Pre-Incentive Fee Net Investment Income is subject to a fee cap and deferral mechanism which is determined based upon a look-back period of up to three 11 may 20.00% zero not three The second 20.00% not The performance based incentive fee expense was $0.1 million and $2.1 million for the three June 30, 2023 2022 six June 30, 2023 2022 three six June 30, 2023 not may three June 30, 2023 December 31, 2025, March 31, 2026 June 30, 2026, not three six June 30, 2022. June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 one Administration Agreement The Company entered into an administration agreement (the “Administration Agreement”) with the Advisor to provide administrative services to the Company. For providing these services, facilities and personnel, the Company reimburses the Advisor for the Company’s allocable portion of overhead and other expenses incurred by the Advisor in performing its obligations under the Administration Agreement, including rent, the fees and expenses associated with performing compliance functions and the Company’s allocable portion of the costs of compensation and related expenses of the Company’s Chief Financial Officer and Chief Compliance Officer and their respective staffs. The administrative fee expense was $0.4 million for the three June 30, 2023 2022 six June 30, 2023 2022 |
Note 4 - Investments
Note 4 - Investments | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Investment Holdings [Text Block] | Note 4. The following table shows the Company’s investments as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 700,162 $ 683,309 $ 701,074 $ 686,458 Warrants 15,061 25,483 14,790 29,712 Other 1,200 1,300 1,200 1,300 Equity 7,210 5,299 4,184 2,556 Total investments $ 723,633 $ 715,391 $ 721,248 $ 720,026 The following table shows the Company’s investments by industry sector as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 182,489 $ 174,598 $ 193,372 $ 195,006 Medical Device 128,203 130,634 132,803 135,960 Technology Communications 22,922 26,170 22,892 26,176 Consumer-Related 113,903 108,275 121,961 114,050 Data Storage 417 1,060 476 1,316 Internet and Media 329 1,634 329 1,159 Networking 8,391 8,274 11,831 11,710 Power Management 1,585 2,898 1,585 2,610 Semiconductors 57 — 56 — Software 142,853 139,934 120,157 118,716 Sustainability Energy Efficiency 111 97 8 27 Other Sustainability 86,095 83,942 84,633 85,524 Healthcare Information and Services Diagnostics 9,960 9,969 9,851 9,858 Other 101 1,374 7,559 3,870 Software 26,217 26,532 13,735 14,044 Total investments $ 723,633 $ 715,391 $ 721,248 $ 720,026 |
Note 5 - Transactions With Affi
Note 5 - Transactions With Affiliated Companies | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Investments in and Advances to Affiliates, Schedule of Investments [Text Block] | Note 5. A non-controlled affiliated company is generally a portfolio company in which the Company owns 5% not 25% Transactions related to investments in non-controlled affiliated companies for the three June 30, 2023 Three months ended June 30, 2023 Fair value at Transfers Net Fair value at Portfolio March 31, in/(out) at Dividends unrealized Net realized June 30, Company 2023 Purchases Sales fair value declared gain/(loss) gain/(loss) 2023 (In thousands) Cadrenal Therapeutics, Inc. 846 — — — — 60 — 906 Total non-controlled affiliates $ 846 $ — $ — $ — $ — $ 60 $ — $ 906 Transactions related to investments in non-controlled affiliated companies for the six June 30, 2023 Six months ended June 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized June 30, Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 (In thousands) Cadrenal Therapeutics, Inc. $ — $ — $ — $ — $ — $ 906 $ — $ 906 Total non-controlled affiliates $ — $ — $ — $ — $ — $ 906 $ — $ 906 For the three six June 30, 2022 A controlled affiliated company is generally a portfolio company in which the Company owns more than 25% For the three six June 30, 2023 Transactions related to investments in controlled affiliated companies for the three June 30, 2022 Three months ended June 30, 2022 Fair value at Transfers Net Fair value at Portfolio March 31, in/(out) at Dividends unrealized Net realized June 30, Company 2022 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 (In thousands) HESP LLC — — (200 ) — — 1,400 (1,200 ) — Total controlled affiliates $ — $ — $ (200 ) $ — $ — $ 1,400 $ (1,200 ) $ — Transactions related to investments in controlled affiliated companies for the six June 30, 2022 Six months ended June 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized June 30, Company 2021 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2022 (In thousands) HESP LLC — — (250 ) — — 1,450 (1,200 ) — Total controlled affiliates $ — $ — $ (250 ) $ — $ — $ 1,450 $ (1,200 ) $ — |
Note 6 - Fair Value
Note 6 - Fair Value | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Fair Value Disclosures [Text Block] | Note 6. Prior to July 30, 2022, 2a 5 1940 July 29, 2022, twelve The Company uses fair value measurements made by the valuation designee to record fair value adjustments to certain assets and liabilities and to determine fair value disclosures. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Fair value is best determined based upon quoted market prices. However, in certain instances, there are no not may not Fair value measurements focus on exit prices in an orderly transaction (that is, not may The Company’s fair value measurements are classified into a fair value hierarchy in accordance with ASC Topic 820, Fair Value Measurement three Level 1 Quoted prices in active markets for identical assets and liabilities. Level 2 Observable inputs other than Level 1 not Level 3 Unobservable inputs that are supported by little or no 3 Due to the inherent uncertainty of determining the fair value of investments that do not may may may may Cash and interest receivable: not 1 Money market funds: 2 Debt investments: 3 Under certain circumstances, the Company may Warrant investments: ● Underlying asset value of the issuer is estimated based on information available, including any information regarding the most recent rounds of borrower funding. Significant increases (decreases) in this unobservable input would result in a significantly higher (lower) fair value measurement. ● Volatility, or the amount of uncertainty or risk about the size of the changes in the warrant price, is based on indices of publicly traded companies similar in nature to the underlying company issuing the warrant. A total of seven ● The risk-free interest rates are derived from the U.S. Treasury yield curve. The risk-free interest rates are calculated based on a weighted average of the risk-free interest rates that correspond closest to the expected remaining life of the warrant. ● Other adjustments, including a marketability discount on private company warrants, are estimated based on management’s judgment about the general industry environment. ● Historical portfolio experience on cancellations and exercises of the Company’s warrants are utilized as the basis for determining the estimated time to exit of the warrants in each financial reporting period. Warrants may Under certain circumstances the Company may may The fair value of the Company’s warrants held in publicly traded companies is determined based on inputs that are readily available in public markets or can be derived from information available in public markets. Therefore, the Company has categorized these warrants as Level 2 3 Equity investments: third may 3 1 Other investments: 3 The following tables detail the investments that are carried at fair value and measured at fair value on a recurring basis as of June 30, 2023 December 31, 2022 June 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 683,309 $ 683,309 Warrant investments — 1,107 24,376 25,483 Other investments — — 1,300 1,300 Equity investments 1,040 — 4,259 5,299 Total investments $ 1,040 $ 1,107 $ 713,244 $ 715,391 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 The following tables provide a summary of quantitative information about the Company’s Level 3 June 30, 2023 December 31, 2022 may The following table is not 3 June 30, 2023 June 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 611,524 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 24% 14 % 71,785 Multiple Probability Weighted Cash Flow Model Probability Weighting 5% - 100% 50 % Warrant investments 24,314 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 59.21 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 4,259 Last Equity Financing Price Per Share $0.03– $215.03 $ 27.56 Total Level 3 investments $ 713,244 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 The following table is not 3 December 31, 2022 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 ( 1 Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) ( 1 2 Borrowings: 2 2026 7 June 30, 2023 2026 1 2027 7 June 30, 2023 2027 1 June 30, 2023 2019 3 June 30, 2023 2022 3 not Off-balance-sheet instruments: 3 The following table shows a reconciliation of the beginning and ending balances for Level 3 three June 30, 2023 Three months ended June 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 684,554 $ 24,638 $ 2,915 $ 1,300 $ 713,407 Purchase of investments 40,545 — — — 40,545 Warrants and equity received and classified as Level 3 — 515 89 — 604 Principal payments received on investments (24,740 ) — — — (24,740 ) Payment-in-kind interest on investments 950 — — — 950 Proceeds from sale of investments (528 ) (1,458 ) — — (1,986 ) Net realized (loss) gain on investments (17,672 ) 1,287 (127 ) — (16,512 ) Unrealized appreciation (depreciation) included in earnings 2,118 (606 ) (1,307 ) — 205 Transfer out of Level 3 — — (111 ) — (111 ) Transfer out of debt investments (2,800 ) — 2,800 — — Other 882 — — — 882 Level 3 assets, end of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 During the three June 30, 2023 one 3. one 3 one 1 The following table shows a reconciliation of the beginning and ending balances for Level 3 three June 30, 2022 Three months ended June 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 492,194 $ 21,645 $ 203 $ 200 $ 514,242 Purchase of investments 158,985 — 250 — 159,235 Warrants received and classified as Level 3 — 669 — — 669 Principal payments received on investments (73,096 ) — — (232 ) (73,328 ) Proceeds from sale of investments (21,750 ) (396 ) — — (22,146 ) Net realized gain (loss) on investments — 239 — (1,168 ) (929 ) Unrealized (depreciation) appreciation included in earnings (3,797 ) 3,010 — 1,400 613 Other (976 ) — — — (976 ) Level 3 assets, end of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 During the three June 30, 2022 3. The following table shows a reconciliation of the beginning and ending balances for Level 3 six June 30, 2023 Six months ended June 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 87,543 — 10 — 87,553 Warrants and equity received and classified as Level 3 — 656 89 — 745 Principal payments received on investments (64,496 ) — — — (64,496 ) Payment-in-kind interest on investments 2,154 — — — 2,154 Proceeds from sale of investments (7,036 ) (1,470 ) — — (8,506 ) Net realized (loss) gain on investments (17,665 ) 1,146 (127 ) — (16,646 ) Unrealized depreciation included in earnings (2,448 ) (2,096 ) (1,118 ) — (5,662 ) Transfer out of Level 3 — — (111 ) — (111 ) Transfer out of debt investments (3,095 ) (5 ) 3,100 — — Other 1,894 — — — 1,894 Level 3 assets, end of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 During the six June 30, 2023 one 3. one 3 one 1 The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 June 30, 2023 The following table shows a reconciliation of the beginning and ending balances for Level 3 six June 30, 2022 Six months ended June 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 253,470 — 250 — 253,720 Warrants received and classified as Level 3 — 1,477 — — 1,477 Principal payments received on investments (87,191 ) — — (282 ) (87,473 ) Proceeds from sale of investments (43,000 ) (426 ) — — (43,426 ) Net realized gain (loss) on investments — 269 — (1,168 ) (899 ) Unrealized (depreciation) appreciation included in earnings (6,967 ) 4,010 — 1,450 (1,507 ) Other (2,069 ) — — — (2,069 ) Level 3 assets, end of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 During the six June 30, 2022 3. The change in unrealized depreciation included in the consolidated statement of operations attributable to Level 3 June 30, 2022 The Company discloses fair value information about financial instruments, whether or not not The fair value amounts have been measured as of the reporting date and have not may As of June 30, 2023 December 31, 2022 Market risk The Company assumes interest rate risk (the risk that general interest rate levels will change) as a result of its normal operations. As a result, the fair values of the Company’s financial instruments will change when interest rate levels change, and that change may |
Note 7 - Borrowings
Note 7 - Borrowings | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Debt Disclosure [Text Block] | Note 7. The following table shows the Company’s borrowings as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ — $ 150,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 176,750 73,250 200,000 176,750 23,250 2019 Asset-Backed Notes 30,807 30,807 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 645,807 422,557 223,250 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,541 ) — — (5,245 ) — Total borrowings outstanding, net $ 645,807 $ 418,016 $ 223,250 $ 582,573 $ 434,078 $ 143,250 As of June 30, 2023 1940 June 30, 2023 Credit Facilities Key Facility The Company entered into the Key Facility with Key effective November 4, 2013. June 29, 2023, may June 22, 2024 June 22, 2026. June 30, 2023 December 31, 2022 three June 30, 2023 2022 six June 30, 2023 2022 June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 NYL Facility On April 21, 2020, June 1, 2018, three On February 25, 2022, three On May 24, 2023, June 2024 June 2029. May 24, 2023, 4.60% 3.50%, There were $176.8 million in advances made by the NYL Noteholders as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 Under the terms of the NYL Facility, the Company is required to maintain a reserve cash balance, which may June 30, 2023 December 31, 2022 Securitizations 2019 On August 13, 2019, 2019 2019 no August 13, 2019. The 2019 2019‑1 August 13, 2019, 2019 2019 July 15, 2021 September 15, 2027. As of June 30, 2023 December 31, 2022 2019 Under the terms of the 2019 2019 may 2019 June 30, 2023 December 31, 2022 2022 On November 9, 2022, 2022 2022 no November 9, 2022. The 2022 2022‑1 November 9, 2022, 2022 2022 November 15, 2024 November 15, 2030. As of June 30, 2023 December 31, 2022 2022 $100.0 Under the terms of the 2022 2022 may 2022 June 30, 2023 December 31, 2022 Unsecured Notes 2026 On March 30, 2021, 2026 “2026 2026 2026 March 30, 2026 may March 30, 2023 2026 4.875% March 30, June 30, September 30 December 30 2026 2026 June 30, 2023 2026 2026 2027 On June 15, 2022, 2027 July 11, 2022, 30 “2027 2027 June 15, 2027 may June 15, 2024 2027 6.25% March 30, June 30, September 30 December 30 September 30, 2022. 2027 2027 June 30, 2023 2027 2027 |
Note 8 - Financial Instruments
Note 8 - Financial Instruments With Off-balance-sheet Risk | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Financial Instruments Disclosure [Text Block] | Note 8. In the normal course of business, the Company is party to financial instruments with off-balance-sheet risk to meet the financing needs of its borrowers. These financial instruments include commitments to extend credit and involve, to varying degrees, elements of credit risk in excess of the amount recognized in the consolidated statement of assets and liabilities. The Company attempts to limit its credit risk by conducting extensive due diligence and obtaining collateral where appropriate. The balance of unfunded commitments to extend credit was $143.4 million and $190.0 million as of June 30, 2023 December 31, 2022 may not The following table provides the Company’s unfunded commitments by portfolio company as of June 30, 2023 June 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. — — 5,000 66 Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Native Microbials, Inc. — — 7,500 72 Nexii Building Solutions, Inc. 1,488 — — — Noodle Partners, Inc. 10,000 123 — — Optoro, Inc. 11,250 — 15,000 38 PDS Biotechnology Corporation 10,000 158 10,000 158 Robin Healthcare, Inc. 5,000 50 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 STS (ABC), LLC 140 — — — Slingshot Aerospace, Inc. 5,000 64 5,000 64 Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 143,378 $ 1,412 $ 190,000 $ 1,761 The table above also provides the fair value of the Company’s unfunded commitment liability as of June 30, 2023 December 31, 2022, |
Note 9 - Concentrations of Cred
Note 9 - Concentrations of Credit Risk | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Concentration Risk Disclosure [Text Block] | Note 9. The Company’s debt investments consist primarily of loans to development-stage companies at various stages of development in the technology, life science, healthcare information and services and sustainability industries. Many of these companies may may The Company’s largest debt investments may five June 30, 2023 December 31, 2022 No 10% June 30, 2023 December 31, 2022 five three June 30, 2023 2022 five three June 30, 2023 2022 five six June 30, 2023 2022 five six June 30, 2023 2022 |
Note 10 - Distributions
Note 10 - Distributions | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Equity [Text Block] | Note 10. The Company’s distributions are recorded on the declaration date. The following table summarizes the Company’s distribution activity for the six June 30, 2023 December 31, 2022 DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Six Months Ended June 30, 2023 4/28/2023 8/17/23 9/15/23 $ 0.11 $ — — $ — 4/28/2023 7/18/23 8/15/23 0.11 — — — 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.66 $ 12,624 28,151 $ 347 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 On July 28, 2023, Monthly distributions Ex-Dividend Date Record Date Payment Date Distributions Declared September 18, 2023 September 19, 2023 October 16, 2023 $ 0.11 October 17, 2023 October 18, 2023 November 15, 2023 $ 0.11 November 16, 2023 November 17, 2023 December 15, 2023 $ 0.11 After paying distributions of $0.33 per share and earning net investment income of $0.54 per share for the quarter, the Company’s undistributed spillover income as of June 30, 2023 not |
Note 11 - Financial Highlights
Note 11 - Financial Highlights | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Investment Company, Financial Highlights [Text Block] | Note 11. The following table shows financial highlights for the Company: Six months ended June 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.00 0.62 Realized loss (0.58 ) (0.04 ) Unrealized depreciation on investments (0.23 ) (0.10 ) Net increase in net assets resulting from operations 0.19 0.48 Distributions declared (1) (0.66 ) (0.60 ) From net investment income (0.66 ) (0.60 ) From net realized gain on investments — — Return of capital — — Other (2) 0.07 0.25 Net asset value at end of period $ 11.07 $ 11.69 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 12.08 $ 11.54 Total return based on a market value (3) 9.8 % (23.7 )% Shares outstanding at end of period 32,096,259 24,857,104 Ratios to average net assets: Expenses without incentive value (4) 14.2 % 10.8 % Incentive fees (4) 1.9 % 2.6 % Net expenses (4) 16.1 % 13.4 % Net investment income with incentive fees (4) 17.5 % 10.5 % Net assets at the end of the period $ 355,419 $ 290,605 Average net asset value $ 331,850 $ 271,976 Average debt per share $ 15.11 $ 12.81 Portfolio turnover ratio 7.6 % (5) 11.3 % (5) ( 1 Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may ( 2 Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share. ( 3 The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price. ( 4 Annualized. ( 5 Calculated by dividing the lesser of purchases or the sum of ( 1 2 |
Note 12 - Subsequent Events
Note 12 - Subsequent Events | 6 Months Ended |
Jun. 30, 2023 | |
Notes to Financial Statements | |
Subsequent Events [Text Block] | Note 12. On July 6, 2023 , July 25, 2023, July 27, 2023, On July 12, 2023, December 15, 2022, On July 13, 2023 , On July 18, 2023, On July 31, 2023, |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended |
Jun. 30, 2023 | |
Accounting Policies [Abstract] | |
Consolidation, Policy [Policy Text Block] | Principles of consolidation As required under GAAP and Regulation S- X, Assets related to transactions that do not 860, Transfers and Servicing 2019‑1 2022 1 not |
Use of Estimates, Policy [Policy Text Block] | Use of estimates In preparing the consolidated financial statements in accordance with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosures of contingent assets and liabilities, as of the date of the balance sheet and income and expenses for the period. Actual results could differ from those estimates. Material estimates that are particularly susceptible to significant change in the near term relate to the valuation of investments. |
Fair Value Measurement, Policy [Policy Text Block] | Fair value The Company records all of its investments at fair value in accordance with relevant GAAP, which establishes a framework used to measure fair value and requires disclosures for fair value measurements. The Company has categorized its investments carried at fair value, based on the priority of the valuation technique, into a three 6. not The availability of observable inputs can vary depending on the financial instrument and is affected by a wide variety of factors, including, for example, the type of product, whether the product is new, whether the product is traded on an active exchange or in the secondary market and the current market conditions. To the extent that the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair value requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for financial instruments classified as Level 3. See Note 6 |
Segment Reporting, Policy [Policy Text Block] | Segments The Company has determined that it has a single reporting segment and operating unit structure. The Company lends to and invests in portfolio companies in various technology, life science, healthcare information and services and sustainability industries. The Company separately evaluates the performance of each of its lending and investment relationships. However, because each of these debt investments and investment relationships has similar business and economic characteristics, they have been aggregated into a single lending and investment segment. |
Investment, Policy [Policy Text Block] | Investments Investments are recorded at fair value. Pursuant to the amended SEC Rule 2a 5 1940 July 29, 2022, Interest on debt investments is accrued and included in income based on contractual rates applied to principal amounts outstanding. Interest income is determined using a method that results in a level rate of return on principal amounts outstanding. Generally, when a debt investment becomes 90 not may may June 30, 2023 two December 31, 2022 three three six June 30, 2023 2022, not The Company has a limited number of debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not three six June 30, 2023 three six June 30, 2022 The Company receives a variety of fees from borrowers in the ordinary course of conducting its business, including advisory fees, commitment fees, amendment fees, non-utilization fees, success fees and prepayment fees. In a limited number of cases, the Company may Certain debt investment agreements also require the borrower to make an ETP, that is accrued into interest receivable and taken into income over the life of the debt investment to the extent such amounts are expected to be collected. The Company will generally cease accruing the income if there is insufficient value to support the accrual or the Company does not not three June 30, 2023 2022 not six June 30, 2023 2022 In connection with substantially all lending arrangements, the Company receives warrants to purchase shares of stock from the borrower. The warrants are recorded as assets at estimated fair value on the grant date using the Black-Scholes valuation model. The warrants are considered loan fees and are recorded as unearned income on the grant date. The unearned income is recognized as interest income over the contractual life of the related debt investment in accordance with the Company’s income recognition policy. Subsequent to debt investment origination, the fair value of the warrants is determined using the Black-Scholes valuation model. Any adjustment to fair value is recorded through earnings as net unrealized appreciation or depreciation on investments. Gains and losses from the disposition of the warrants or stock acquired from the exercise of warrants are recognized as realized gains and losses on investments. Realized gains or losses on the sale of investments, or upon the determination that an investment balance, or portion thereof, is not |
Debt, Policy [Policy Text Block] | Debt issuance costs Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing from its lenders and issuing debt securities. The unamortized balance of debt issuance costs as of June 30, 2023 December 31, 2022 June 30, 2023 December 31, 2022 three June 30, 2023 2022 six June 30, 2023 2022 |
Income Tax, Policy [Policy Text Block] | Income taxes As a BDC, the Company has elected to be treated as a RIC under Subchapter M of the Code and operates in a manner so as to qualify for the tax treatment applicable to RICs. In order to qualify as a RIC and to avoid the imposition of corporate-level income tax on the portion of its taxable income distributed to stockholders, among other things, the Company is required to meet certain source of income and asset diversification requirements and to timely distribute dividends out of assets legally available for distribution to its stockholders of an amount generally at least equal to 90% no 946, Financial Services Investment Companies no Depending on the level of taxable income earned in a tax year, the Company may three June 30, 2023 2022, six June 30, 2023 2022, The Company evaluates tax positions taken in the course of preparing the Company’s tax returns to determine whether the tax positions are “more-likely-than- not” 740, Income Taxes 946. not not no June 30, 2023 December 31, 2022 2021, 2020 2019 |
Distributions [Policy Text Block] | Distributions Distributions to common stockholders are recorded on the declaration date. The amount to be paid out as distributions is determined by the Board. Net realized capital gains, if any, may may The Company has adopted a dividend reinvestment plan that provides for reinvestment of cash distributions on behalf of its stockholders, unless a stockholder elects to receive cash. As a result, if the Board declares a cash distribution, then stockholders who have not may |
Stockholders' Equity, Policy [Policy Text Block] | Stockholders Equity On August 2, 2021, “2021 2021 may may 415 During the three June 30, 2023 2021 During the three June 30, 2022 2021 During the six June 30, 2023 2021 During the six June 30, 2022, 2021 The Company generally uses net proceeds from these offerings to make investments, to pay down liabilities and for general corporate purposes. As of June 30, 2023 2021 On March 14, 2022, On June 2, 2023, |
Stock Repurchase Program [Policy Text Block] | Stock Repurchase Program On April 28, 2023, may, not 10b‑18 1934, 1940 June 30, 2024 $5.0 three six June 30, 2023 2022 not June 30, 2023 |
Transfers and Servicing of Financial Assets, Policy [Policy Text Block] | Transfers of financial assets Assets related to transactions that do not 860, Transfers and Servicing not Transfers of financial assets are accounted for as sales when control over the assets has been surrendered. Control over transferred assets is deemed to be surrendered when ( 1 2 3 not |
New Accounting Pronouncements, Policy [Policy Text Block] | Recently issued accounting pronouncement In June 2022, No. 2022 03, 2022 03” 2022 03 2022 03 December 15, 2023, 2022 03 |
Consolidated Schedule of Inve_2
Consolidated Schedule of Investments (Unaudited) (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Investment [Table Text Block] | Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 201.1% Non-Affiliate Debt Investments — 192.3% Non-Affiliate Debt Investments — Life Science — 82.9% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,055 $ 2,011 $ 1,938 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,028 1,982 1,910 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,014 991 955 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,028 1,980 1,907 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,028 1,980 1,907 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,014 987 951 Term Loan 14.50 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,014 987 951 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,899 4,899 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,982 2,982 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,971 4,971 Term Loan 13.13 % Prime 4.88 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,982 2,982 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,968 1,968 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % June 1, 2024 1,979 1,969 1,969 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % November 1, 2025 5,000 4,936 4,936 Term Loan 12.97 % Prime 4.72 % 9.75 % - 5.00 % May 1, 2026 5,000 4,930 4,930 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 10,000 9,887 9,887 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 15,000 14,830 14,830 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,932 5,932 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 6,000 5,932 5,932 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,955 3,955 Term Loan 12.50 % Prime 4.25 % 11.00 % - 4.25 % January 1, 2028 4,000 3,955 3,955 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 4,000 3,886 3,859 Term Loan 14.00 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,000 1,944 1,931 IMV Inc. (5)(12)(13)(15) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,035 4,988 2,814 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,476 1,397 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 2,795 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,953 2,794 KSQ Therapeutics, Inc. (2)(12) Biotechnology Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,188 6,188 Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,188 6,188 Native Microbials, Inc (2)(12) Biotechnology Term Loan 13.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 3,750 3,711 3,711 Term Loan 13.50 % Prime 5.25 % 8.50 % - 5.00 % November 1, 2026 2,500 2,475 2,475 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 10,000 9,727 9,727 Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,707 3,707 Term Loan 14.00 % Prime 5.75 % 9.75 % - 3.75 % September 1, 2026 3,750 3,707 3,707 Provivi, Inc. (2)(12) Biotechnology Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,605 4,605 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 4,667 4,605 4,605 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,289 2,289 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,289 2,289 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,284 2,284 Term Loan 13.61 % Prime 5.36 % 9.50 % - 5.50 % December 1, 2024 2,333 2,284 2,284 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Stealth Biotherapeutics Inc. (2)(12) Biotechnology Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 4,750 4,680 4,680 Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % October 1, 2025 2,375 2,338 2,338 Aerobiotix, LLC (2)(12) Medical Device Term Loan 14.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,471 2,358 Term Loan 14.50 % Prime 6.25 % 9.50 % - 6.00 % April 1, 2026 2,500 2,471 2,358 Ceribell, Inc. (2)(12) Medical Device Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,981 4,981 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 5,000 4,981 4,981 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,485 2,485 Term Loan 11.75 % Prime 3.50 % 8.25 % - 5.50 % October 1, 2024 2,500 2,485 2,485 Cognoa, Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 5,000 4,948 4,948 Term Loan 13.75 % Prime 5.50 % 8.75 % - 6.00 % August 1, 2026 2,500 2,474 2,474 Conventus Orthopaedics, Inc. (2)(12) Medical Device Term Loan 13.07 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,910 3,910 Term Loan 13.07 % Prime 4.82 % 9.25 % - 10.36 % July 1, 2025 3,960 3,910 3,910 CSA Medical, Inc. (2)(12) Medical Device Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 875 867 867 Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % January 1, 2024 58 58 58 Term Loan 13.34 % Prime 5.09 % 10.00 % - 5.00 % March 1, 2024 1,200 1,191 1,191 InfoBionic, Inc. (2)(12) Medical Device Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % October 1, 2024 2,771 2,724 2,724 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % June 1, 2025 1,000 979 979 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,953 4,953 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,953 4,953 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,948 4,948 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % March 1, 2025 5,000 4,949 4,949 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,927 4,927 Term Loan 13.25 % Prime 5.00 % 9.75 % - 4.00 % January 1, 2027 5,000 4,927 4,927 Robin Healthcare, Inc. (2)(12) Medical Device Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,417 3,417 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % November 1, 2026 3,500 3,467 3,467 Scientia Vascular, Inc. (2)(12) Medical Device Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,659 3,659 Term Loan 13.00 % Prime 4.75 % 8.50 % - 5.00 % January 1, 2027 3,750 3,714 3,714 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % March 1, 2027 5,000 4,928 4,928 Sonex Health, Inc. (2)(12) Medical Device Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % June 1, 2025 2,500 2,481 2,481 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % April 1, 2026 2,500 2,463 2,463 Term Loan 14.75 % Prime 6.50 % 9.75 % - 8.00 % May 1, 2026 2,500 2,462 2,462 Spineology, Inc. (2)(12) Medical Device Term Loan 15.25 % Prime 7.00 % 10.25 % - 1.00 % October 1, 2025 5,000 4,972 4,972 Term Loan 15.25 % Prime 7.00 % 10.25 % - 1.00 % April 1, 2026 2,500 2,485 2,485 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Swift Health Systems Inc. (2)(12) Medical Device Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,460 3,460 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,460 3,460 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,450 3,450 Term Loan 13.50 % Prime 5.25 % 9.00 % - 5.00 % July 1, 2027 3,500 3,450 3,450 Total Non-Affiliate Debt Investments — Life Science 302,687 294,452 Non-Affiliate Debt Investments — Sustainability — 23.4% Aerofarms, Inc. (12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,710 3,585 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % April 1, 2026 3,750 3,710 3,585 Nexii Building Solutions, Inc. (2)(12)(15) Other Sustainability Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % August 27, 2025 7,500 7,395 7,024 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % June 8, 2026 5,000 4,922 4,675 Term Loan 15.25 % Prime 7.00 % 10.25 % - 2.50 % June 8, 2026 5,000 4,922 4,675 Term Loan 15.25 % (11) Prime 7.00 % 10.25 % - - September 30, 2023 680 680 646 Term Loan 15.25 % (11) Prime 7.00 % 10.25 % - - September 30, 2023 542 542 515 Soli Organic, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 5,000 4,942 4,942 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % April 1, 2026 2,500 2,471 2,471 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 5,000 4,940 4,940 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.75 % May 1, 2026 2,500 2,470 2,470 Term Loan 13.75 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 5,000 4,917 4,917 Term Loan 13.75 % Prime 5.50 % 11.75 % - 2.75 % December 1, 2026 2,500 2,458 2,458 Temperpack Technologies, Inc. (2)(12) Other Sustainability Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2026 3,750 3,709 3,709 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % June 1, 2026 3,750 3,723 3,723 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 7,500 7,436 7,436 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 3,750 3,718 3,718 Term Loan 15.00 % Prime 6.75 % 10.00 % - 2.50 % October 1, 2026 3,750 3,718 3,718 Total Non-Affiliate Debt Investments — Sustainability 85,173 83,255 Non-Affiliate Debt Investments — Technology — 75.9% Axiom Space, Inc. (2)(12) Communications Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Term Loan 14.25 % Prime 6.00 % 9.25 % - 2.50 % June 1, 2026 7,500 7,462 7,462 Better Place Forests Co. (12)(13) Consumer-related Technologies Term Loan 14.50 % Prime 6.25 % 9.50 % - 1.85 % July 1, 2025 5,104 5,056 3,426 Term Loan 14.50 % Prime 6.25 % 9.50 % - 1.85 % October 1, 2025 2,500 2,474 1,677 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 150 150 102 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 250 250 169 Term Loan 14.50 % Prime 6.25 % 9.50 % - 100.00 % September 30, 2023 250 250 169 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % May 1, 2026 3,500 3,467 3,467 Clara Foods Co. (2)(12) Consumer-related Technologies Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,083 2,069 2,069 Term Loan 14.00 % Prime 5.75 % 9.00 % - 5.50 % August 1, 2025 2,083 2,069 2,069 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,602 3,602 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,720 3,720 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 3,750 3,720 3,720 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2027 1,250 1,240 1,240 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % January 1, 2028 3,750 3,700 3,700 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % April 1, 2028 3,750 3,705 3,705 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,698 3,698 Term Loan 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 3,750 3,698 3,698 Term Loan (14) 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 1,250 1,250 1,250 Term Loan (14) 11.25 % Prime 6.00 % 9.50 % 11.25 % 3.00 % July 1, 2028 1,250 1,250 1,250 Havenly, Inc. (2)(12) Consumer-related Technologies Term Loan 13.25 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 2,000 1,250 1,250 Term Loan 13.25 % Prime 5.00 % 5.00 % - 4.00 % March 1, 2027 3,000 1,875 1,875 Term Loan 11.75 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Term Loan 11.75 % Prime 3.50 % 10.50 % - 7.78 % February 1, 2028 2,813 2,813 2,813 Lyrical Foods, Inc. (2)(12) Consumer-related Technologies Term Loan 10.75 % Prime 2.50 % 8.00 % - - September 1, 2027 2,598 2,589 2,330 MyForest Foods Co. (2)(12) Consumer-related Technologies Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 4,667 4,635 4,635 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % October 1, 2025 2,333 2,317 2,317 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,352 5,304 4,630 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,141 2,124 1,854 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,658 2,320 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 3,211 3,189 2,784 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,644 2,308 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,644 2,308 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 5,351 5,287 4,614 Term Loan 14.00 % (11) Prime 5.75 % 9.00 % - 5.25 % October 31, 2023 2,676 2,642 2,306 Optoro, Inc. (2)(12) Consumer-related Technologies Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % August 1, 2027 2,500 2,400 2,400 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2028 1,875 1,779 1,779 Primary Kids, Inc. (2)(12) Consumer-related Technologies Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,000 1,980 1,980 Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % March 1, 2025 2,000 1,980 1,980 Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % September 1, 2025 2,600 2,573 2,573 Unagi, Inc. (2)(12) Consumer-related Technologies Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 1,108 1,086 868 Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 434 Term Loan 16.00 % (11) Prime 7.75 % 11.00 % - - May 1, 2027 554 543 434 Liqid, Inc. (2)(12) Networking Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,333 2,300 2,300 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 2,333 2,300 2,300 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,149 1,149 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,149 1,149 Term Loan 14.50 % Prime 6.25 % 9.50 % - 4.00 % September 1, 2024 1,167 1,129 1,129 BriteCore Holdings, Inc. (2)(12) Software Term Loan 15.00 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,489 2,489 Term Loan 15.00 % Prime 6.75 % 10.00 % - 5.00 % March 1, 2026 2,500 2,489 2,489 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,469 2,469 Term Loan 15.00 % Prime 6.75 % 10.00 % - 3.00 % March 1, 2027 2,500 2,469 2,469 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Dropoff, Inc. (2)(12) Software Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,500 6,370 6,370 Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % April 1, 2026 6,000 5,880 5,880 Term Loan 14.75 % Prime 6.50 % 9.75 % - 3.50 % August 1, 2026 2,500 2,447 2,447 Engage3, LLC (2)(12) Software Term Loan 14.50 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,723 3,723 Term Loan 14.50 % Prime 6.25 % 9.75 % - 4.50 % July 1, 2027 3,750 3,723 3,723 Kodiak Robotics, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,860 9,860 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 10,000 9,860 9,860 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,930 4,930 Term Loan 13.75 % Prime 5.50 % 10.25 % - 4.00 % April 1, 2026 5,000 4,930 4,930 Lemongrass Holdings, Inc. (2)(12) Software Term Loan 14.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 5,000 4,959 4,959 Term Loan 14.75 % Prime 6.50 % 9.75 % - 2.50 % March 1, 2026 2,500 2,480 2,480 Lytics, Inc. (2)(12) Software Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % November 1, 2026 2,500 2,414 2,414 Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % December 1, 2026 1,250 1,234 1,234 Term Loan 14.25 % Prime 6.00 % 12.25 % - 3.00 % April 1, 2027 1,000 985 985 Noodle Partners, Inc. (2)(12) Software Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 10,000 9,741 9,741 Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,932 4,932 Term Loan 13.25 % Prime 5.00 % 12.00 % - 3.00 % March 1, 2027 5,000 4,933 4,933 Reputation Institute, Inc. (2)(12) Software Term Loan 15.50 % Prime 7.25 % 10.50 % - 3.00 % August 1, 2025 4,333 4,278 4,278 Slingshot Aerospace, Inc. (2)(12) Software Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,882 4,882 Term Loan 14.00 % Prime 5.75 % 9.75 % - 5.00 % August 1, 2026 5,000 4,946 4,946 Supply Network Visibility Holdings LLC (2)(12) Software Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,456 2,456 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 3,500 3,488 3,488 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 2,500 2,491 2,491 Term Loan 12.50 % Prime 4.25 % 12.00 % - 2.50 % June 1, 2028 1,500 1,495 1,495 Viken Detection Corporation (2)(12) Software Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 5,000 4,762 4,762 Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,461 2,461 Term Loan 12.25 % Prime 4.00 % 11.75 % - 3.50 % June 1, 2027 2,500 2,461 2,461 Total Non-Affiliate Debt Investments — Technology 276,563 269,863 Non-Affiliate Debt Investments — Healthcare information and services — 10.1% Hound Labs inc. (2) (12) Diagnostics Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 2,500 2,478 2,478 Term Loan 14.25 % Prime 6.00 % 9.25 % - 3.50 % June 1, 2026 5,000 4,957 4,957 BrightInsight, Inc. (2)(12) Software Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 7,000 6,670 6,670 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,455 3,455 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % August 1, 2027 3,500 3,455 3,455 Term Loan 13.75 % Prime 5.50 % 9.50 % - 3.00 % April 1, 2028 2,750 2,706 2,706 SafelyYou, Inc. (2)(12) Software Term Loan 11.50 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,635 4,635 Term Loan 11.50 % Prime 3.25 % 11.00 % - 5.00 % June 1, 2027 5,000 4,905 4,905 Total Non-Affiliate Debt Investments — Healthcare information and services 35,739 35,739 Total Non- Affiliate Debt Investments 700,162 683,309 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrant Investments — 7.2% Non-Affiliate Warrants — Life Science — 1.8% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 26,444 311 — Castle Creek Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 7,404 212 338 Corvium, Inc. (2)(12) Biotechnology Preferred Stock Warrant 661,956 53 — Emalex Biosciences, Inc. (2)(12) Biotechnology Preferred Stock Warrant 110,402 175 264 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 23,196 126 — Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 47,452 366 — Imunon, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 19,671 66 — IMV Inc. (2)(5)(12)(15) Biotechnology Common Stock Warrant 39,774 67 — KSQ Therapeutics, Inc. (2) (12) Biotechnology Preferred Stock Warrant 48,076 50 58 Mustang Bio, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 16,611 146 — Native Microbials, Inc (2)(12) Biotechnology Preferred Stock Warrant 103,679 64 163 PDS Biotechnology Corporation (2)(5)(12) Biotechnology Common Stock Warrant 299,848 160 651 Provivi, Inc. (2)(12) Biotechnology Preferred Stock Warrant 293,488 442 173 Stealth Biotherapeutics Inc. (2)(12) Biotechnology Common Stock Warrant 318,181 264 125 vTv Therapeutics Inc. (2)(5)(12) Biotechnology Common Stock Warrant 95,293 44 — Xeris Pharmaceuticals, Inc. (2)(5)(12) Biotechnology Common Stock Warrant 126,000 72 58 AccuVein Inc. (2)(12) Medical Device Common Stock Warrant 1,175 24 — Aerin Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,818,183 66 1,204 Aerobiotix, LLC (2)(12) Medical Device Preferred Stock Warrant 27,330 48 32 Canary Medical Inc. (2)(12) Medical Device Preferred Stock Warrant 12,153 86 1,319 Ceribell, Inc. (2)(12) Medical Device Preferred Stock Warrant 145,483 69 211 Cognoa, Inc. (2)(12) Medical Device Preferred Stock Warrant 4,106,174 145 178 Conventus Orthopaedics, Inc. (2)(12) Medical Device Preferred Stock Warrant 7,972,222 221 229 CSA Medical, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,375,727 150 154 CVRx, Inc. (2)(5)(12) Medical Device Common Stock Warrant 47,410 76 278 Infobionic, Inc. (2)(12) Medical Device Preferred Stock Warrant 317,647 124 52 Magnolia Medical Technologies, Inc. (2)(12) Medical Device Preferred Stock Warrant 809,931 194 390 Meditrina, Inc. (2)(12) Medical Device Preferred Stock Warrant 233,993 83 101 Robin Healthcare, Inc. (2)(12) Medical Device Preferred Stock Warrant 86,066 16 16 Scientia Vascular, Inc (2)(12) Medical Device Preferred Stock Warrant 27,036 57 64 Sonex Health, Inc. (2)(12) Medical Device Preferred Stock Warrant 1,098,805 98 125 VERO Biotech LLC (2)(12) Medical Device Preferred Stock Warrant 408 53 1 Swift Health Systems Inc. (2)(12) Medical Device Preferred Stock Warrant 135,484 71 84 Total Non-Affiliate Warrants — Life Science 4,199 6,268 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Sustainability — 0.2% Aerofarms, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 201,537 61 — LiquiGlide, Inc. (2)(12) Other Sustainability Common Stock Warrant 61,359 36 56 Nexii Building Solutions, Inc. (2)(12)(15) Other Sustainability Common Stock Warrant 213,746 490 — Soli Organic, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 681 214 365 Temperpack Technologies, Inc. (2)(12) Other Sustainability Preferred Stock Warrant 34,604 121 266 Total Non-Affiliate Warrants — Sustainability 922 687 Non-Affiliate Warrants — Technology — 4.6% Axiom Space, Inc. (2)(12) Communications Common Stock Warrant 1,991 45 67 Intelepeer Holdings, Inc. (2)(12) Communications Preferred Stock Warrant 2,936,535 138 3,272 PebblePost, Inc. (2)(12) Communications Preferred Stock Warrant 598,850 92 139 Alula Holdings, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 20,000 93 — Aterian, Inc. (2)(5)(12) Consumer-related Technologies Common Stock Warrant 76,923 195 — Better Place Forests Co. (12) Consumer-related Technologies Preferred Stock Warrant 10,690 26 — Caastle, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 268,591 67 1,058 CAMP NYC, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 75,997 22 30 Clara Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 46,745 30 126 Divergent Technologies, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 37,294 95 276 Havenly, Inc. (2)(12) Consumer-related Technologies Common Stock Warrant 1,312,500 2,947 2,677 MyForest Foods Co. (2)(12) Consumer-related Technologies Preferred Stock Warrant 250 29 61 NextCar Holding Company, Inc. (2)(12) Consumer-related Technologies Preferred and Common Stock Warrant 1,237,370 197 — Optoro, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 11,550 182 182 Primary Kids, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 553,778 57 595 Quip NYC Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 6,191 325 536 Unagi, Inc. (2)(12) Consumer-related Technologies Preferred Stock Warrant 171,081 32 — Updater, Inc.(2)(12) Consumer-related Technologies Common Stock Warrant 108,333 34 11 CPG Beyond, Inc. (2)(12) Data Storage Preferred Stock Warrant 500,000 242 912 Silk, Inc. (2)(12) Data Storage Preferred Stock Warrant 394,110 175 148 Global Worldwide LLC (2)(12) Internet and Media Preferred Stock Warrant 245,810 75 63 Rocket Lawyer Incorporated (2)(12) Internet and Media Preferred Stock Warrant 261,721 92 360 Skillshare, Inc. (2)(12) Internet and Media Preferred Stock Warrant 139,074 162 1,211 Liqid, Inc. (2)(12) Networking Preferred Stock Warrant 344,102 364 247 Halio, Inc. (2)(12) Power Management Preferred Stock Warrant 5,002,574 1,585 2,898 Avalanche Technology, Inc. (2)(12) Semiconductors Preferred and Common Stock Warrant 6,081 57 — BriteCore Holdings, Inc. (2)(12) Software Preferred Stock Warrant 77,828 21 70 Dropoff, Inc. (2)(12) Software Common Stock Warrant 516,732 455 169 E La Carte, Inc. (2)(5)(12) Software Common Stock Warrant 147,361 60 121 Everstream Holdings, LLC (2)(12) Software Preferred Stock Warrant 350,000 70 70 Kodiak Robotics, Inc. (2)(12) Software Preferred Stock Warrant 639,918 273 299 Lemongrass Holdings, Inc. (2)(12) Software Preferred Stock Warrant 101,308 34 41 Lotame Solutions, Inc. (2)(12) Software Preferred Stock Warrant 71,305 21 57 Lytics, Inc. (2)(12) Software Preferred Stock Warrant 85,543 46 18 Noodle Partners, Inc. (2)(12) Software Preferred Stock Warrant 84,037 116 120 Reputation Institute, Inc. (2)(12) Software Preferred Stock Warrant 3,731 56 50 Revinate Holdings, Inc. (2)(12) Software Preferred Stock Warrant 682,034 44 101 SIGNiX, Inc. (12) Software Preferred Stock Warrant 186,235 225 — Slingshot Aerospace, Inc. (2)(12) Software Preferred Stock Warrant 309,208 123 135 Supply Network Visibility Holdings LLC (2)(12) Software Preferred Stock Warrant 682 64 140 Topia Mobility, Inc. (2)(12) Software Preferred Stock Warrant 3,049,607 138 — Viken Detection Corporation (2)(12) Software Preferred Stock Warrant 345,443 120 120 xAd, Inc. (2)(12) Software Preferred Stock Warrant 4,343,348 177 12 Total Non-Affiliate Warrants — Technology 9,401 16,392 Cost of Fair Portfolio Company (1)(3) Sector Type of Investment (7) Number of Shares Investments (6)(9) Value (9) Non-Affiliate Warrants — Healthcare information and services — 0.6% Hound Labs, Inc (2) (12) Diagnostics Preferred Stock Warrant 171,370 47 56 Kate Farms, Inc. (2)(12) Other Healthcare Preferred Stock Warrant 82,965 101 1,374 BrightInsight, Inc. (2)(12) Software Preferred Stock Warrant 85,066 167 181 Medsphere Systems Corporation (2)(12) Software Preferred Stock Warrant 7,097,792 61 362 SafelyYou, Inc. (2)(12) Software Preferred Stock Warrant 150,353 163 163 Total Non-Affiliate Warrants — Healthcare information and services 539 2,136 Total Non-Affiliate Warrants 15,061 25,483 Non-Affiliate Other Investments — 0.4% Lumithera, Inc. (12) Medical Device Royalty Agreement 1,200 1,100 ZetrOZ, Inc. (12) Medical Device Royalty Agreement — 200 Total Non-Affiliate Other Investments 1,200 1,300 Non-Affiliate Equity — 1.2% Castle Creek Biosciences, Inc. (12) Biotechnology Common Stock 1,162 250 250 Emalex Biosciences, Inc. (12) Biotechnology Common Stock 32,831 356 356 Getaround, Inc. (2)(5) Consumer-related Technologies Common Stock 87,082 253 30 NextCar Holding Company, Inc. (2)(12) Technology Preferred Stock 2,688,971 89 89 SnagAJob.com, Inc. (12) Consumer-related Technologies Common Stock 82,974 9 83 Lumithera, Inc. (12) Medical Device Common Stock 392,651 2,000 1,700 Tigo Energy, Inc. (5)(12) Other Sustainability Common Stock 5,205 111 97 Branded Online, Inc. (2)(5) Software Common Stock 5,398 1,079 8 Decisyon, Inc. (12) Software Preferred Stock 280,000 2,800 1,281 Lotame, Inc. (12) Software Preferred Stock 66,127 2 193 Axiom Space, Inc. (12) Technology Preferred Stock 1,810 261 306 Total Non-Affiliate Equity 7,210 4,393 Total Non-Affiliate Portfolio Investment Assets $ 723,633 $ 714,485 Non-controlled Affiliate Investments — 0.3% Non-controlled Affiliate Equity — Life Science — 0.3% Cadrenal Therapeutics, Inc. (5) Biotechnology Common Stock 600,000 — 906 Total Non-Controlled Affiliate Equity $ — 906 Total Non-Controlled Affiliate Portfolio Investment Assets $ — 906 Total Portfolio Investment Assets — 201.4% $ 723,633 $ 715,391 Portfolio Company (1)(3) Sector Type of Investment (7) Cash Rate (4) Index Margin Floor Ceiling ETP (10) Maturity Date Principal Amount Cost of Investments (6)(9) Fair Value (9) Non-Affiliate Investments — 226.1% Non-Affiliate Debt Investments — 215.5% Non-Affiliate Debt Investments — Life Science — 99.7% Avalo Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 $ 2,885 $ 2,853 $ 2,777 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 2,885 2,823 2,750 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % January 1, 2025 1,442 1,411 1,374 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % February 1, 2025 2,885 2,821 2,748 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Term Loan 13.75 % Prime 6.25 % 9.50 % - 3.00 % April 1, 2025 1,442 1,408 1,371 Castle Creek Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,891 4,891 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 5,000 4,963 4,963 Term Loan 12.50 % Prime 6.05 % 9.55 % 13.50 % 5.50 % May 1, 2026 3,000 2,978 2,978 Emalex Biosciences, Inc. (2)(12) Biotechnology Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,962 1,962 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % June 1, 2024 1,979 1,963 1,963 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % November 1, 2025 5,000 4,923 4,923 Term Loan 12.07 % Libor 7.90 % 9.75 % - 5.00 % May 1, 2026 5,000 4,912 4,912 Evelo Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 10,000 9,872 9,872 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 15,000 14,808 14,808 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 6,000 5,923 5,923 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 Term Loan 11.75 % Prime 4.75 % 11.00 % - 4.25 % January 1, 2028 4,000 3,949 3,949 F-Star Therapeutics, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % April 1, 2025 2,500 2,476 2,476 Term Loan 13.25 % Prime 6.25 % 9.50 % - 4.00 % July 1, 2025 2,500 2,473 2,473 Greenlight Biosciences, Inc. (2)(5)(12) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 5,000 4,857 4,857 Term Loan 13.25 % Prime 5.75 % 9.00 % - 3.00 % July 1, 2025 2,500 2,430 2,430 IMV Inc. (2)(5)(12)(14) Biotechnology Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 5,000 4,946 4,946 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % July 1, 2025 2,500 2,473 2,473 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 Term Loan 13.25 % Prime 5.75 % 9.00 % - 5.00 % January 1, 2026 5,000 4,947 4,947 KSQ Therapeutics, Inc. (2) (12) Biotechnology Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,077 6,077 Term Loan 12.25 % Prime 4.75 % 8.50 % - 5.50 % May 1, 2027 6,250 6,177 6,177 Native Microbials, Inc (2) (12) Biotechnology Term Loan 12.75 % Prime 5.25 % 8.50 % - 5.00 % No |
Note 4 - Investments (Tables)
Note 4 - Investments (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Investment Holdings, Schedule of Investments [Table Text Block] | June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Investments Debt $ 700,162 $ 683,309 $ 701,074 $ 686,458 Warrants 15,061 25,483 14,790 29,712 Other 1,200 1,300 1,200 1,300 Equity 7,210 5,299 4,184 2,556 Total investments $ 723,633 $ 715,391 $ 721,248 $ 720,026 June 30, 2023 December 31, 2022 Cost Fair Value Cost Fair Value (In thousands) Life Science Biotechnology $ 182,489 $ 174,598 $ 193,372 $ 195,006 Medical Device 128,203 130,634 132,803 135,960 Technology Communications 22,922 26,170 22,892 26,176 Consumer-Related 113,903 108,275 121,961 114,050 Data Storage 417 1,060 476 1,316 Internet and Media 329 1,634 329 1,159 Networking 8,391 8,274 11,831 11,710 Power Management 1,585 2,898 1,585 2,610 Semiconductors 57 — 56 — Software 142,853 139,934 120,157 118,716 Sustainability Energy Efficiency 111 97 8 27 Other Sustainability 86,095 83,942 84,633 85,524 Healthcare Information and Services Diagnostics 9,960 9,969 9,851 9,858 Other 101 1,374 7,559 3,870 Software 26,217 26,532 13,735 14,044 Total investments $ 723,633 $ 715,391 $ 721,248 $ 720,026 |
Note 5 - Transactions With Af_2
Note 5 - Transactions With Affiliated Companies (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Investments in and Advances to Affiliates [Table Text Block] | Three months ended June 30, 2023 Fair value at Transfers Net Fair value at Portfolio March 31, in/(out) at Dividends unrealized Net realized June 30, Company 2023 Purchases Sales fair value declared gain/(loss) gain/(loss) 2023 (In thousands) Cadrenal Therapeutics, Inc. 846 — — — — 60 — 906 Total non-controlled affiliates $ 846 $ — $ — $ — $ — $ 60 $ — $ 906 Six months ended June 30, 2023 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized June 30, Company 2022 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2023 (In thousands) Cadrenal Therapeutics, Inc. $ — $ — $ — $ — $ — $ 906 $ — $ 906 Total non-controlled affiliates $ — $ — $ — $ — $ — $ 906 $ — $ 906 Three months ended June 30, 2022 Fair value at Transfers Net Fair value at Portfolio March 31, in/(out) at Dividends unrealized Net realized June 30, Company 2022 Purchases Sales fair value declared gain/(loss) gain/(loss) 2022 (In thousands) HESP LLC — — (200 ) — — 1,400 (1,200 ) — Total controlled affiliates $ — $ — $ (200 ) $ — $ — $ 1,400 $ (1,200 ) $ — Six months ended June 30, 2022 Fair value at Transfers Net Fair value at Portfolio December 31, Principal in/(out) at Discount unrealized Net realized June 30, Company 2021 Purchases Payments fair value accretion gain/(loss) gain/(loss) 2022 (In thousands) HESP LLC — — (250 ) — — 1,450 (1,200 ) — Total controlled affiliates $ — $ — $ (250 ) $ — $ — $ 1,450 $ (1,200 ) $ — |
Note 6 - Fair Value (Tables)
Note 6 - Fair Value (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Fair Value, Assets Measured on Recurring Basis [Table Text Block] | June 30, 2023 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 683,309 $ 683,309 Warrant investments — 1,107 24,376 25,483 Other investments — — 1,300 1,300 Equity investments 1,040 — 4,259 5,299 Total investments $ 1,040 $ 1,107 $ 713,244 $ 715,391 December 31, 2022 Level 1 Level 2 Level 3 Total (In thousands) Debt investments $ — $ — $ 686,458 $ 686,458 Warrant investments — 3,567 26,145 29,712 Other investments — — 1,300 1,300 Equity investments 140 — 2,416 2,556 Total investments $ 140 $ 3,567 $ 716,319 $ 720,026 |
Fair Value Measurement Inputs and Valuation Techniques [Table Text Block] | June 30, 2023 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 611,524 Discounted Expected Future Cash Flows Hypothetical Market Yield 11% – 24% 14 % 71,785 Multiple Probability Weighted Cash Flow Model Probability Weighting 5% - 100% 50 % Warrant investments 24,314 Black-Scholes Valuation Model Price Per Share 0.000 –1,89999 $ 59.21 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 62 Expected Proceeds Price Per Share $0.25 $ 0.25 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 4,259 Last Equity Financing Price Per Share $0.03– $215.03 $ 27.56 Total Level 3 investments $ 713,244 December 31, 2022 Fair Valuation Techniques/ Unobservable Weighted Investment Type Value Methodologies Input Range Average(1) (Dollars in thousands, except per share data) Debt investments $ 669,617 Discounted Expected Future Cash Flows Hypothetical Market Yield 3% – 22% 14 % 16,545 Multiple Probability Weighted Cash Flow Model Probability Weighting 10% - 75% 31 % 296 Convertible Note Analysis Price Per Share $168.93 $ 168.93 Warrant investments 26,145 Black-Scholes Valuation Model Price Per Share 0.000 –1.89999 $ 58.52 Average Industry Volatility 28% 28 % Marketability Discount 20% 20 % Estimated Time to Exit (in years) 1 to 5 3 Other investments 1,300 Multiple Probability Weighted Cash Flow Model Discount Rate 25% 25 % Probability Weighting 100% 100 % Equity investments 2,416 Last Equity Financing Price Per Share $1.00– $215.03 $ 26.93 Total Level 3 investments $ 716,319 |
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block] | Three months ended June 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 684,554 $ 24,638 $ 2,915 $ 1,300 $ 713,407 Purchase of investments 40,545 — — — 40,545 Warrants and equity received and classified as Level 3 — 515 89 — 604 Principal payments received on investments (24,740 ) — — — (24,740 ) Payment-in-kind interest on investments 950 — — — 950 Proceeds from sale of investments (528 ) (1,458 ) — — (1,986 ) Net realized (loss) gain on investments (17,672 ) 1,287 (127 ) — (16,512 ) Unrealized appreciation (depreciation) included in earnings 2,118 (606 ) (1,307 ) — 205 Transfer out of Level 3 — — (111 ) — (111 ) Transfer out of debt investments (2,800 ) — 2,800 — — Other 882 — — — 882 Level 3 assets, end of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Three months ended June 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 492,194 $ 21,645 $ 203 $ 200 $ 514,242 Purchase of investments 158,985 — 250 — 159,235 Warrants received and classified as Level 3 — 669 — — 669 Principal payments received on investments (73,096 ) — — (232 ) (73,328 ) Proceeds from sale of investments (21,750 ) (396 ) — — (22,146 ) Net realized gain (loss) on investments — 239 — (1,168 ) (929 ) Unrealized (depreciation) appreciation included in earnings (3,797 ) 3,010 — 1,400 613 Other (976 ) — — — (976 ) Level 3 assets, end of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 Six months ended June 30, 2023 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 686,458 $ 26,145 $ 2,416 $ 1,300 $ 716,319 Purchase of investments 87,543 — 10 — 87,553 Warrants and equity received and classified as Level 3 — 656 89 — 745 Principal payments received on investments (64,496 ) — — — (64,496 ) Payment-in-kind interest on investments 2,154 — — — 2,154 Proceeds from sale of investments (7,036 ) (1,470 ) — — (8,506 ) Net realized (loss) gain on investments (17,665 ) 1,146 (127 ) — (16,646 ) Unrealized depreciation included in earnings (2,448 ) (2,096 ) (1,118 ) — (5,662 ) Transfer out of Level 3 — — (111 ) — (111 ) Transfer out of debt investments (3,095 ) (5 ) 3,100 — — Other 1,894 — — — 1,894 Level 3 assets, end of period $ 683,309 $ 24,376 $ 4,259 $ 1,300 $ 713,244 Six months ended June 30, 2022 Debt Warrant Equity Other Investments Investments Investments Investments Total (In thousands) Level 3 assets, beginning of period $ 437,317 $ 19,837 $ 203 $ 200 $ 457,557 Purchase of investments 253,470 — 250 — 253,720 Warrants received and classified as Level 3 — 1,477 — — 1,477 Principal payments received on investments (87,191 ) — — (282 ) (87,473 ) Proceeds from sale of investments (43,000 ) (426 ) — — (43,426 ) Net realized gain (loss) on investments — 269 — (1,168 ) (899 ) Unrealized (depreciation) appreciation included in earnings (6,967 ) 4,010 — 1,450 (1,507 ) Other (2,069 ) — — — (2,069 ) Level 3 assets, end of period $ 551,560 $ 25,167 $ 453 $ 200 $ 577,380 |
Note 7 - Borrowings (Tables)
Note 7 - Borrowings (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Schedule of Debt [Table Text Block] | June 30, 2023 December 31, 2022 Total Balance Unused Total Balance Unused Commitment Outstanding Commitment Commitment Outstanding Commitment (In thousands) Key Facility $ 150,000 $ — $ 150,000 $ 125,000 $ 5,000 $ 120,000 NYL Facility 250,000 176,750 73,250 200,000 176,750 23,250 2019 Asset-Backed Notes 30,807 30,807 — 42,573 42,573 — 2022 Asset-Backed Notes 100,000 100,000 — 100,000 100,000 — 2027 Notes 57,500 57,500 — 57,500 57,500 — 2026 Notes 57,500 57,500 — 57,500 57,500 — Total before debt issuance costs 645,807 422,557 223,250 582,573 439,323 143,250 Unamortized debt issuance costs attributable to term borrowings — (4,541 ) — — (5,245 ) — Total borrowings outstanding, net $ 645,807 $ 418,016 $ 223,250 $ 582,573 $ 434,078 $ 143,250 |
Note 8 - Financial Instrument_2
Note 8 - Financial Instruments With Off-balance-sheet Risk (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Schedule of Fair Value, off-Balance-Sheet Risks [Table Text Block] | June 30, 2023 December 31, 2022 Fair Value of Fair Value of Unfunded Unfunded Principal Commitment Principal Commitment Balance Liability Balance Liability (In thousands) (In thousands) BrightInsight, Inc. $ 18,250 $ 241 $ 21,000 $ 278 Britecore Holdings, Inc. — — 5,000 66 Castle Creek Biosciences 4,000 72 4,000 72 Divergent Technologies, Inc. 11,250 118 22,500 236 Engage3, LLC — — 8,000 40 Groundspeed Analytics, Inc. — — 15,000 150 Hound Labs, Inc. — — 7,500 88 KSQ Therapeutics, Inc. — — 10,000 100 Lytics, Inc. 4,000 52 5,000 65 Native Microbials, Inc. — — 7,500 72 Nexii Building Solutions, Inc. 1,488 — — — Noodle Partners, Inc. 10,000 123 — — Optoro, Inc. 11,250 — 15,000 38 PDS Biotechnology Corporation 10,000 158 10,000 158 Robin Healthcare, Inc. 5,000 50 10,000 100 SafelyYou, Inc. 20,000 270 — — Scientia Vascular, Inc. 5,000 55 10,000 110 STS (ABC), LLC 140 — — — Slingshot Aerospace, Inc. 5,000 64 5,000 64 Supply Network Visibility Holdings, LLC 10,000 35 — — Swift Health Systems Inc. 11,500 — 25,500 105 Temperpack Technologies, Inc. 6,500 14 9,000 19 Viken Detection Corporation 10,000 160 — — Total $ 143,378 $ 1,412 $ 190,000 $ 1,761 |
Note 10 - Distributions (Tables
Note 10 - Distributions (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Dividends Declared [Table Text Block] | DRIP DRIP Date Amount Cash Shares Share Declared Record Date Payment Date Per Share Distribution Issued Value (In thousands, except share and per share data) Six Months Ended June 30, 2023 4/28/2023 8/17/23 9/15/23 $ 0.11 $ — — $ — 4/28/2023 7/18/23 8/15/23 0.11 — — — 4/28/2023 6/16/23 7/14/23 0.11 3,434 7,424 96 2/23/2023 5/18/23 6/14/23 0.11 3,087 7,128 86 2/23/2023 4/18/23 5/16/23 0.11 3,068 6,705 84 2/23/2023 3/17/23 4/14/23 0.11 3,035 6,894 81 $ 0.66 $ 12,624 28,151 $ 347 Year Ended December 31, 2022 10/28/2022 2/17/23 3/15/23 $ 0.11 $ 3,040 6,764 $ 75 10/28/2022 1/18/23 2/15/23 0.11 3,021 5,754 74 10/28/2022 12/19/22 1/13/23 0.11 2,978 5,618 69 10/28/2022 11/17/22 12/15/22 0.05 1,319 2,171 27 7/29/2022 11/17/22 12/15/22 0.10 2,638 4,341 57 7/29/2022 10/18/22 11/15/22 0.10 2,580 4,621 60 7/29/2022 9/19/22 10/14/22 0.10 2,558 7,703 81 4/29/2022 8/18/22 9/15/22 0.10 2,528 4,925 60 4/29/2022 7/19/22 8/16/22 0.10 2,484 3,939 55 4/29/2022 6/17/22 7/15/22 0.10 2,434 4,286 51 2/25/2022 5/18/22 6/15/22 0.10 2,378 4,428 50 2/25/2022 4/19/22 5/16/22 0.10 2,349 4,088 49 2/25/2022 3/18/22 4/14/22 0.10 2,352 3,221 46 $ 1.28 $ 32,659 61,859 $ 754 Ex-Dividend Date Record Date Payment Date Distributions Declared September 18, 2023 September 19, 2023 October 16, 2023 $ 0.11 October 17, 2023 October 18, 2023 November 15, 2023 $ 0.11 November 16, 2023 November 17, 2023 December 15, 2023 $ 0.11 |
Note 11 - Financial Highlights
Note 11 - Financial Highlights (Tables) | 6 Months Ended |
Jun. 30, 2023 | |
Notes Tables | |
Investment Company, Financial Highlights [Table Text Block] | Six months ended June 30, 2023 2022 (In thousands, except share and per share data) Per share data: Net asset value at beginning of period $ 11.47 $ 11.56 Net investment income 1.00 0.62 Realized loss (0.58 ) (0.04 ) Unrealized depreciation on investments (0.23 ) (0.10 ) Net increase in net assets resulting from operations 0.19 0.48 Distributions declared (1) (0.66 ) (0.60 ) From net investment income (0.66 ) (0.60 ) From net realized gain on investments — — Return of capital — — Other (2) 0.07 0.25 Net asset value at end of period $ 11.07 $ 11.69 Per share market value, beginning of period $ 11.60 $ 15.92 Per share market value, end of period $ 12.08 $ 11.54 Total return based on a market value (3) 9.8 % (23.7 )% Shares outstanding at end of period 32,096,259 24,857,104 Ratios to average net assets: Expenses without incentive value (4) 14.2 % 10.8 % Incentive fees (4) 1.9 % 2.6 % Net expenses (4) 16.1 % 13.4 % Net investment income with incentive fees (4) 17.5 % 10.5 % Net assets at the end of the period $ 355,419 $ 290,605 Average net asset value $ 331,850 $ 271,976 Average debt per share $ 15.11 $ 12.81 Portfolio turnover ratio 7.6 % (5) 11.3 % (5) |
Consolidated Schedule of Inve_3
Consolidated Schedule of Investments (Unaudited) (Details Textual) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Aug. 13, 2019 |
Debt Instrument, Face Amount | $ 645,807 | $ 582,573 | ||
Percentage of Nonqualifying Assets on a Cost Basis | 6.40% | 6.50% | ||
Percentage of Nonqualifying Assets on a Fair Value Basis | 5.30% | 6.60% | ||
Asset-backed Notes 2019 [Member] | ||||
Debt Instrument, Face Amount | $ 30,807 | $ 42,573 | $ 160,000 | |
Asset-backed Notes 2019 [Member] | Affiliated Entity [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 | |||
Asset-backed Notes 2022 [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 | $ 100,000 | $ 157,800 | |
Asset-backed Notes 2022 [Member] | Affiliated Entity [Member] | ||||
Debt Instrument, Face Amount | $ 100,000 |
Consolidated Schedule of Inve_4
Consolidated Schedule of Investments (Unaudited) - Investments (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Mar. 31, 2023 | Dec. 31, 2022 |
Investments at cost | $ 723,633 | $ 721,248 | |
Investments at fair value | 715,391 | 720,026 | |
Investment, Unaffiliated Issuer [Member] | |||
Investments at cost | 723,633 | 721,248 | |
Investments at fair value | 714,485 | 720,026 | |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
Investments at cost | 700,162 | 701,074 | |
Investments at fair value | 683,309 | 686,458 | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 15,061 | 14,790 | |
Investments at fair value | 25,483 | 29,712 | |
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | |||
Investments at cost | 1,200 | 1,200 | |
Investments at fair value | 1,300 | 1,300 | |
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member] | |||
Investments at cost | 7,210 | 4,184 | |
Investments at fair value | 4,393 | 2,556 | |
Investment, Affiliated Issuer, Noncontrolled [Member] | |||
Investments at cost | 0 | 0 | |
Investments at fair value | 906 | $ 846 | 0 |
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | |||
Investments at cost | 0 | ||
Investments at fair value | 906 | ||
Biotechnology Sector [Member] | |||
Investments at cost | 182,489 | 193,372 | |
Investments at fair value | 174,598 | 195,006 | |
Medical Device Sector [Member] | |||
Investments at cost | 128,203 | 132,803 | |
Investments at fair value | 130,634 | 135,960 | |
Software Sector [Member] | |||
Investments at cost | 142,853 | 120,157 | |
Investments at fair value | 139,934 | 118,716 | |
Other Sustainability Sector [Member] | |||
Investments at cost | 86,095 | 84,633 | |
Investments at fair value | 83,942 | 85,524 | |
Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
Investments at cost | 85,173 | ||
Investments at fair value | 83,255 | ||
Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 922 | ||
Investments at fair value | $ 687 | ||
Number of Shares (in shares) | |||
Diagnostics Sector [Member] | |||
Investments at cost | $ 9,960 | 9,851 | |
Investments at fair value | 9,969 | 9,858 | |
Communications Sector [Member] | |||
Investments at cost | 22,922 | 22,892 | |
Investments at fair value | 26,170 | 26,176 | |
Other Healthcare Sector [Member] | |||
Investments at cost | 101 | 7,559 | |
Investments at fair value | 1,374 | 3,870 | |
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
Investments at cost | 302,687 | 318,172 | |
Investments at fair value | 294,452 | 317,568 | |
Life Science [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 4,197 | ||
Investments at fair value | $ 9,792 | ||
Number of Shares (in shares) | |||
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
Investments at cost | 35,739 | $ 30,729 | |
Investments at fair value | 35,739 | 25,819 | |
Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 539 | 416 | |
Investments at fair value | $ 2,136 | 1,953 | |
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
ETP | |||
Investments at cost | $ 276,563 | 268,468 | |
Investments at fair value | 269,863 | 259,366 | |
Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 9,401 | 9,249 | |
Investments at fair value | 16,392 | 16,148 | |
Data Storage Sector [Member] | |||
Investments at cost | 417 | 476 | |
Investments at fair value | 1,060 | 1,316 | |
Internet and Media Sector [Member] | |||
Investments at cost | 329 | 329 | |
Investments at fair value | 1,634 | 1,159 | |
Networking Sector [Member] | |||
Investments at cost | 8,391 | 11,831 | |
Investments at fair value | 8,274 | 11,710 | |
Power Management Sector [Member] | |||
Investments at cost | 1,585 | 1,585 | |
Investments at fair value | 2,898 | 2,610 | |
Semiconductor Sector [Member] | |||
Investments at cost | 57 | 56 | |
Investments at fair value | 0 | 0 | |
Life Science Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 4,199 | ||
Investments at fair value | 6,268 | ||
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | |||
Investments at cost | 83,705 | ||
Investments at fair value | 83,705 | ||
Sustainability Segment [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | 928 | ||
Investments at fair value | $ 1,819 | ||
Number of Shares (in shares) | |||
Software, Healthcare Information and Service [Member] | |||
Investments at cost | 26,217 | $ 13,735 | |
Investments at fair value | $ 26,532 | $ 14,044 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Jan. 01, 2025 | Jan. 01, 2025 | |
Principal Amount | $ 2,055 | $ 2,885 | |
Investments at cost | 2,011 | 2,853 | |
Investments at fair value | $ 1,938 | $ 2,777 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Jan. 01, 2025 | Jan. 01, 2025 | |
Principal Amount | $ 2,028 | $ 2,885 | |
Investments at cost | 1,982 | 2,823 | |
Investments at fair value | 1,910 | 2,750 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 311 | 311 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 26,444 | 26,442 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Jan. 01, 2025 | Jan. 01, 2025 | |
Principal Amount | $ 1,014 | $ 1,442 | |
Investments at cost | 991 | 1,411 | |
Investments at fair value | $ 955 | $ 1,374 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Feb. 01, 2025 | Feb. 01, 2025 | |
Principal Amount | $ 2,028 | $ 2,885 | |
Investments at cost | 1,980 | 2,821 | |
Investments at fair value | $ 1,907 | $ 2,748 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Feb. 01, 2025 | Feb. 01, 2025 | |
Principal Amount | $ 2,028 | $ 2,885 | |
Investments at cost | 1,980 | 2,821 | |
Investments at fair value | $ 1,907 | $ 2,748 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Apr. 01, 2025 | Apr. 01, 2025 | |
Principal Amount | $ 1,014 | $ 1,442 | |
Investments at cost | 987 | 1,408 | |
Investments at fair value | $ 951 | $ 1,371 | |
Avalo Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Apr. 01, 2025 | Apr. 01, 2025 | |
Principal Amount | $ 1,014 | $ 1,442 | |
Investments at cost | 987 | 1,408 | |
Investments at fair value | $ 951 | $ 1,371 | |
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 8.75% | 8.75% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 4,750 | $ 5,000 | |
Investments at cost | 4,680 | 4,914 | |
Investments at fair value | $ 4,680 | $ 4,914 | |
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 8.75% | 8.75% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 2,375 | $ 2,500 | |
Investments at cost | 2,338 | 2,457 | |
Investments at fair value | 2,338 | 2,457 | |
Stealth BioTherapeutics Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 264 | 264 | |
Investments at fair value | $ 125 | $ 37 | |
Number of Shares (in shares) | 318,181 | 318,181 | |
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.50% | 12.25% | |
Margin | 5.25% | 5.25% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,500 | $ 3,500 | |
Investments at cost | 3,460 | 3,349 | |
Investments at fair value | $ 3,460 | $ 3,349 | |
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.50% | 12.25% | |
Margin | 5.25% | 5.25% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,500 | $ 3,500 | |
Investments at cost | 3,460 | 3,454 | |
Investments at fair value | 3,460 | 3,454 | |
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 71 | 71 | |
Investments at fair value | $ 84 | $ 83 | |
Number of Shares (in shares) | 135,484 | 135,484 | |
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.50% | ||
Margin | 5.25% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jul. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,450 | ||
Investments at fair value | $ 3,450 | ||
Swift Health Systems Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.50% | ||
Margin | 5.25% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jul. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,450 | ||
Investments at fair value | $ 3,450 | ||
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,602 | 3,478 | |
Investments at fair value | $ 3,602 | $ 3,478 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 1,250 | $ 1,250 | |
Investments at cost | 1,240 | 1,238 | |
Investments at fair value | 1,240 | 1,238 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 95 | 56 | |
Investments at fair value | $ 276 | $ 233 | |
Number of Shares (in shares) | 37,294 | 31,966 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,720 | 3,715 | |
Investments at fair value | $ 3,720 | $ 3,715 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 1,250 | $ 1,250 | |
Investments at cost | 1,240 | 1,238 | |
Investments at fair value | $ 1,240 | $ 1,238 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,720 | 3,715 | |
Investments at fair value | $ 3,720 | $ 3,715 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 1,250 | $ 1,250 | |
Investments at cost | 1,240 | 1,238 | |
Investments at fair value | $ 1,240 | $ 1,238 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,705 | 3,698 | |
Investments at fair value | $ 3,705 | $ 3,698 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member] | |||
Cash Rate | 11.25% | 11.25% | |
Margin | 6% | 6% | |
Floor | 9.50% | 9.50% | |
Ceiling | 11.25% | 11.25% | |
ETP | 3% | 3% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,700 | 3,698 | |
Investments at fair value | $ 3,700 | $ 3,698 | |
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Nine [Member] | |||
Cash Rate | 11.25% | ||
Margin | 6% | ||
Floor | 9.50% | ||
Ceiling | 11.25% | ||
ETP | 3% | ||
Maturity Date | Apr. 01, 2028 | ||
Principal Amount | $ 3,750 | ||
Investments at cost | 3,705 | ||
Investments at fair value | $ 3,705 | ||
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Ten [Member] | |||
Cash Rate | 11.25% | ||
Margin | 6% | ||
Floor | 9.50% | ||
Ceiling | 11.25% | ||
ETP | 3% | ||
Maturity Date | Jul. 01, 2028 | ||
Principal Amount | $ 3,750 | ||
Investments at cost | 3,698 | ||
Investments at fair value | $ 3,698 | ||
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eleven [Member] | |||
Cash Rate | 11.25% | ||
Margin | 6% | ||
Floor | 9.50% | ||
Ceiling | 11.25% | ||
ETP | 3% | ||
Maturity Date | Jul. 01, 2028 | ||
Principal Amount | $ 3,750 | ||
Investments at cost | 3,698 | ||
Investments at fair value | $ 3,698 | ||
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Twelve [Member] | |||
Cash Rate | 11.25% | ||
Margin | 6% | ||
Floor | 9.50% | ||
Ceiling | 11.25% | ||
ETP | 3% | ||
Maturity Date | Jul. 01, 2028 | ||
Principal Amount | $ 1,250 | ||
Investments at cost | 1,250 | ||
Investments at fair value | $ 1,250 | ||
Divergent Technologies, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Thirteen [Member] | |||
Cash Rate | 11.25% | ||
Margin | 6% | ||
Floor | 9.50% | ||
Ceiling | 11.25% | ||
ETP | 3% | ||
Maturity Date | Jul. 01, 2028 | ||
Principal Amount | $ 1,250 | ||
Investments at cost | 1,250 | ||
Investments at fair value | $ 1,250 | ||
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.75% | 14% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 6,500 | $ 6,500 | |
Investments at cost | 6,370 | 6,347 | |
Investments at fair value | $ 6,370 | $ 6,347 | |
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.75% | 14% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 6,000 | $ 6,000 | |
Investments at cost | 5,880 | 5,859 | |
Investments at fair value | 5,880 | 5,859 | |
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 455 | ||
Investments at fair value | $ 197 | ||
Number of Shares (in shares) | 516,732 | ||
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 455 | ||
Investments at fair value | $ 169 | ||
Number of Shares (in shares) | 516,732 | ||
DropOff, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.75% | 14% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,447 | 2,436 | |
Investments at fair value | $ 2,447 | $ 2,436 | |
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.25% | ||
Margin | 5.25% | ||
Floor | 8.50% | ||
Ceiling | 0% | ||
ETP | 20% | ||
Maturity Date | Sep. 15, 2022 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,500 | ||
Investments at fair value | $ 2,500 | ||
Corinth Medtech, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.25% | ||
Margin | 5.25% | ||
Floor | 8.50% | ||
Ceiling | 0% | ||
ETP | 20% | ||
Maturity Date | Sep. 15, 2022 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,500 | ||
Investments at fair value | $ 2,500 | ||
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,710 | 3,699 | |
Investments at fair value | $ 3,585 | $ 3,699 | |
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,710 | 3,699 | |
Investments at fair value | 3,585 | 3,699 | |
Aerofarms, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 61 | 61 | |
Investments at fair value | $ 0 | $ 74 | |
Number of Shares (in shares) | 201,537 | 201,537 | |
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.25% | 13.50% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,478 | 2,385 | |
Investments at fair value | $ 2,478 | $ 2,385 | |
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.25% | 13.50% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,478 | 2,473 | |
Investments at fair value | 2,478 | 2,473 | |
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 47 | 47 | |
Investments at fair value | $ 56 | $ 54 | |
Number of Shares (in shares) | 171,370 | 159,893 | |
Hound Labs, Inc. [Member] | Diagnostics Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.25% | 13.50% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 3.50% | 3.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,957 | 4,946 | |
Investments at fair value | $ 4,957 | $ 4,946 | |
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.25% | 13% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,462 | 7,455 | |
Investments at fair value | $ 7,462 | $ 7,455 | |
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.25% | 13% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,462 | 7,455 | |
Investments at fair value | 7,462 | 7,455 | |
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 45 | 46 | |
Investments at fair value | $ 67 | $ 67 | |
Number of Shares (in shares) | 1,991 | 1,991 | |
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.25% | 13% | |
Margin | 6% | 6% | |
Floor | 9.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2026 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,462 | 7,455 | |
Investments at fair value | 7,462 | $ 7,455 | |
Axiom Space, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Convertible Debt Securities [Member] | |||
Cash Rate | 3% | ||
Maturity Date | Jul. 01, 2023 | ||
Principal Amount | $ 250 | ||
Investments at cost | 250 | ||
Investments at fair value | $ 306 | ||
Axiom Space, Inc [Member] | Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member] | |||
Investments at cost | 261 | ||
Investments at fair value | $ 306 | ||
Number of Shares (in shares) | 1,810 | ||
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,471 | 2,463 | |
Investments at fair value | $ 2,358 | $ 2,364 | |
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,471 | 2,463 | |
Investments at fair value | 2,358 | 2,364 | |
Aerobiotix, LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 48 | 48 | |
Investments at fair value | $ 32 | $ 31 | |
Number of Shares (in shares) | 27,330 | 27,330 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,899 | 4,891 | |
Investments at fair value | $ 4,899 | $ 4,891 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,971 | 4,963 | |
Investments at fair value | 4,971 | 4,963 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 212 | 214 | |
Investments at fair value | $ 338 | $ 335 | |
Number of Shares (in shares) | 7,404 | 7,404 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 3,000 | $ 3,000 | |
Investments at cost | 2,982 | 2,978 | |
Investments at fair value | $ 2,982 | $ 2,978 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,971 | 4,963 | |
Investments at fair value | $ 4,971 | $ 4,963 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,971 | 4,963 | |
Investments at fair value | $ 4,971 | $ 4,963 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 13.13% | 12.50% | |
Margin | 4.88% | 6.05% | |
Floor | 9.55% | 9.55% | |
Ceiling | 13.50% | 13.50% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 3,000 | $ 3,000 | |
Investments at cost | 2,982 | 2,978 | |
Investments at fair value | 2,982 | 2,978 | |
Castle Creek Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | 250 | 250 | |
Investments at fair value | $ 250 | $ 250 | |
Number of Shares (in shares) | 1,162 | 1,162 | |
LiquiGlide, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 36 | $ 39 | |
Investments at fair value | $ 56 | $ 55 | |
Number of Shares (in shares) | 61,359 | 61,539 | |
Kate Farms, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 101 | $ 102 | |
Investments at fair value | $ 1,374 | $ 1,370 | |
Number of Shares (in shares) | 82,965 | 82,965 | |
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.34% | ||
Margin | 5.09% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jan. 01, 2024 | ||
Principal Amount | $ 875 | ||
Investments at cost | 867 | ||
Investments at fair value | $ 867 | ||
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.34% | ||
Margin | 5.09% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jan. 01, 2024 | ||
Principal Amount | $ 58 | ||
Investments at cost | 58 | ||
Investments at fair value | 58 | ||
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 150 | $ 153 | |
Investments at fair value | $ 154 | $ 150 | |
Number of Shares (in shares) | 1,375,727 | 1,375,727 | |
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.34% | ||
Margin | 5.09% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Mar. 01, 2024 | ||
Principal Amount | $ 1,200 | ||
Investments at cost | 1,191 | ||
Investments at fair value | 1,191 | ||
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member] | |||
Cash Rate | 12.37% | ||
Margin | 8.20% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jan. 01, 2024 | ||
Principal Amount | $ 1,625 | ||
Investments at cost | 1,610 | ||
Investments at fair value | $ 1,610 | ||
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member] | |||
Cash Rate | 12.37% | ||
Margin | 8.20% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jan. 01, 2024 | ||
Principal Amount | $ 108 | ||
Investments at cost | 107 | ||
Investments at fair value | $ 107 | ||
CSA Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member] | |||
Cash Rate | 12.37% | ||
Margin | 8.20% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Mar. 01, 2024 | ||
Principal Amount | $ 2,000 | ||
Investments at cost | 1,983 | ||
Investments at fair value | 1,983 | ||
Intelepeer Holdings, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 138 | 139 | |
Investments at fair value | $ 3,272 | $ 3,265 | |
Number of Shares (in shares) | 2,936,535 | 2,936,535 | |
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4.50% | 4.50% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,723 | 3,678 | |
Investments at fair value | $ 3,723 | $ 3,678 | |
Engage3, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4.50% | 4.50% | |
Maturity Date | Jul. 01, 2027 | Jul. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,723 | 3,718 | |
Investments at fair value | 3,723 | 3,718 | |
Corvium, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 53 | 53 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 661,956 | 661,956 | |
Nexii Building Solutions, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 490 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 213,746 | ||
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 7,000 | ||
Investments at cost | 6,670 | ||
Investments at fair value | $ 6,670 | ||
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,455 | ||
Investments at fair value | 3,455 | ||
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 167 | ||
Investments at fair value | $ 181 | ||
Number of Shares (in shares) | 85,066 | ||
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.75% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,455 | ||
Investments at fair value | $ 3,455 | ||
BrightInsight, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.75% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Apr. 01, 2028 | ||
Principal Amount | $ 2,750 | ||
Investments at cost | 2,706 | ||
Investments at fair value | 2,706 | ||
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.50% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 7,000 | ||
Investments at cost | 6,619 | ||
Investments at fair value | $ 6,619 | ||
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.50% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,448 | ||
Investments at fair value | 3,448 | ||
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 160 | ||
Investments at fair value | $ 170 | ||
Number of Shares (in shares) | 80,544 | ||
BrightInsight, Inc. [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.50% | ||
Margin | 5.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Aug. 01, 2027 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,448 | ||
Investments at fair value | 3,448 | ||
PebblePost, Inc [Member] | Communications Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 92 | 92 | |
Investments at fair value | $ 139 | $ 173 | |
Number of Shares (in shares) | 598,850 | 598,850 | |
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 11.75% | 10.50% | |
Margin | 3.50% | 3.50% | |
Floor | 8.25% | 8.25% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,981 | 4,973 | |
Investments at fair value | $ 4,981 | $ 4,973 | |
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 11.75% | 10.50% | |
Margin | 3.50% | 3.50% | |
Floor | 8.25% | 8.25% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,981 | 4,973 | |
Investments at fair value | 4,981 | 4,973 | |
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 69 | 69 | |
Investments at fair value | $ 211 | $ 209 | |
Number of Shares (in shares) | 145,483 | 145,483 | |
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 11.75% | 10.50% | |
Margin | 3.50% | 3.50% | |
Floor | 8.25% | 8.25% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,485 | 2,478 | |
Investments at fair value | $ 2,485 | $ 2,478 | |
Ceribell, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 11.75% | 10.50% | |
Margin | 3.50% | 3.50% | |
Floor | 8.25% | 8.25% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,485 | 2,478 | |
Investments at fair value | $ 2,485 | 2,478 | |
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.97% | ||
Margin | 4.72% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2024 | ||
Principal Amount | $ 1,979 | ||
Investments at cost | 1,968 | ||
Investments at fair value | $ 1,968 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.97% | ||
Margin | 4.72% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2024 | ||
Principal Amount | $ 1,979 | ||
Investments at cost | 1,969 | ||
Investments at fair value | 1,969 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 175 | 176 | |
Investments at fair value | $ 264 | $ 263 | |
Number of Shares (in shares) | 110,402 | 110,402 | |
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.97% | ||
Margin | 4.72% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Nov. 01, 2025 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,936 | ||
Investments at fair value | $ 4,936 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member] | |||
Cash Rate | 12.07% | ||
Margin | 7.90% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2024 | ||
Principal Amount | $ 1,979 | ||
Investments at cost | 1,962 | ||
Investments at fair value | $ 1,962 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 12.97% | ||
Margin | 4.72% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | May 01, 2026 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,930 | ||
Investments at fair value | 4,930 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member] | |||
Cash Rate | 12.07% | ||
Margin | 7.90% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2024 | ||
Principal Amount | $ 1,979 | ||
Investments at cost | 1,963 | ||
Investments at fair value | $ 1,963 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member] | |||
Cash Rate | 12.07% | ||
Margin | 7.90% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Nov. 01, 2025 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,923 | ||
Investments at fair value | 4,923 | ||
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | 356 | 356 | |
Investments at fair value | $ 356 | $ 356 | |
Number of Shares (in shares) | 32,831 | 32,831 | |
Emalex Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member] | |||
Cash Rate | 12.07% | ||
Margin | 7.90% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | May 01, 2026 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,912 | ||
Investments at fair value | $ 4,912 | ||
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 5,000 | $ 2,500 | |
Investments at cost | 4,942 | 2,463 | |
Investments at fair value | $ 4,942 | $ 2,463 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 2,500 | $ 5,000 | |
Investments at cost | 2,471 | 4,927 | |
Investments at fair value | 2,471 | 4,927 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 214 | 214 | |
Investments at fair value | $ 365 | $ 361 | |
Number of Shares (in shares) | 681 | 681 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,940 | 4,924 | |
Investments at fair value | $ 4,940 | $ 4,924 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,470 | 2,462 | |
Investments at fair value | $ 2,470 | $ 2,462 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 11.75% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,917 | 4,900 | |
Investments at fair value | $ 4,917 | $ 4,900 | |
Soli Organic, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 11.75% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.75% | 2.75% | |
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,458 | 2,450 | |
Investments at fair value | 2,458 | 2,450 | |
Medsphere Systems Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 61 | ||
Investments at fair value | $ 362 | ||
Number of Shares (in shares) | 7,097,792 | ||
Medsphere Systems Corporation [Member] | Software, Healthcare Information and Service [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 60 | ||
Investments at fair value | $ 359 | ||
Number of Shares (in shares) | 7,097,792 | ||
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Jan. 01, 2025 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,966 | ||
Investments at fair value | $ 4,966 | ||
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Jan. 01, 2025 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,966 | ||
Investments at fair value | 4,966 | ||
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 93 | 93 | |
Investments at fair value | $ 0 | $ 64 | |
Number of Shares (in shares) | 20,000 | 20,000 | |
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.75% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Jan. 01, 2025 | ||
Principal Amount | $ 3,000 | ||
Investments at cost | 2,979 | ||
Investments at fair value | $ 2,979 | ||
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.75% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Dec. 01, 2025 | ||
Principal Amount | $ 1,000 | ||
Investments at cost | 976 | ||
Investments at fair value | $ 976 | ||
Alula Holdings, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 13.75% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Feb. 01, 2026 | ||
Principal Amount | $ 1,000 | ||
Investments at cost | 977 | ||
Investments at fair value | $ 977 | ||
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 10,000 | $ 10,000 | |
Investments at cost | 9,860 | 9,826 | |
Investments at fair value | $ 9,860 | $ 9,826 | |
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 10,000 | $ 10,000 | |
Investments at cost | 9,860 | 9,826 | |
Investments at fair value | 9,860 | 9,826 | |
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 273 | 273 | |
Investments at fair value | $ 299 | $ 296 | |
Number of Shares (in shares) | 639,918 | 639,918 | |
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,930 | 4,913 | |
Investments at fair value | $ 4,930 | $ 4,913 | |
Kodiak Robotics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,930 | 4,913 | |
Investments at fair value | $ 4,930 | $ 4,913 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 10,000 | $ 10,000 | |
Investments at cost | 9,887 | 9,872 | |
Investments at fair value | $ 9,887 | $ 9,872 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 15,000 | $ 15,000 | |
Investments at cost | 14,830 | 14,808 | |
Investments at fair value | 14,830 | 14,808 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 126 | 126 | |
Investments at fair value | $ 0 | $ 125 | |
Number of Shares (in shares) | 23,196 | 463,915 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 6,000 | $ 6,000 | |
Investments at cost | 5,932 | 5,923 | |
Investments at fair value | $ 5,932 | $ 5,923 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 6,000 | $ 6,000 | |
Investments at cost | 5,932 | 5,923 | |
Investments at fair value | $ 5,932 | $ 5,923 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 4,000 | $ 4,000 | |
Investments at cost | 3,955 | 3,949 | |
Investments at fair value | $ 3,955 | $ 3,949 | |
Evelo Biosciences, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 12.50% | 11.75% | |
Margin | 4.25% | 4.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 4.25% | 4.25% | |
Maturity Date | Jan. 01, 2028 | Jan. 01, 2028 | |
Principal Amount | $ 4,000 | $ 4,000 | |
Investments at cost | 3,955 | 3,949 | |
Investments at fair value | $ 3,955 | $ 3,949 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2025 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,709 | 3,697 | |
Investments at fair value | $ 3,709 | $ 3,697 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 01, 2026 | Jun. 01, 2025 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,723 | 3,717 | |
Investments at fair value | 3,723 | 3,717 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 121 | 126 | |
Investments at fair value | $ 266 | $ 268 | |
Number of Shares (in shares) | 34,604 | 35,906 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Oct. 01, 2026 | Oct. 01, 2025 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,436 | 7,424 | |
Investments at fair value | $ 7,436 | $ 7,424 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Oct. 01, 2026 | Oct. 01, 2025 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,718 | 3,712 | |
Investments at fair value | $ 3,718 | $ 3,712 | |
Temperpack Technologies, Inc [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Oct. 01, 2026 | Oct. 01, 2025 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,718 | 3,712 | |
Investments at fair value | $ 3,718 | $ 3,712 | |
SafelyYou, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 11.50% | ||
Margin | 3.25% | ||
Floor | 11% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,635 | ||
Investments at fair value | $ 4,635 | ||
SafelyYou, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 11.50% | ||
Margin | 3.25% | ||
Floor | 11% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Jun. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,905 | ||
Investments at fair value | 4,905 | ||
SafelyYou, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 163 | ||
Investments at fair value | $ 163 | ||
Number of Shares (in shares) | 150,353 | ||
Embody, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 28% | ||
Maturity Date | Aug. 01, 2026 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,482 | ||
Investments at fair value | 2,482 | ||
Aterian, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 195 | 195 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 76,923 | 76,923 | |
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |
Principal Amount | $ 4,000 | $ 5,000 | |
Investments at cost | 3,886 | 4,857 | |
Investments at fair value | $ 3,859 | $ 4,857 | |
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |
Principal Amount | $ 2,000 | $ 2,500 | |
Investments at cost | 1,944 | 2,430 | |
Investments at fair value | 1,931 | 2,430 | |
Greenlight Biosciences, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 366 | 366 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 47,452 | 47,452 | |
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Oct. 01, 2024 | Oct. 01, 2024 | |
Principal Amount | $ 2,771 | $ 3,208 | |
Investments at cost | 2,724 | 3,143 | |
Investments at fair value | $ 2,724 | $ 3,143 | |
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Jun. 01, 2025 | Jun. 01, 2025 | |
Principal Amount | $ 1,000 | $ 1,000 | |
Investments at cost | 979 | 974 | |
Investments at fair value | 979 | 974 | |
InfoBionic, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 124 | 124 | |
Investments at fair value | $ 52 | $ 113 | |
Number of Shares (in shares) | 317,647 | 317,647 | |
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.25% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Apr. 01, 2025 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,476 | ||
Investments at fair value | $ 2,476 | ||
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.25% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Jul. 01, 2025 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,473 | ||
Investments at fair value | 2,473 | ||
F-Star Therapeutics, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 35 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 21,120 | ||
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | ||
ETP | 1.85% | 1.85% | |
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |
Principal Amount | $ 5,104 | $ 5,000 | |
Investments at cost | 5,056 | 4,951 | |
Investments at fair value | $ 3,426 | $ 3,834 | |
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.75% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 1.85% | 1.85% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,474 | 2,474 | |
Investments at fair value | 1,677 | 1,916 | |
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 26 | 26 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 10,690 | 10,690 | |
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.50% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 100% | ||
Maturity Date | Sep. 30, 2023 | ||
Principal Amount | $ 150 | ||
Investments at cost | 150 | ||
Investments at fair value | $ 102 | ||
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14.50% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 100% | ||
Maturity Date | Sep. 30, 2023 | ||
Principal Amount | $ 250 | ||
Investments at cost | 250 | ||
Investments at fair value | $ 169 | ||
Better Place Forests Co. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 14.50% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 100% | ||
Maturity Date | Sep. 30, 2023 | ||
Principal Amount | $ 250 | ||
Investments at cost | 250 | ||
Investments at fair value | $ 169 | ||
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Aug. 27, 2025 | Sep. 01, 2025 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,395 | 7,371 | |
Investments at fair value | $ 7,024 | $ 7,371 | |
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Aug. 27, 2025 | Sep. 01, 2025 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,395 | 7,371 | |
Investments at fair value | $ 7,024 | 7,371 | |
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 488 | ||
Investments at fair value | $ 1,061 | ||
Number of Shares (in shares) | 204,832 | ||
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Aug. 27, 2025 | Sep. 01, 2025 | |
Principal Amount | $ 7,500 | $ 7,500 | |
Investments at cost | 7,395 | 7,371 | |
Investments at fair value | $ 7,024 | $ 7,371 | |
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 08, 2026 | Jul. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,922 | 4,903 | |
Investments at fair value | $ 4,675 | $ 4,903 | |
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Jun. 08, 2026 | Jul. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,922 | 4,903 | |
Investments at fair value | $ 4,675 | 4,903 | |
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 15.25% | ||
Margin | 7% | ||
Floor | 10.25% | ||
Ceiling | 0% | ||
ETP | 0% | ||
Maturity Date | Sep. 30, 2023 | ||
Principal Amount | $ 680 | ||
Investments at cost | 680 | ||
Investments at fair value | $ 646 | ||
Nexii Building Solutions, Inc1 [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member] | |||
Cash Rate | 15.25% | ||
Margin | 7% | ||
Floor | 10.25% | ||
Ceiling | 0% | ||
ETP | 0% | ||
Maturity Date | Sep. 30, 2023 | ||
Principal Amount | $ 542 | ||
Investments at cost | 542 | ||
Investments at fair value | 515 | ||
Imunon, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 66 | 66 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 19,671 | 16,502 | |
Caastle, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 67 | $ 68 | |
Investments at fair value | $ 1,058 | $ 1,069 | |
Number of Shares (in shares) | 268,591 | 268,591 | |
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 8.75% | 8.75% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 5,000 | $ 2,500 | |
Investments at cost | 4,948 | 2,466 | |
Investments at fair value | $ 4,948 | $ 2,466 | |
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 8.75% | 8.75% | |
Ceiling | 0% | 0% | |
ETP | 6% | 6% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 2,500 | $ 5,000 | |
Investments at cost | 2,474 | 4,932 | |
Investments at fair value | 2,474 | 4,932 | |
Cognoa, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 145 | 148 | |
Investments at fair value | $ 178 | $ 179 | |
Number of Shares (in shares) | 4,106,174 | 775,000 | |
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |
Principal Amount | $ 5,035 | $ 5,000 | |
Investments at cost | 4,988 | 4,946 | |
Investments at fair value | $ 2,814 | $ 4,946 | |
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jul. 01, 2025 | Jul. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,476 | 2,473 | |
Investments at fair value | 1,397 | 2,473 | |
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 67 | 67 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 39,774 | 39,774 | |
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jan. 01, 2026 | Jan. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,953 | 4,947 | |
Investments at fair value | $ 2,795 | $ 4,947 | |
IMV Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jan. 01, 2026 | Jan. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,953 | 4,947 | |
Investments at fair value | 2,794 | 4,947 | |
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member] | |||
Investments at cost | 1,200 | 1,200 | |
Investments at fair value | 1,100 | 1,100 | |
Lumithera, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | 2,000 | 2,000 | |
Investments at fair value | $ 1,700 | $ 1,700 | |
Number of Shares (in shares) | 392,651 | 392,651 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.25% | 12% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,953 | 4,939 | |
Investments at fair value | $ 4,953 | $ 4,939 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.25% | 12% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,953 | 4,939 | |
Investments at fair value | 4,953 | 4,939 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 194 | 194 | |
Investments at fair value | $ 390 | $ 385 | |
Number of Shares (in shares) | 809,931 | 809,931 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.25% | 12% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,948 | 4,933 | |
Investments at fair value | $ 4,948 | $ 4,933 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.25% | 12% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,949 | 4,933 | |
Investments at fair value | $ 4,949 | $ 4,933 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 13.25% | 12.50% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,927 | 4,913 | |
Investments at fair value | $ 4,927 | $ 4,913 | |
Magnolia Medical Technologies, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 13.25% | 12.50% | |
Margin | 5% | 5% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,927 | 4,913 | |
Investments at fair value | $ 4,927 | $ 4,913 | |
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.25% | 12.50% | |
Margin | 5% | 5% | |
Floor | 5% | 5% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2027 | Mar. 01, 2027 | |
Principal Amount | $ 2,000 | $ 2,000 | |
Investments at cost | 1,250 | 1,082 | |
Investments at fair value | $ 1,250 | $ 1,082 | |
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.25% | 12.50% | |
Margin | 5% | 5% | |
Floor | 5% | 5% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Mar. 01, 2027 | Mar. 01, 2027 | |
Principal Amount | $ 3,000 | $ 3,000 | |
Investments at cost | 1,875 | 1,623 | |
Investments at fair value | 1,875 | 1,623 | |
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 2,947 | 2,947 | |
Investments at fair value | $ 2,677 | $ 2,947 | |
Number of Shares (in shares) | 1,312,500 | 1,312,500 | |
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 11.75% | 11% | |
Margin | 3.50% | 3.50% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 7.78% | 7.78% | |
Maturity Date | Feb. 01, 2028 | Feb. 01, 2028 | |
Principal Amount | $ 2,813 | $ 2,813 | |
Investments at cost | 2,813 | 2,813 | |
Investments at fair value | $ 2,813 | $ 2,813 | |
Havenly, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 11.75% | 11% | |
Margin | 3.50% | 3.50% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 7.78% | 7.78% | |
Maturity Date | Feb. 01, 2028 | Feb. 01, 2028 | |
Principal Amount | $ 2,813 | $ 2,813 | |
Investments at cost | 2,813 | 2,813 | |
Investments at fair value | $ 2,813 | $ 2,813 | |
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15.50% | 14.75% | |
Margin | 7.25% | 7.25% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 3,500 | $ 3,500 | |
Investments at cost | 3,467 | 3,461 | |
Investments at fair value | 3,467 | 3,461 | |
CAMP NYC, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 22 | 20 | |
Investments at fair value | $ 30 | $ 61 | |
Number of Shares (in shares) | 75,997 | 17,605 | |
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.75% | 14% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,959 | 4,947 | |
Investments at fair value | $ 4,959 | $ 4,947 | |
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.75% | 14% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 2.50% | 2.50% | |
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,480 | 2,474 | |
Investments at fair value | 2,480 | 2,474 | |
Lemongrass Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 34 | 34 | |
Investments at fair value | $ 41 | $ 41 | |
Number of Shares (in shares) | 101,308 | 101,308 | |
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13% | 12.25% | |
Margin | 4.75% | 4.75% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2027 | May 01, 2027 | |
Principal Amount | $ 6,250 | $ 6,250 | |
Investments at cost | 6,188 | 6,077 | |
Investments at fair value | $ 6,188 | $ 6,077 | |
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13% | 12.25% | |
Margin | 4.75% | 4.75% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | May 01, 2027 | May 01, 2027 | |
Principal Amount | $ 6,250 | $ 6,250 | |
Investments at cost | 6,188 | 6,177 | |
Investments at fair value | 6,188 | 6,177 | |
KSQ Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 50 | 51 | |
Investments at fair value | $ 58 | $ 60 | |
Number of Shares (in shares) | 48,076 | 48,077 | |
ZetrOZ, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Royalty Agreement [Member] | |||
Investments at cost | $ 0 | $ 0 | |
Investments at fair value | $ 200 | $ 200 | |
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |
Principal Amount | $ 2,083 | $ 2,500 | |
Investments at cost | 2,069 | 2,482 | |
Investments at fair value | $ 2,069 | $ 2,482 | |
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.50% | 5.50% | |
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |
Principal Amount | $ 2,083 | $ 2,500 | |
Investments at cost | 2,069 | 2,482 | |
Investments at fair value | 2,069 | 2,482 | |
Clara Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 30 | 30 | |
Investments at fair value | $ 126 | $ 125 | |
Number of Shares (in shares) | 46,745 | 46,745 | |
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.07% | ||
Margin | 4.82% | ||
Floor | 9.25% | ||
Ceiling | 0% | ||
ETP | 10.36% | ||
Maturity Date | Jul. 01, 2025 | ||
Principal Amount | $ 3,960 | ||
Investments at cost | 3,910 | ||
Investments at fair value | $ 3,910 | ||
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.07% | ||
Margin | 4.82% | ||
Floor | 9.25% | ||
Ceiling | 0% | ||
ETP | 10.36% | ||
Maturity Date | Jul. 01, 2025 | ||
Principal Amount | $ 3,960 | ||
Investments at cost | 3,910 | ||
Investments at fair value | 3,910 | ||
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 221 | $ 221 | |
Investments at fair value | $ 229 | $ 226 | |
Number of Shares (in shares) | 7,972,222 | 7,972,222 | |
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member] | |||
Cash Rate | 12.17% | ||
Margin | 8% | ||
Floor | 9.25% | ||
Ceiling | 0% | ||
ETP | 10.36% | ||
Maturity Date | Jul. 01, 2025 | ||
Principal Amount | $ 3,960 | ||
Investments at cost | 3,898 | ||
Investments at fair value | $ 3,898 | ||
Conventus Orthopaedics, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member] | |||
Cash Rate | 12.17% | ||
Margin | 8% | ||
Floor | 9.25% | ||
Ceiling | 0% | ||
ETP | 10.36% | ||
Maturity Date | Jul. 01, 2025 | ||
Principal Amount | $ 3,960 | ||
Investments at cost | 3,898 | ||
Investments at fair value | 3,898 | ||
Mustang Bio, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 146 | 146 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 16,611 | 252,161 | |
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.25% | 13% | |
Margin | 6% | 6% | |
Floor | 12.25% | 9.25% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Nov. 01, 2026 | Jul. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,414 | 2,396 | |
Investments at fair value | $ 2,414 | $ 2,396 | |
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.25% | 13% | |
Margin | 6% | 6% | |
Floor | 12.25% | 12.25% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Dec. 01, 2026 | Dec. 01, 2026 | |
Principal Amount | $ 1,250 | $ 1,250 | |
Investments at cost | 1,234 | 1,231 | |
Investments at fair value | 1,234 | 1,231 | |
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 46 | 40 | |
Investments at fair value | $ 18 | $ 44 | |
Number of Shares (in shares) | 85,543 | 80,197 | |
Lytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.25% | ||
Margin | 6% | ||
Floor | 12.25% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Apr. 01, 2027 | ||
Principal Amount | $ 1,000 | ||
Investments at cost | 985 | ||
Investments at fair value | $ 985 | ||
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.50% | 12.75% | |
Margin | 5.25% | 5.25% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,711 | 3,630 | |
Investments at fair value | $ 3,711 | $ 3,630 | |
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.50% | 12.75% | |
Margin | 5.25% | 5.25% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,475 | 2,469 | |
Investments at fair value | 2,475 | 2,469 | |
Native Microbials, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 64 | 64 | |
Investments at fair value | $ 163 | $ 162 | |
Number of Shares (in shares) | 103,679 | 103,679 | |
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.75% | 3.75% | |
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |
Principal Amount | $ 10,000 | $ 10,000 | |
Investments at cost | 9,727 | 9,701 | |
Investments at fair value | $ 9,727 | $ 9,701 | |
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.75% | 3.75% | |
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,707 | 3,697 | |
Investments at fair value | 3,707 | 3,697 | |
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 160 | 160 | |
Investments at fair value | $ 651 | $ 3,024 | |
Number of Shares (in shares) | 299,848 | 299,848 | |
PDS Biotechnology Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 3.75% | 3.75% | |
Maturity Date | Sep. 01, 2026 | Sep. 01, 2026 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,707 | 3,697 | |
Investments at fair value | $ 3,707 | $ 3,697 | |
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Jan. 01, 2026 | ||
Principal Amount | $ 3,210 | ||
Investments at cost | 3,151 | ||
Investments at fair value | $ 0 | ||
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Jan. 01, 2026 | ||
Principal Amount | $ 2,963 | ||
Investments at cost | 2,886 | ||
Investments at fair value | 0 | ||
Interior Define, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 103 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 553,710 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 4,667 | ||
Investments at cost | 4,605 | ||
Investments at fair value | $ 4,605 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 4,667 | ||
Investments at cost | 4,605 | ||
Investments at fair value | 4,605 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 442 | $ 399 | |
Investments at fair value | $ 173 | $ 648 | |
Number of Shares (in shares) | 293,488 | 203,017 | |
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,289 | ||
Investments at fair value | $ 2,289 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, One [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 4,667 | ||
Investments at cost | 4,597 | ||
Investments at fair value | $ 4,597 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,289 | ||
Investments at fair value | $ 2,289 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Two [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 4,667 | ||
Investments at cost | 4,597 | ||
Investments at fair value | $ 4,597 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,284 | ||
Investments at fair value | $ 2,284 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Three [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,280 | ||
Investments at fair value | $ 2,280 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 13.61% | ||
Margin | 5.36% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,284 | ||
Investments at fair value | 2,284 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Four [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,280 | ||
Investments at fair value | $ 2,280 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Five [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,274 | ||
Investments at fair value | $ 2,274 | ||
Provivi, Inc. [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, LIBOR Index, Six [Member] | |||
Cash Rate | 12.67% | ||
Margin | 8.50% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 5.50% | ||
Maturity Date | Dec. 01, 2024 | ||
Principal Amount | $ 2,333 | ||
Investments at cost | 2,274 | ||
Investments at fair value | 2,274 | ||
Getaround, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | 253 | 253 | |
Investments at fair value | $ 30 | $ 57 | |
Number of Shares (in shares) | 87,082 | 87,082 | |
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 4,667 | $ 5,000 | |
Investments at cost | 4,635 | 4,954 | |
Investments at fair value | $ 4,635 | $ 4,954 | |
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15% | 14.25% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 2,333 | $ 2,500 | |
Investments at cost | 2,317 | 2,477 | |
Investments at fair value | 2,317 | 2,477 | |
MyForest Foods Co [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 29 | 29 | |
Investments at fair value | $ 61 | $ 37 | |
Number of Shares (in shares) | 250 | 143 | |
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.25% | ||
Margin | 5% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 10,000 | ||
Investments at cost | 9,741 | ||
Investments at fair value | $ 9,741 | ||
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.25% | ||
Margin | 5% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,932 | ||
Investments at fair value | 4,932 | ||
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 116 | ||
Investments at fair value | $ 120 | ||
Number of Shares (in shares) | 84,037 | ||
Noodle Partners, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.25% | ||
Margin | 5% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,933 | ||
Investments at fair value | $ 4,933 | ||
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 5,352 | $ 5,000 | |
Investments at cost | 5,304 | 4,943 | |
Investments at fair value | $ 4,630 | $ 4,715 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 2,141 | $ 2,000 | |
Investments at cost | 2,124 | 1,981 | |
Investments at fair value | $ 1,854 | 1,890 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 197 | ||
Investments at fair value | $ 17 | ||
Number of Shares (in shares) | 1,261,253 | ||
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 2,676 | $ 2,500 | |
Investments at cost | 2,658 | 2,477 | |
Investments at fair value | $ 2,320 | $ 2,363 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 3,211 | $ 3,000 | |
Investments at cost | 3,189 | 2,971 | |
Investments at fair value | $ 2,784 | $ 2,835 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 2,676 | $ 2,500 | |
Investments at cost | 2,644 | 2,459 | |
Investments at fair value | $ 2,308 | $ 2,345 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Six [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 2,676 | $ 2,500 | |
Investments at cost | 2,644 | 2,459 | |
Investments at fair value | $ 2,308 | $ 2,345 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Seven [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 5,351 | $ 5,000 | |
Investments at cost | 5,287 | 4,914 | |
Investments at fair value | $ 4,614 | $ 4,688 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Eight [Member] | |||
Cash Rate | 14% | 12.75% | |
Margin | 5.75% | 5.75% | |
Floor | 9% | 9% | |
Ceiling | 0% | 0% | |
ETP | 5.25% | 2% | |
Maturity Date | Oct. 31, 2023 | Dec. 30, 2022 | |
Principal Amount | $ 2,676 | $ 2,500 | |
Investments at cost | 2,642 | 2,456 | |
Investments at fair value | 2,306 | $ 2,342 | |
NextCar Holding Company, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred and Common Stock [Member] | |||
Investments at cost | 197 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 1,237,370 | ||
NextCar Holding Company, Inc [Member] | Technology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 89 | ||
Investments at fair value | $ 89 | ||
Number of Shares (in shares) | 2,688,971 | ||
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |
Principal Amount | $ 3,500 | $ 3,500 | |
Investments at cost | 3,417 | 3,360 | |
Investments at fair value | $ 3,417 | $ 3,360 | |
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.75% | 13% | |
Margin | 5.50% | 5.50% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Nov. 01, 2026 | Nov. 01, 2026 | |
Principal Amount | $ 3,500 | $ 3,500 | |
Investments at cost | 3,467 | 3,460 | |
Investments at fair value | 3,467 | 3,460 | |
Robin Healthcare, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 16 | 16 | |
Investments at fair value | $ 16 | $ 16 | |
Number of Shares (in shares) | 86,066 | 86,066 | |
Lyrical Foods, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 10.75% | 10% | |
Margin | 2.50% | 6.75% | |
Floor | 8% | 10% | |
Ceiling | 0% | 0% | |
ETP | 0% | 0% | |
Maturity Date | Sep. 01, 2027 | Sep. 01, 2027 | |
Principal Amount | $ 2,598 | $ 2,500 | |
Investments at cost | 2,589 | 2,588 | |
Investments at fair value | 2,330 | 2,279 | |
vTv Therapeutics Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 44 | 44 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 95,293 | 95,293 | |
SnagAJob.com, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | $ 9 | $ 8 | |
Investments at fair value | $ 83 | $ 83 | |
Number of Shares (in shares) | 82,974 | 82,974 | |
Rocket Pharmaceuticals Corporation [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 17 | ||
Investments at fair value | $ 14 | ||
Number of Shares (in shares) | 7,051 | ||
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Aug. 01, 2027 | Aug. 01, 2027 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,400 | 2,347 | |
Investments at fair value | $ 2,400 | 2,347 | |
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | ||
Margin | 6.25% | ||
Floor | 9.50% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Jul. 01, 2028 | ||
Principal Amount | $ 1,875 | ||
Investments at cost | 1,779 | ||
Investments at fair value | 1,779 | ||
Optoro, Inc. [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 182 | 104 | |
Investments at fair value | $ 182 | $ 104 | |
Number of Shares (in shares) | 11,550 | 6,600 | |
Xeris Pharmaceuticals, Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 72 | $ 72 | |
Investments at fair value | $ 58 | $ 3 | |
Number of Shares (in shares) | 126,000 | 126,000 | |
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13% | 11.75% | |
Margin | 4.75% | 4.75% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,659 | 3,597 | |
Investments at fair value | $ 3,659 | $ 3,597 | |
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13% | 11.75% | |
Margin | 4.75% | 4.75% | |
Floor | 8.50% | 8.50% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Jan. 01, 2027 | Jan. 01, 2027 | |
Principal Amount | $ 3,750 | $ 3,750 | |
Investments at cost | 3,714 | 3,706 | |
Investments at fair value | 3,714 | 3,706 | |
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 57 | 40 | |
Investments at fair value | $ 64 | $ 46 | |
Number of Shares (in shares) | 27,036 | 19,662 | |
Scientia Vascular, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.50% | ||
Margin | 5.25% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 5% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,928 | ||
Investments at fair value | $ 4,928 | ||
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15.50% | 14.25% | |
Margin | 7.25% | 7.25% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 2,000 | $ 2,700 | |
Investments at cost | 1,980 | 2,673 | |
Investments at fair value | $ 1,980 | $ 2,673 | |
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15.50% | 14.25% | |
Margin | 7.25% | 7.25% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Mar. 01, 2025 | Mar. 01, 2025 | |
Principal Amount | $ 2,000 | $ 2,700 | |
Investments at cost | 1,980 | 2,673 | |
Investments at fair value | 1,980 | 2,673 | |
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 57 | 57 | |
Investments at fair value | $ 595 | $ 429 | |
Number of Shares (in shares) | 553,778 | 553,778 | |
Primary Kids, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 15.50% | 14.25% | |
Margin | 7.25% | 7.25% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Sep. 01, 2025 | Sep. 01, 2025 | |
Principal Amount | $ 2,600 | $ 3,000 | |
Investments at cost | 2,573 | 2,967 | |
Investments at fair value | $ 2,573 | $ 2,967 | |
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15.50% | 14.25% | |
Margin | 7.25% | 7.25% | |
Floor | 10.50% | 10.50% | |
Ceiling | 0% | 0% | |
ETP | 3% | 3% | |
Maturity Date | Aug. 01, 2025 | Aug. 01, 2025 | |
Principal Amount | $ 4,333 | $ 5,000 | |
Investments at cost | 4,278 | 4,932 | |
Investments at fair value | 4,278 | 4,932 | |
Reputation Institute, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 56 | 56 | |
Investments at fair value | $ 50 | $ 39 | |
Number of Shares (in shares) | 3,731 | 3,731 | |
AccuVein Inc [Member] | Biotechnology Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 24 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 1,175 | ||
AccuVein Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 24 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 1,175 | ||
Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Number of Shares (in shares) | 5,205 | ||
Tigo Energy, Inc. [Member] | Other Sustainability Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member] | |||
Investments at cost | $ 111 | $ 8 | |
Investments at fair value | 97 | $ 27 | |
Number of Shares (in shares) | 22,313 | ||
Quip NYC Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 325 | $ 325 | |
Investments at fair value | $ 536 | $ 534 | |
Number of Shares (in shares) | 6,191 | 6,191 | |
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,946 | 4,870 | |
Investments at fair value | $ 4,946 | $ 4,870 | |
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,946 | 4,933 | |
Investments at fair value | 4,946 | 4,933 | |
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 123 | 123 | |
Investments at fair value | $ 135 | $ 133 | |
Number of Shares (in shares) | 309,208 | 309,208 | |
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,882 | 4,933 | |
Investments at fair value | $ 4,882 | $ 4,933 | |
Slingshot Aerospace, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14% | 13.25% | |
Margin | 5.75% | 5.75% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Aug. 01, 2026 | Aug. 01, 2026 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,946 | 4,933 | |
Investments at fair value | 4,946 | 4,933 | |
Aerin Medical, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 66 | 64 | |
Investments at fair value | $ 1,204 | $ 1,200 | |
Number of Shares (in shares) | 1,818,183 | 1,818,183 | |
Branded Online, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock [Member] | |||
Investments at cost | $ 1,079 | $ 1,079 | |
Investments at fair value | $ 8 | $ 83 | |
Number of Shares (in shares) | 5,398 | 108,004 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.75% | 13.50% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 8% | 8% | |
Maturity Date | Jun. 01, 2025 | Jun. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,481 | 2,476 | |
Investments at fair value | $ 2,481 | $ 2,476 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.75% | 13.50% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 8% | 8% | |
Maturity Date | Jun. 01, 2025 | Jun. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,481 | 2,476 | |
Investments at fair value | 2,481 | 2,476 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 98 | 98 | |
Investments at fair value | $ 125 | $ 123 | |
Number of Shares (in shares) | 1,098,805 | 605,313 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.75% | 13.50% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 8% | 8% | |
Maturity Date | Jun. 01, 2025 | Jun. 01, 2025 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,481 | 2,476 | |
Investments at fair value | $ 2,481 | $ 2,476 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14.75% | 13.50% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 8% | 8% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,463 | 2,453 | |
Investments at fair value | $ 2,463 | $ 2,453 | |
Sonex Health, Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 14.75% | 13.50% | |
Margin | 6.50% | 6.50% | |
Floor | 9.75% | 9.75% | |
Ceiling | 0% | 0% | |
ETP | 8% | 8% | |
Maturity Date | May 01, 2026 | May 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,462 | 2,455 | |
Investments at fair value | $ 2,462 | $ 2,455 | |
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 16% | 15.25% | |
Margin | 7.75% | 7.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 0% | 0% | |
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |
Principal Amount | $ 1,108 | $ 2,500 | |
Investments at cost | 1,086 | 2,473 | |
Investments at fair value | $ 868 | $ 2,473 | |
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 16% | 15.25% | |
Margin | 7.75% | 7.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 0% | 0% | |
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |
Principal Amount | $ 554 | $ 1,250 | |
Investments at cost | 543 | 1,236 | |
Investments at fair value | 434 | 1,236 | |
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 32 | 32 | |
Investments at fair value | $ 0 | $ 22 | |
Number of Shares (in shares) | 171,081 | 171,081 | |
Unagi, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 16% | 15.25% | |
Margin | 7.75% | 7.75% | |
Floor | 11% | 11% | |
Ceiling | 0% | 0% | |
ETP | 0% | 0% | |
Maturity Date | May 01, 2027 | Jul. 01, 2025 | |
Principal Amount | $ 554 | $ 1,250 | |
Investments at cost | 543 | 1,236 | |
Investments at fair value | 434 | $ 1,236 | |
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 16.93% | ||
Margin | 9.43% | ||
Floor | 12.68% | ||
Ceiling | 0% | ||
ETP | 50.43% | ||
Maturity Date | Dec. 31, 2022 | ||
Principal Amount | $ 3,295 | ||
Investments at cost | 3,295 | ||
Investments at fair value | 3,295 | ||
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | 46 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 82,967 | ||
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member] | |||
Investments at cost | 2,800 | ||
Investments at fair value | $ 1,281 | ||
Number of Shares (in shares) | 280,000 | ||
Decisyon, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Equity Securities [Member] | |||
Investments at cost | $ 230 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 72,638,663 | ||
Updater, Inc [Member] | Consumer-related Technologies [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 34 | $ 34 | |
Investments at fair value | $ 11 | $ 42 | |
Number of Shares (in shares) | 108,333 | 108,333 | |
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.75% | ||
Margin | 5.75% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 7% | ||
Maturity Date | Nov. 01, 2024 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,475 | ||
Investments at fair value | $ 2,475 | ||
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.75% | ||
Margin | 5.75% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 7% | ||
Maturity Date | Nov. 01, 2024 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,489 | ||
Investments at fair value | 2,489 | ||
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 86 | 84 | |
Investments at fair value | $ 1,319 | $ 1,864 | |
Number of Shares (in shares) | 12,153 | 12,153 | |
Canary Medical Inc. [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.75% | ||
Margin | 5.75% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 7% | ||
Maturity Date | Nov. 01, 2024 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,473 | ||
Investments at fair value | 2,473 | ||
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 21 | 22 | |
Investments at fair value | $ 57 | $ 312 | |
Number of Shares (in shares) | 71,305 | 288,115 | |
Lotame Solutions, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock [Member] | |||
Investments at cost | $ 2 | ||
Investments at fair value | $ 193 | ||
Number of Shares (in shares) | 66,127 | ||
CPG Beyond, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 242 | $ 242 | |
Investments at fair value | $ 912 | $ 909 | |
Number of Shares (in shares) | 500,000 | 500,000 | |
Silk, Inc [Member] | Data Storage Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 175 | $ 234 | |
Investments at fair value | $ 148 | $ 407 | |
Number of Shares (in shares) | 394,110 | 442,110 | |
Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.50% | ||
Margin | 4.25% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 2.50% | ||
Maturity Date | Jun. 01, 2028 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,456 | ||
Investments at fair value | $ 2,456 | ||
Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.50% | ||
Margin | 4.25% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 2.50% | ||
Maturity Date | Jun. 01, 2028 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,488 | ||
Investments at fair value | 3,488 | ||
Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 64 | ||
Investments at fair value | $ 140 | ||
Number of Shares (in shares) | 682 | ||
Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.50% | ||
Margin | 4.25% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 2.50% | ||
Maturity Date | Jun. 01, 2028 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,491 | ||
Investments at fair value | $ 2,491 | ||
Supply Network Visibility Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 12.50% | ||
Margin | 4.25% | ||
Floor | 12% | ||
Ceiling | 0% | ||
ETP | 2.50% | ||
Maturity Date | Jun. 01, 2028 | ||
Principal Amount | $ 1,500 | ||
Investments at cost | 1,495 | ||
Investments at fair value | 1,495 | ||
Global Worldwide LLC [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 75 | $ 75 | |
Investments at fair value | $ 63 | $ 0 | |
Number of Shares (in shares) | 245,810 | 245,810 | |
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 1% | 1% | |
Maturity Date | Oct. 01, 2025 | Oct. 01, 2025 | |
Principal Amount | $ 5,000 | $ 5,000 | |
Investments at cost | 4,972 | 4,966 | |
Investments at fair value | $ 4,972 | $ 4,966 | |
Spineology, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15.25% | 14.50% | |
Margin | 7% | 7% | |
Floor | 10.25% | 10.25% | |
Ceiling | 0% | 0% | |
ETP | 1% | 1% | |
Maturity Date | Apr. 01, 2026 | Apr. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,485 | 2,481 | |
Investments at fair value | 2,485 | 2,481 | |
Rocket Lawyer Incorporated [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 92 | 92 | |
Investments at fair value | $ 360 | $ 357 | |
Number of Shares (in shares) | 261,721 | 261,721 | |
Cadrenal Therapeutics, Inc. [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | |||
Investments at fair value | $ 906 | $ 846 | $ 0 |
Cadrenal Therapeutics, Inc. [Member] | Biotechnology Sector [Member] | Investment, Affiliated Issuer, Noncontrolled [Member] | Common Stock [Member] | |||
Investments at cost | 0 | ||
Investments at fair value | $ 906 | ||
Number of Shares (in shares) | 600,000 | ||
Skillshare, Inc [Member] | Internet and Media Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 162 | 162 | |
Investments at fair value | $ 1,211 | $ 802 | |
Number of Shares (in shares) | 139,074 | 139,074 | |
CVRx, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 76 | $ 76 | |
Investments at fair value | $ 278 | $ 394 | |
Number of Shares (in shares) | 47,410 | 47,410 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |
Principal Amount | $ 2,333 | $ 3,333 | |
Investments at cost | 2,300 | 3,286 | |
Investments at fair value | $ 2,300 | $ 3,286 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |
Principal Amount | $ 2,333 | $ 3,333 | |
Investments at cost | 2,300 | 3,286 | |
Investments at fair value | 2,300 | 3,286 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 364 | 364 | |
Investments at fair value | $ 247 | $ 243 | |
Number of Shares (in shares) | 344,102 | 344,102 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |
Principal Amount | $ 1,167 | $ 1,667 | |
Investments at cost | 1,149 | 1,641 | |
Investments at fair value | $ 1,149 | $ 1,641 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |
Principal Amount | $ 1,167 | $ 1,667 | |
Investments at cost | 1,149 | 1,641 | |
Investments at fair value | $ 1,149 | $ 1,641 | |
Liqid, Inc [Member] | Networking Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Five [Member] | |||
Cash Rate | 14.50% | 13.25% | |
Margin | 6.25% | 6.25% | |
Floor | 9.50% | 9.50% | |
Ceiling | 0% | 0% | |
ETP | 4% | 4% | |
Maturity Date | Sep. 01, 2024 | Sep. 01, 2024 | |
Principal Amount | $ 1,167 | $ 1,667 | |
Investments at cost | 1,129 | 1,613 | |
Investments at fair value | $ 1,129 | 1,613 | |
Viken Detection Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 12.25% | ||
Margin | 4% | ||
Floor | 11.75% | ||
Ceiling | 0% | ||
ETP | 3.50% | ||
Maturity Date | Jun. 01, 2027 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,762 | ||
Investments at fair value | $ 4,762 | ||
Viken Detection Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 12.25% | ||
Margin | 4% | ||
Floor | 11.75% | ||
Ceiling | 0% | ||
ETP | 3.50% | ||
Maturity Date | Jun. 01, 2027 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,461 | ||
Investments at fair value | 2,461 | ||
Viken Detection Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 120 | ||
Investments at fair value | $ 120 | ||
Number of Shares (in shares) | 345,443 | ||
Viken Detection Corporation [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 12.25% | ||
Margin | 4% | ||
Floor | 11.75% | ||
Ceiling | 0% | ||
ETP | 3.50% | ||
Maturity Date | Jun. 01, 2027 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,461 | ||
Investments at fair value | 2,461 | ||
Halio, Inc [Member] | Power Management Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 1,585 | 1,585 | |
Investments at fair value | $ 2,898 | $ 2,610 | |
Number of Shares (in shares) | 5,002,574 | 5,002,574 | |
Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | $ 56 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 6,081 | ||
Avalanche Technology, Inc [Member] | Semiconductor Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred and Common Stock [Member] | |||
Investments at cost | $ 57 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 6,081 | ||
Meditrina, Inc [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 83 | $ 83 | |
Investments at fair value | $ 101 | $ 101 | |
Number of Shares (in shares) | 233,993 | 233,993 | |
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 15% | 13.75% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,489 | 2,421 | |
Investments at fair value | $ 2,489 | $ 2,421 | |
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 15% | 13.75% | |
Margin | 6.75% | 6.75% | |
Floor | 10% | 10% | |
Ceiling | 0% | 0% | |
ETP | 5% | 5% | |
Maturity Date | Mar. 01, 2026 | Mar. 01, 2026 | |
Principal Amount | $ 2,500 | $ 2,500 | |
Investments at cost | 2,489 | 2,487 | |
Investments at fair value | 2,489 | 2,487 | |
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 21 | 21 | |
Investments at fair value | $ 70 | $ 69 | |
Number of Shares (in shares) | 77,828 | 77,828 | |
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 15% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,469 | ||
Investments at fair value | $ 2,469 | ||
Britecore Holdings, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 15% | ||
Margin | 6.75% | ||
Floor | 10% | ||
Ceiling | 0% | ||
ETP | 3% | ||
Maturity Date | Mar. 01, 2027 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,469 | ||
Investments at fair value | 2,469 | ||
E La Carte, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Common Stock Warrants [Member] | |||
Investments at cost | $ 60 | ||
Investments at fair value | $ 3 | ||
Number of Shares (in shares) | 147,361 | ||
E La Carte, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 60 | ||
Investments at fair value | $ 121 | ||
Number of Shares (in shares) | 147,361 | ||
VERO Biotech LLC [Member] | Medical Device Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 53 | $ 53 | |
Investments at fair value | $ 1 | $ 1 | |
Number of Shares (in shares) | 408 | 408 | |
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13% | ||
Margin | 5.50% | ||
Floor | 11% | ||
Ceiling | 18% | ||
ETP | 3% | ||
Maturity Date | Dec. 01, 2026 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,798 | ||
Investments at fair value | $ 4,798 | ||
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13% | ||
Margin | 5.50% | ||
Floor | 11% | ||
Ceiling | 18% | ||
ETP | 3% | ||
Maturity Date | Dec. 01, 2026 | ||
Principal Amount | $ 5,000 | ||
Investments at cost | 4,948 | ||
Investments at fair value | 4,948 | ||
Groundspeed Analytics, Inc. [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 6 | ||
Investments at fair value | $ 6 | ||
Number of Shares (in shares) | 86,300 | ||
Everstream Holdings, LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 70 | ||
Investments at fair value | $ 70 | ||
Number of Shares (in shares) | 350,000 | ||
Revinate Holdings, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 44 | $ 46 | |
Investments at fair value | $ 101 | $ 99 | |
Number of Shares (in shares) | 682,034 | 682,034 | |
Riv Data Corp [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 12 | ||
Investments at fair value | $ 296 | ||
Number of Shares (in shares) | 321,428 | ||
SIGNiX, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 225 | $ 225 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 186,235 | 186,235 | |
Skyword, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Warrant [Member] | |||
Investments at cost | $ 48 | ||
Investments at fair value | $ 1 | ||
Number of Shares (in shares) | 301,055 | ||
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Feb. 01, 2025 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,472 | ||
Investments at fair value | $ 3,472 | ||
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Feb. 01, 2025 | ||
Principal Amount | $ 3,500 | ||
Investments at cost | 3,472 | ||
Investments at fair value | 3,472 | ||
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 64 | ||
Investments at fair value | $ 83 | ||
Number of Shares (in shares) | 682 | ||
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Three [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Dec. 01, 2025 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,472 | ||
Investments at fair value | $ 2,472 | ||
Supply Network Visiblity Holdings LLC [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, Four [Member] | |||
Cash Rate | 13.50% | ||
Margin | 6.50% | ||
Floor | 9.75% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Dec. 01, 2025 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,472 | ||
Investments at fair value | 2,472 | ||
Topia Mobility, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 138 | 138 | |
Investments at fair value | $ 0 | $ 0 | |
Number of Shares (in shares) | 3,049,607 | 3,049,607 | |
xAd, Inc [Member] | Software Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | $ 177 | $ 177 | |
Investments at fair value | $ 12 | $ 12 | |
Number of Shares (in shares) | 4,343,348 | 4,343,348 | |
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index, One [Member] | |||
Cash Rate | 13.25% | ||
Margin | 5.75% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Oct. 01, 2025 | ||
Principal Amount | $ 4,943 | ||
Investments at cost | 4,943 | ||
Investments at fair value | $ 1,668 | ||
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Term Loan, Prime Index Two [Member] | |||
Cash Rate | 13.25% | ||
Margin | 5.75% | ||
Floor | 9% | ||
Ceiling | 0% | ||
ETP | 4% | ||
Maturity Date | Dec. 31, 2025 | ||
Principal Amount | $ 2,500 | ||
Investments at cost | 2,467 | ||
Investments at fair value | 832 | ||
Secure Transfusion Services, Inc [Member] | Other Healthcare Sector [Member] | Investment, Unaffiliated Issuer [Member] | Preferred Stock Warrants [Member] | |||
Investments at cost | 47 | ||
Investments at fair value | $ 0 | ||
Number of Shares (in shares) | 77,690 |
Consolidated Schedule of Inve_5
Consolidated Schedule of Investments (Unaudited) - Investments (Details) (Parentheticals) | Jun. 30, 2023 | Dec. 31, 2022 |
NAV % | 201.40% | 226.10% |
Investment, Unaffiliated Issuer [Member] | ||
NAV % | 201.10% | 226.10% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | ||
NAV % | 7.20% | 9.40% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Healthcare Sector [Member] | ||
NAV % | 0.60% | 0.60% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science [Member] | ||
NAV % | 3.10% | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Life Science Segment [Member] | ||
NAV % | 1.80% | |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Sustainability Segment [Member] | ||
NAV % | 0.20% | 0.60% |
Investment, Unaffiliated Issuer [Member] | Warrant [Member] | Technology Sector [Member] | ||
NAV % | 4.60% | 5.10% |
Investment, Unaffiliated Issuer [Member] | Other Long-Term Investments [Member] | ||
NAV % | 0.40% | 0.40% |
Investment, Unaffiliated Issuer [Member] | Equity Securities [Member] | ||
NAV % | 1.20% | 0.80% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | ||
NAV % | 192.30% | 215.50% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Healthcare Sector [Member] | ||
NAV % | 10.10% | 8.10% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Life Science [Member] | ||
NAV % | 82.90% | 99.70% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Sustainability Segment [Member] | ||
NAV % | 23.40% | 26.30% |
Investment, Unaffiliated Issuer [Member] | Debt Securities [Member] | Technology Sector [Member] | ||
NAV % | 75.90% | 81.40% |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||
NAV % | 0.30% | |
Investment, Affiliated Issuer, Noncontrolled [Member] | Equity Securities [Member] | Life Science [Member] | ||
NAV % | 0.30% |
Note 2 - Basis of Presentatio_2
Note 2 - Basis of Presentation and Significant Accounting Policies (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 26 Months Ended | |||||||
Jun. 02, 2023 | Mar. 14, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Dec. 31, 2022 | Apr. 28, 2022 | Aug. 02, 2021 | |
Investments, Nonaccrual, Interest Income | $ 0 | $ 0 | $ 0 | $ 0 | ||||||
Interest Income, Operating, Paid in Kind | $ 1,000 | $ 0 | $ 2,154 | $ 0 | ||||||
Investment, Nonaccrual, Income Not Received in Cash, Percent | 3.10% | 6.80% | 4.70% | 8% | ||||||
Debt Issuance Costs, Net | $ 6,900 | $ 6,900 | $ 6,900 | $ 7,100 | ||||||
Accumulated Amortization, Debt Issuance Costs | 5,800 | 5,800 | $ 5,800 | 4,800 | ||||||
Amortization of Debt Issuance Costs | $ 500 | $ 400 | $ 950 | $ 705 | ||||||
Federal Excise Tax, Percent | 4% | 4% | 4% | |||||||
Investment Income, Operating, Tax Expense (Benefit) | $ 179 | $ 106 | $ 363 | 206 | ||||||
Open Tax Year | 2019 2020 2021 | |||||||||
Proceeds from Issuance of Common Stock | $ 51,175 | $ 48,529 | ||||||||
Stock Repurchase Program, Remaining Authorized Repurchase Amount | $ 5,000 | |||||||||
Stock Repurchased During Period, Shares (in shares) | 0 | 0 | 0 | 0 | 167,465 | |||||
Stock Repurchased During Period, Per Share (in dollars per share) | $ 11.22 | |||||||||
Stock Repurchased During Period, Value | $ 1,900 | |||||||||
The 2021 Equity Distribution Agreement [Member] | ||||||||||
Equity Sales Agreement, Maximum Value | $ 100,000 | |||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 448,175 | 868,230 | 1,054,023 | 1,118,401 | ||||||
Proceeds from Issuance of Common Stock | $ 5,100 | $ 10,300 | $ 12,300 | $ 14,200 | ||||||
Payments of Stock Issuance Costs | 100 | $ 200 | 300 | $ 200 | ||||||
Equity Sales Agreement, Remaining Amount Available for Issuance | 18,900 | 18,900 | 18,900 | |||||||
Public Offering [Member] | ||||||||||
Stock Issued During Period, Shares, New Issues (in shares) | 3,250,000 | 2,500,000 | ||||||||
Proceeds from Issuance of Common Stock | $ 38,900 | $ 34,300 | ||||||||
Shares Issued, Price Per Share (in dollars per share) | $ 12.50 | $ 14.35 | ||||||||
Two Investments [Member] | ||||||||||
Investments, Cost, Nonaccrual Status | 25,600 | 25,600 | 25,600 | |||||||
Investments, Fair Value, Nonaccrual Status | $ 15,300 | $ 15,300 | $ 15,300 | |||||||
Three Investments [Member] | ||||||||||
Investments, Cost, Nonaccrual Status | 20,900 | |||||||||
Investments, Fair Value, Nonaccrual Status | $ 8,300 |
Note 3 - Related Party Transa_2
Note 3 - Related Party Transactions (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Management Fee Payable | $ 1,063 | $ 1,063 | $ 1,065 | ||
Management Fee Expense | 3,207 | $ 2,523 | 6,408 | $ 4,767 | |
Incentive Fee Payable | 118 | 118 | 1,392 | ||
Administrative Fees Expense | $ 368 | 374 | 808 | 735 | |
Investment Management Agreement [Member] | |||||
Base Management Fee, Annual, Percent | 2% | ||||
Base Management Fee, Annual, Percent, Gross Assets Exceeding $250 Million | 1.60% | ||||
Management Fee Payable | $ 1,100 | 1,100 | 1,100 | ||
Management Fee Expense | $ 3,200 | 2,500 | 6,400 | 4,800 | |
Incentive Fee to Pre-incentive Net Investment Income | 20% | ||||
Pre-Incentive Fee Net Investment Income, Hurdle Rate | 1.75% | ||||
Pre-Incentive Fee Net Investment Income, Hurdle Rate, Annualized | 7% | ||||
Pre-Incentive Fee Net Investment Income, Catch-up, Percent | 100% | ||||
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up | 2.1875% | ||||
Pre-Incentive Fee Net Investment Income, Maximum Rate to Trigger Catch-up, Annualized | 8.75% | ||||
Incentive Fee Expense | $ 100 | 2,100 | 3,100 | 3,600 | |
Incentive Fee Cap and Deferral Mechanism Reduction to Expense | 3,100 | 3,300 | |||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 4,400 | 4,400 | |||
Incentive Fee Payable | 100 | 100 | $ 1,400 | ||
Investment Management Agreement [Member] | December 31, 2025 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 1,100 | 1,100 | |||
Investment Management Agreement [Member] | March 31, 2026 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 200 | 200 | |||
Investment Management Agreement [Member] | June 30, 2026 Expiration [Member] | |||||
Incentive Fee Cap and Deferral Mechanism, Contingent Future Liability | 3,100 | 3,100 | |||
Administration Agreement [Member] | |||||
Administrative Fees Expense | $ 400 | $ 400 | $ 800 | $ 700 |
Note 4 - Investments - Investme
Note 4 - Investments - Investments (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Investments at cost | $ 723,633 | $ 721,248 |
Investments at fair value | 715,391 | 720,026 |
Biotechnology Sector [Member] | ||
Investments at cost | 182,489 | 193,372 |
Investments at fair value | 174,598 | 195,006 |
Medical Device Sector [Member] | ||
Investments at cost | 128,203 | 132,803 |
Investments at fair value | 130,634 | 135,960 |
Communications Sector [Member] | ||
Investments at cost | 22,922 | 22,892 |
Investments at fair value | 26,170 | 26,176 |
Consumer-related Sector [Member] | ||
Investments at cost | 113,903 | 121,961 |
Investments at fair value | 108,275 | 114,050 |
Data Storage Sector [Member] | ||
Investments at cost | 417 | 476 |
Investments at fair value | 1,060 | 1,316 |
Internet and Media Sector [Member] | ||
Investments at cost | 329 | 329 |
Investments at fair value | 1,634 | 1,159 |
Networking Sector [Member] | ||
Investments at cost | 8,391 | 11,831 |
Investments at fair value | 8,274 | 11,710 |
Power Management Sector [Member] | ||
Investments at cost | 1,585 | 1,585 |
Investments at fair value | 2,898 | 2,610 |
Semiconductor Sector [Member] | ||
Investments at cost | 57 | 56 |
Investments at fair value | 0 | 0 |
Software Sector [Member] | ||
Investments at cost | 142,853 | 120,157 |
Investments at fair value | 139,934 | 118,716 |
Energy Efficiency [Member] | ||
Investments at cost | 111 | 8 |
Investments at fair value | 97 | 27 |
Other Sustainability Sector [Member] | ||
Investments at cost | 86,095 | 84,633 |
Investments at fair value | 83,942 | 85,524 |
Diagnostics Sector [Member] | ||
Investments at cost | 9,960 | 9,851 |
Investments at fair value | 9,969 | 9,858 |
Other Healthcare Sector [Member] | ||
Investments at cost | 101 | 7,559 |
Investments at fair value | 1,374 | 3,870 |
Software, Healthcare Information and Service [Member] | ||
Investments at cost | 26,217 | 13,735 |
Investments at fair value | 26,532 | 14,044 |
Debt [Member] | ||
Investments at cost | 700,162 | 701,074 |
Investments at fair value | 683,309 | 686,458 |
Warrant [Member] | ||
Investments at cost | 15,061 | 14,790 |
Investments at fair value | 25,483 | 29,712 |
Other Debt Obligations [Member] | ||
Investments at cost | 1,200 | 1,200 |
Investments at fair value | 1,300 | 1,300 |
Equity Securities [Member] | ||
Investments at cost | 7,210 | 4,184 |
Investments at fair value | $ 5,299 | $ 2,556 |
Note 5 - Transactions With Af_3
Note 5 - Transactions With Affiliated Companies (Details Textual) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Investment, Affiliated Issuer, Noncontrolled [Member] | ||||
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease) | $ 0 | $ 0 | ||
Investment, Affiliated Issuer, Controlled [Member] | ||||
Investments in and Advances to Affiliates, at Fair Value, Period Increase (Decrease) | $ 0 | $ 0 |
Note 5 - Transactions With Af_4
Note 5 - Transactions With Affiliated Companies - Investments in Affiliated Companies (Details) - USD ($) $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Investments, fair value | $ 720,026 | |||
Unrealized Gain (Loss) on Investments | $ 608 | $ (36) | (6,929) | $ (2,273) |
Net realized gain (loss) on investments | (16,529) | (929) | (16,697) | (899) |
Investments, fair value | 715,391 | 715,391 | ||
Investment, Affiliated Issuer, Noncontrolled [Member] | ||||
Investments, fair value | 846 | 0 | ||
Purchases | 0 | 0 | ||
Principal payments | 0 | 0 | ||
Transfers in/(out) at fair value | 0 | 0 | ||
Dividends declared | 0 | |||
Unrealized Gain (Loss) on Investments | 60 | 0 | 906 | 0 |
Net realized gain (loss) on investments | 0 | 0 | ||
Investments, fair value | 906 | 906 | ||
Discount accretion | 0 | |||
Investment, Affiliated Issuer, Noncontrolled [Member] | Cadrenal Therapeutics, Inc. [Member] | ||||
Investments, fair value | 846 | 0 | ||
Purchases | 0 | 0 | ||
Principal payments | 0 | 0 | ||
Transfers in/(out) at fair value | 0 | 0 | ||
Dividends declared | 0 | |||
Unrealized Gain (Loss) on Investments | 60 | 906 | ||
Net realized gain (loss) on investments | 0 | 0 | ||
Investments, fair value | 906 | 906 | ||
Discount accretion | 0 | |||
Investment, Affiliated Issuer, Controlled [Member] | ||||
Investments, fair value | 0 | 0 | ||
Purchases | 0 | 0 | ||
Principal payments | (200) | (250) | ||
Transfers in/(out) at fair value | 0 | 0 | ||
Dividends declared | 0 | |||
Unrealized Gain (Loss) on Investments | 0 | 1,400 | 0 | 1,450 |
Net realized gain (loss) on investments | $ 0 | (1,200) | $ 0 | (1,200) |
Investments, fair value | 0 | 0 | ||
Discount accretion | 0 | |||
Investment, Affiliated Issuer, Controlled [Member] | HESP LLC [Member] | ||||
Investments, fair value | 0 | 0 | ||
Purchases | 0 | 0 | ||
Principal payments | (200) | (250) | ||
Transfers in/(out) at fair value | 0 | 0 | ||
Dividends declared | 0 | |||
Unrealized Gain (Loss) on Investments | 1,400 | 1,450 | ||
Net realized gain (loss) on investments | (1,200) | (1,200) | ||
Investments, fair value | $ 0 | 0 | ||
Discount accretion | $ 0 |
Note 6 - Fair Value (Details Te
Note 6 - Fair Value (Details Textual) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 USD ($) $ / shares | Jun. 30, 2022 USD ($) | Jun. 30, 2023 USD ($) $ / shares | Jun. 30, 2022 USD ($) | |
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | $ (111) | $ 0 | $ (111) | $ 0 |
Unrealized Gain (Loss) on Investments | 608 | $ (36) | (6,929) | (2,273) |
Equity Securities [Member] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | (111) | (111) | ||
Debt [Member] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | 0 | 0 | ||
Warrant [Member] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | 0 | 0 | ||
Fair Value, Inputs, Level 1 [Member] | Equity Securities [Member] | ||||
Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers, Net | $ 100 | 100 | ||
Fair Value, Inputs, Level 3 [Member] | Equity Securities [Member] | ||||
Unrealized Gain (Loss) on Investments | 1,300 | |||
Fair Value, Inputs, Level 3 [Member] | Debt [Member] | ||||
Unrealized Gain (Loss) on Investments | (13,100) | (7,000) | ||
Fair Value, Inputs, Level 3 [Member] | Warrant [Member] | ||||
Unrealized Gain (Loss) on Investments | $ (1,900) | $ 4,700 | ||
The 2026 Notes [Member] | ||||
Debt Instrument, Share Price (in dollars per share) | $ / shares | $ 23.35 | $ 23.35 | ||
The 2026 Notes [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Debt Instrument, Fair Value Disclosure | $ 53,700 | $ 53,700 | ||
The 2027 Notes [Member] | ||||
Debt Instrument, Share Price (in dollars per share) | $ / shares | $ 24.14 | $ 24.14 | ||
The 2027 Notes [Member] | Fair Value, Inputs, Level 1 [Member] | ||||
Debt Instrument, Fair Value Disclosure | $ 55,500 | $ 55,500 | ||
Asset-backed Notes 2019 [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Debt Instrument, Fair Value Disclosure | 30,800 | 30,800 | ||
Asset-backed Notes 2022 [Member] | Fair Value, Inputs, Level 3 [Member] | ||||
Debt Instrument, Fair Value Disclosure | $ 100,000 | $ 100,000 | ||
Measurement Input, Hypothetical Market Yields [Member] | ||||
Debt Instrument, Measurement Input | 0.25 | 0.25 |
Note 6 - Fair Value - Assets at
Note 6 - Fair Value - Assets at Fair Value on a Recurring Basis (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Fair Value, Recurring [Member] | ||
Investments, fair value | $ 715,391 | $ 720,026 |
Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 683,309 | 686,458 |
Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 25,483 | 29,712 |
Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 1,300 | 1,300 |
Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 5,299 | 2,556 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 1,040 | 140 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 1 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 1,040 | 140 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 1,107 | 3,567 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 1,107 | 3,567 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 2 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | 0 | 0 |
Fair Value, Inputs, Level 3 [Member] | ||
Investments, fair value | 713,244 | 716,319 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | ||
Investments, fair value | 713,244 | 716,319 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Debt [Member] | ||
Investments, fair value | 683,309 | 686,458 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Warrant [Member] | ||
Investments, fair value | 24,376 | 26,145 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Other Investments [Member] | ||
Investments, fair value | 1,300 | 1,300 |
Fair Value, Inputs, Level 3 [Member] | Fair Value, Recurring [Member] | Equity Securities [Member] | ||
Investments, fair value | $ 4,259 | $ 2,416 |
Note 6 - Fair Value - Significa
Note 6 - Fair Value - Significant Level 3 Fair Value Measurement Inputs (Details) - Fair Value, Inputs, Level 3 [Member] $ in Thousands | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | |||
Investments, fair value | $ 713,244 | $ 716,319 | |||
Investments, measurement input | 100 | ||||
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | |||||
Investments, fair value | $ 611,524 | $ 669,617 | |||
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Minimum [Member] | Hypothetical Market Yield [Member] | |||||
Investments, measurement input | 0.11 | 0.03 | |||
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Maximum [Member] | Hypothetical Market Yield [Member] | |||||
Investments, measurement input | 0.24 | [1] | 0.22 | ||
Debt [Member] | Valuation Technique, Discounted Cash Flow [Member] | Weighted Average [Member] | Hypothetical Market Yield [Member] | |||||
Investments, measurement input | 0.14 | 0.14 | [1] | ||
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | |||||
Investments, fair value | $ 71,785 | $ 16,545 | |||
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Minimum [Member] | Probability Weighting [Member] | |||||
Investments, measurement input | 0.05 | 0.10 | |||
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Maximum [Member] | Probability Weighting [Member] | |||||
Investments, measurement input | 1 | [1] | 0.75 | ||
Debt [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member] | |||||
Investments, measurement input | 0.50 | 0.31 | [1] | ||
Debt [Member] | Black-scholes Valuation Model [Member] | |||||
Investments, fair value | $ 26,145 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member] | |||||
Investments, measurement input | 0.28 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||||
Investments, measurement input | 20 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 0 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | 1 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 1.899 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | 5 | ||||
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | [1] | 58.52 | |||
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member] | |||||
Investments, measurement input | [1] | 0.28 | |||
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||||
Investments, measurement input | [1] | 20 | |||
Debt [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | [1] | 3 | |||
Debt [Member] | Convertible Note Analysis [Member] | |||||
Investments, fair value | $ 296 | ||||
Debt [Member] | Convertible Note Analysis [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 168.93 | ||||
Debt [Member] | Convertible Note Analysis [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | [1] | 168.93 | |||
Warrant [Member] | Black-scholes Valuation Model [Member] | |||||
Investments, fair value | $ 24,314 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Price Volatility [Member] | |||||
Investments, measurement input | 0.28 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||||
Investments, measurement input | 0.20 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 0 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Measurement Input, Discount for Lack of Marketability [Member] | |||||
Investments, measurement input | 0.20 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Minimum [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | 1 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | [1] | 1,899 | |||
Warrant [Member] | Black-scholes Valuation Model [Member] | Maximum [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | [1] | 5 | |||
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 59.21 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Measurement Input, Price Volatility [Member] | |||||
Investments, measurement input | 0.28 | ||||
Warrant [Member] | Black-scholes Valuation Model [Member] | Weighted Average [Member] | Estimated Time to Exit [Member] | |||||
Investments, measurement input | 3 | ||||
Warrant [Member] | Expected Proceeds [Member] | |||||
Investments, fair value | $ 62 | ||||
Warrant [Member] | Expected Proceeds [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 0.25 | ||||
Warrant [Member] | Expected Proceeds [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 0.25 | ||||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | |||||
Investments, fair value | $ 1,300 | $ 1,300 | |||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Probability Weighting [Member] | |||||
Investments, measurement input | 100 | ||||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Measurement Input, Discount Rate [Member] | |||||
Investments, measurement input | 0.25 | 0.25 | |||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Probability Weighting [Member] | |||||
Investments, measurement input | [1] | 100 | |||
Other Investments [Member] | Multiple Probability Weighted Cash Flow Model [Member] | Weighted Average [Member] | Measurement Input, Discount Rate [Member] | |||||
Investments, measurement input | 0.25 | 0.25 | [1] | ||
Equity Securities [Member] | Last Equity Financing [Member] | |||||
Investments, fair value | $ 4,259 | $ 2,416 | |||
Equity Securities [Member] | Last Equity Financing [Member] | Weighted Average [Member] | Measurement Input, Share Price [Member] | |||||
Investments, measurement input | 27.56 | 26.93 | [1] | ||
[1]Weighted average is calculated by multiplying (a) the unobservable input for each investment in the investment type by (b) (1) the fair value of the related investment in the investment type divided by (2) the total fair value of the investment type. |
Note 6 - Fair Value - Reconcili
Note 6 - Fair Value - Reconciliation of Level 3 Assets Measured on a Recurring Basis (Details) - USD ($) | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Balance | $ 713,407,000 | $ 514,242,000 | $ 716,319,000 | $ 457,557,000 |
Purchase of investments | 40,545,000 | 159,235,000 | 87,553,000 | 253,720,000 |
Warrants and equity received and classified as Level 3 | 604,000 | 669,000 | 745,000 | 1,477,000 |
Principal payments received on investments | (24,740,000) | 73,328,000 | (64,496,000) | 87,473,000 |
Payment-in-kind interest on investments | 950,000 | 2,154,000 | ||
Proceeds from sale of investments | (1,986,000) | 22,146,000 | (8,506,000) | 43,426,000 |
Net realized (loss) gain on investments | (16,512,000) | (929,000) | (16,646,000) | (899,000) |
Unrealized appreciation (depreciation) included in earnings | 205,000 | 613,000 | (5,662) | (1,507,000) |
Transfer out of Level 3 | (111,000) | 0 | (111,000) | 0 |
Transfer out of debt investments | 0 | 0 | ||
Other | 882,000 | (976,000) | 1,894,000 | (2,069,000) |
Balance | 713,244,000 | 577,380,000 | 713,244,000 | 577,380,000 |
Principal payments received on investments | 24,740,000 | (73,328,000) | 64,496,000 | (87,473,000) |
Proceeds from sale of investments | 1,986,000 | (22,146,000) | 8,506,000 | (43,426,000) |
Debt [Member] | ||||
Balance | 684,554,000 | 492,194,000 | 686,458,000 | 437,317,000 |
Purchase of investments | 40,545,000 | 158,985,000 | 87,543,000 | 253,470,000 |
Warrants and equity received and classified as Level 3 | 0 | 0 | 0 | 0 |
Principal payments received on investments | (24,740,000) | 73,096,000 | (64,496,000) | 87,191,000 |
Payment-in-kind interest on investments | 950,000 | 2,154,000 | ||
Proceeds from sale of investments | (528,000) | 21,750,000 | (7,036,000) | 43,000,000 |
Net realized (loss) gain on investments | (17,672,000) | 0 | (17,665,000) | 0 |
Unrealized appreciation (depreciation) included in earnings | 2,118,000 | (3,797,000) | (2,448) | (6,967,000) |
Transfer out of Level 3 | 0 | 0 | ||
Transfer out of debt investments | (2,800,000) | (3,095,000) | ||
Other | 882,000 | (976,000) | 1,894,000 | (2,069,000) |
Balance | 683,309,000 | 551,560,000 | 683,309,000 | 551,560,000 |
Principal payments received on investments | 24,740,000 | (73,096,000) | 64,496,000 | (87,191,000) |
Proceeds from sale of investments | 528,000 | (21,750,000) | 7,036,000 | (43,000,000) |
Warrant [Member] | ||||
Balance | 24,638,000 | 21,645,000 | 26,145,000 | 19,837,000 |
Purchase of investments | 0 | 0 | 0 | 0 |
Warrants and equity received and classified as Level 3 | 515,000 | 669,000 | 656,000 | 1,477,000 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | (1,458,000) | 396,000 | (1,470,000) | 426,000 |
Net realized (loss) gain on investments | 1,287,000 | 239,000 | 1,146,000 | 269,000 |
Unrealized appreciation (depreciation) included in earnings | (606,000) | 3,010,000 | (2,096) | 4,010,000 |
Transfer out of Level 3 | 0 | 0 | ||
Transfer out of debt investments | 0 | (5,000) | ||
Other | 0 | 0 | 0 | 0 |
Balance | 24,376,000 | 25,167,000 | 24,376,000 | 25,167,000 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Proceeds from sale of investments | 1,458,000 | (396,000) | 1,470,000 | (426,000) |
Equity Securities [Member] | ||||
Balance | 2,915,000 | 203,000 | 2,416,000 | 203,000 |
Purchase of investments | 0 | 250,000 | 10,000 | 250,000 |
Warrants and equity received and classified as Level 3 | 89,000 | 0 | 89,000 | 0 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | 0 | 0 | 0 | 0 |
Net realized (loss) gain on investments | (127,000) | 0 | (127,000) | 0 |
Unrealized appreciation (depreciation) included in earnings | (1,307,000) | 0 | (1,118) | 0 |
Transfer out of Level 3 | (111,000) | (111,000) | ||
Transfer out of debt investments | 2,800,000 | 3,100,000 | ||
Other | 0 | 0 | 0 | 0 |
Balance | 4,259,000 | 453,000 | 4,259,000 | 453,000 |
Principal payments received on investments | 0 | 0 | 0 | 0 |
Proceeds from sale of investments | 0 | 0 | 0 | 0 |
Other Investments [Member] | ||||
Balance | 1,300,000 | 200,000 | 1,300,000 | 200,000 |
Purchase of investments | 0 | 0 | 0 | 0 |
Warrants and equity received and classified as Level 3 | 0 | 0 | 0 | 0 |
Principal payments received on investments | 0 | 232,000 | 0 | 282,000 |
Payment-in-kind interest on investments | 0 | 0 | ||
Proceeds from sale of investments | 0 | 0 | 0 | 0 |
Net realized (loss) gain on investments | 0 | (1,168,000) | 0 | (1,168,000) |
Unrealized appreciation (depreciation) included in earnings | 0 | 1,400,000 | 0 | 1,450,000 |
Transfer out of Level 3 | 0 | 0 | ||
Transfer out of debt investments | 0 | 0 | ||
Other | 0 | 0 | 0 | 0 |
Balance | 1,300,000 | 200,000 | 1,300,000 | 200,000 |
Principal payments received on investments | 0 | (232,000) | 0 | (282,000) |
Proceeds from sale of investments | $ 0 | $ 0 | $ 0 | $ 0 |
Note 7 - Borrowings (Details Te
Note 7 - Borrowings (Details Textual) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | |||||||||||
May 24, 2023 | Feb. 25, 2022 | Apr. 21, 2020 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Jun. 29, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Jun. 15, 2022 | Mar. 30, 2021 | Aug. 13, 2019 | |
Asset Coverage to Borrowings, Ratio, Percent | 184% | ||||||||||||
Restricted Investments | $ 2,904 | $ 2,904 | $ 2,788 | ||||||||||
Long-Term Debt, Gross | 422,557 | 422,557 | 439,323 | ||||||||||
Debt Instrument, Face Amount | $ 645,807 | $ 645,807 | 582,573 | ||||||||||
Key Facility [Member] | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Accordian Feature | $ 150,000 | ||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 300,000 | ||||||||||||
Line of Credit Facility, Advance Rate of Eligible Debt Investments | 60% | ||||||||||||
Long-Term Debt, Weighted Average Interest Rate, over Time | 8.41% | 4.25% | 8.17% | 4.25% | |||||||||
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage | 0.50% | ||||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 150,000 | $ 150,000 | 120,000 | ||||||||||
Line of Credit Facility, Remaining Borrowing Capacity | 61,400 | 61,400 | 40,200 | ||||||||||
Long-Term Debt, Gross | 0 | 0 | 5,000 | ||||||||||
Debt Instrument, Face Amount | $ 150,000 | $ 150,000 | $ 125,000 | ||||||||||
Key Facility [Member] | Prime Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 0.25% | ||||||||||||
Debt Instrument, Variable Rate | 8.25% | 8.25% | 7.50% | ||||||||||
NYL Facility [Member] | |||||||||||||
Line of Credit Facility, Maximum Borrowing Capacity | $ 250,000 | $ 100,000 | |||||||||||
Line of Credit Facility, Current Borrowing Capacity | $ 73,200 | $ 73,200 | $ 23,200 | ||||||||||
Line of Credit Facility, Remaining Borrowing Capacity | 3,000 | 3,000 | 23,200 | ||||||||||
Line of Credit Facility, Maximum Borrowing Capacity, Accordion Feature | $ 200,000 | ||||||||||||
Line of Credit Facility, Advance Rate | 67% | ||||||||||||
Line of Credit Facility, Change in Maximum Borrowing Capacity | $ 50,000 | $ 100,000 | |||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.60% | ||||||||||||
Long-Term Line of Credit | $ 176,800 | $ 176,800 | $ 176,800 | ||||||||||
Line of Credit Facility, Interest Rate at Period End | 5.62% | 5.62% | 5.57% | ||||||||||
Restricted Investments | $ 1,300 | $ 1,300 | $ 1,000 | ||||||||||
Long-Term Debt, Gross | 176,750 | 176,750 | 176,750 | ||||||||||
Debt Instrument, Face Amount | 250,000 | 250,000 | 200,000 | ||||||||||
NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3% | ||||||||||||
NYL Facility [Member] | Three Year I Curve [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3.50% | ||||||||||||
Asset-backed Notes 2019 [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.21% | ||||||||||||
Restricted Investments | 500 | 500 | 600 | ||||||||||
Long-Term Debt, Gross | 30,807 | 30,807 | 42,573 | ||||||||||
Debt Instrument, Face Amount | 30,807 | 30,807 | 42,573 | $ 160,000 | |||||||||
Asset-backed Notes 2022 [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 7.56% | ||||||||||||
Restricted Investments | 1,100 | 1,100 | 1,200 | ||||||||||
Long-Term Debt, Gross | 100,000 | 100,000 | 100,000 | ||||||||||
Debt Instrument, Face Amount | 100,000 | 100,000 | 100,000 | $ 157,800 | |||||||||
The 2026 Notes [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 4.875% | ||||||||||||
Long-Term Debt, Gross | 57,500 | 57,500 | 57,500 | ||||||||||
Debt Instrument, Face Amount | 57,500 | 57,500 | 57,500 | $ 57,500 | |||||||||
The 2026 Notes Underwriter Option [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 7,500 | ||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 25 | ||||||||||||
The 2027 Notes [Member] | |||||||||||||
Debt Instrument, Interest Rate, Stated Percentage | 6.25% | ||||||||||||
Long-Term Debt, Gross | 57,500 | 57,500 | 57,500 | ||||||||||
Debt Instrument, Face Amount | $ 57,500 | $ 57,500 | $ 57,500 | $ 50,000 | |||||||||
The 2027 Notes Underwriter Option [Member] | |||||||||||||
Debt Instrument, Face Amount | $ 7,500 | ||||||||||||
Debt Instrument, Convertible, Conversion Price (in dollars per share) | $ 25 | ||||||||||||
Minimum [Member] | |||||||||||||
Asset Coverage to Borrowings, Ratio, Percent | 150% | ||||||||||||
Minimum [Member] | Key Facility [Member] | Prime Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 4.25% | ||||||||||||
Minimum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 3.55% | ||||||||||||
Maximum [Member] | NYL Facility [Member] | USD Mid-market Swap Rate [Member] | |||||||||||||
Debt Instrument, Basis Spread on Variable Rate | 5.15% |
Note 7 - Borrowings - Borrowing
Note 7 - Borrowings - Borrowings (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 | Nov. 09, 2022 | Jun. 15, 2022 | Mar. 30, 2021 | Aug. 13, 2019 |
Total commitment | $ 645,807 | $ 582,573 | ||||
Balance outstanding | 422,557 | 439,323 | ||||
Unused commitment | 223,250 | 143,250 | ||||
Unamortized debt issuance costs attributable to term borrowings | (4,541) | (5,245) | ||||
Total borrowings outstanding, net | 418,016 | 434,078 | ||||
Key Facility [Member] | ||||||
Total commitment | 150,000 | 125,000 | ||||
Balance outstanding | 0 | 5,000 | ||||
Unused commitment | 150,000 | 120,000 | ||||
NYL Facility [Member] | ||||||
Total commitment | 250,000 | 200,000 | ||||
Balance outstanding | 176,750 | 176,750 | ||||
Unused commitment | 73,250 | 23,250 | ||||
Asset-backed Notes 2019 [Member] | ||||||
Total commitment | 30,807 | 42,573 | $ 160,000 | |||
Balance outstanding | 30,807 | 42,573 | ||||
Unused commitment | 0 | 0 | ||||
Asset-backed Notes 2022 [Member] | ||||||
Total commitment | 100,000 | 100,000 | $ 157,800 | |||
Balance outstanding | 100,000 | 100,000 | ||||
Unused commitment | 0 | 0 | ||||
The 2027 Notes [Member] | ||||||
Total commitment | 57,500 | 57,500 | $ 50,000 | |||
Balance outstanding | 57,500 | 57,500 | ||||
Unused commitment | 0 | 0 | ||||
The 2026 Notes [Member] | ||||||
Total commitment | 57,500 | 57,500 | $ 57,500 | |||
Balance outstanding | 57,500 | 57,500 | ||||
Unused commitment | $ 0 | $ 0 |
Note 8 - Financial Instrument_3
Note 8 - Financial Instruments With Off-balance-sheet Risk (Details Textual) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Fair Value Disclosure, off-Balance-Sheet Risks, Amount, Liability | $ 1,412 | $ 1,761 |
Commitments to Extend Credit [Member] | ||
Other Commitment | $ 143,400 | $ 190,000 |
Note 8 - Financial Instrument_4
Note 8 - Financial Instruments With Off-balance-sheet Risk - Unfunded Commitments (Details) - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
Unfunded commitments, principal balance | $ 143,378 | $ 190,000 |
Fair value of unfunded commitment liability | 1,412 | 1,761 |
BrightInsight, Inc. [Member] | ||
Unfunded commitments, principal balance | 18,250 | 21,000 |
Fair value of unfunded commitment liability | 241 | 278 |
Britecore Holdings, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 5,000 |
Fair value of unfunded commitment liability | 0 | 66 |
Castle Creek Biosciences [Member] | ||
Unfunded commitments, principal balance | 4,000 | 4,000 |
Fair value of unfunded commitment liability | 72 | 72 |
Divergent Technologies, Inc. [Member] | ||
Unfunded commitments, principal balance | 11,250 | 22,500 |
Fair value of unfunded commitment liability | 118 | 236 |
Engage3, LLC [Member] | ||
Unfunded commitments, principal balance | 0 | 8,000 |
Fair value of unfunded commitment liability | 0 | 40 |
Groundspeed Analytics, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 15,000 |
Fair value of unfunded commitment liability | 0 | 150 |
Hound Labs, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 7,500 |
Fair value of unfunded commitment liability | 0 | 88 |
KSQ Therapeutics, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 10,000 |
Fair value of unfunded commitment liability | 0 | 100 |
Lytics, Inc. [Member] | ||
Unfunded commitments, principal balance | 4,000 | 5,000 |
Fair value of unfunded commitment liability | 52 | 65 |
Native Microbials, Inc. [Member] | ||
Unfunded commitments, principal balance | 0 | 7,500 |
Fair value of unfunded commitment liability | 0 | 72 |
Nexii Building Solutions, Inc1 [Member] | ||
Unfunded commitments, principal balance | 1,488 | 0 |
Fair value of unfunded commitment liability | 0 | 0 |
Noodle Partners, Inc. [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | 123 | 0 |
Optoro, Inc. [Member] | ||
Unfunded commitments, principal balance | 11,250 | 15,000 |
Fair value of unfunded commitment liability | 0 | 38 |
PDS Biotechnology Corporation [Member] | ||
Unfunded commitments, principal balance | 10,000 | 10,000 |
Fair value of unfunded commitment liability | 158 | 158 |
Robin Healthcare, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 10,000 |
Fair value of unfunded commitment liability | 50 | 100 |
SafelyYou, Inc [Member] | ||
Unfunded commitments, principal balance | 20,000 | 0 |
Fair value of unfunded commitment liability | 270 | 0 |
Scientia Vascular, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 10,000 |
Fair value of unfunded commitment liability | 55 | 110 |
STS (ABC), LLC [Member] | ||
Unfunded commitments, principal balance | 140 | 0 |
Fair value of unfunded commitment liability | 0 | 0 |
Slingshot Aerospace, Inc. [Member] | ||
Unfunded commitments, principal balance | 5,000 | 5,000 |
Fair value of unfunded commitment liability | 64 | 64 |
Supply Network Visibility Holdings, LLC [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | 35 | 0 |
Swift Health Systems Inc. [Member] | ||
Unfunded commitments, principal balance | 11,500 | 25,500 |
Fair value of unfunded commitment liability | 0 | 105 |
Temperpack Technologies, Inc [Member] | ||
Unfunded commitments, principal balance | 6,500 | 9,000 |
Fair value of unfunded commitment liability | 14 | 19 |
Viken Detection Corporation [Member] | ||
Unfunded commitments, principal balance | 10,000 | 0 |
Fair value of unfunded commitment liability | $ 160 | $ 0 |
Note 9 - Concentrations of Cr_2
Note 9 - Concentrations of Credit Risk (Details Textual) - Debt Investments [Member] - Five Largest Debt Investments [Member] | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Investment Concentration Risk [Member] | |||||
Concentration Risk, Percentage | 25% | 23% | |||
Investment Concentration Risk [Member] | Reported Value Measurement [Member] | |||||
Concentration Risk, Percentage | 23% | 22% | |||
Investment Concentration Risk [Member] | Estimate of Fair Value Measurement [Member] | |||||
Concentration Risk, Percentage | 23% | 23% | 23% | 22% | |
Investment Income Concentration Risk [Member] | Reported Value Measurement [Member] | |||||
Concentration Risk, Percentage | 23% | 22% |
Note 10 - Distributions (Detail
Note 10 - Distributions (Details Textual) - $ / shares | 3 Months Ended | 6 Months Ended | ||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
Common Stock, Dividends, Per Share, Cash Paid (in dollars per share) | $ 0.33 | |||
Earnings Per Share, Basic (in dollars per share) | 0.54 | $ 0.35 | $ 1 | $ 0.62 |
Earnings Per Share, Basic, Undistributed (in dollars per share) | $ 1.02 |
Note 10 - Distributions - Distr
Note 10 - Distributions - Distribution Activity (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2023 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | |
Distributions declared per share (in dollars per share) | $ 0.33 | $ 0.30 | $ 0.66 | $ 0.60 | $ 1.28 | |
Dividends, cash | $ 12,624 | $ 32,659 | ||||
Dividends, shares (in shares) | 28,151 | 61,859 | ||||
Dividends, stock | $ 347 | $ 754 | ||||
September 18, 2023 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
October 17, 2023 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | 0.11 | |||||
First 4/28/2023 Dividend [Member] | ||||||
Record date | Aug. 17, 2023 | |||||
Payment date | Sep. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 0 | |||||
Dividends, shares (in shares) | 0 | |||||
Dividends, stock | $ 0 | |||||
November 16, 2023 Dividend [Member] | Forecast [Member] | ||||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Second 4/28/2023 [Member] | ||||||
Record date | Jul. 18, 2023 | |||||
Payment date | Aug. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 0 | |||||
Dividends, shares (in shares) | 0 | |||||
Dividends, stock | $ 0 | |||||
Third 4/28/2023 Dividend [Member] | ||||||
Record date | Jun. 16, 2023 | |||||
Payment date | Jul. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,434 | |||||
Dividends, shares (in shares) | 7,424 | |||||
Dividends, stock | $ 96 | |||||
First 2/23/2023 Dividend [Member] | ||||||
Record date | May 18, 2023 | |||||
Payment date | Jun. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,087 | |||||
Dividends, shares (in shares) | 7,128 | |||||
Dividends, stock | $ 86 | |||||
Second 2/23/2023 Dividend [Member] | ||||||
Record date | Apr. 18, 2023 | |||||
Payment date | May 16, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,068 | |||||
Dividends, shares (in shares) | 6,705 | |||||
Dividends, stock | $ 84 | |||||
Third 2/23/2023 Dividend [Member] | ||||||
Record date | Mar. 17, 2023 | |||||
Payment date | Apr. 14, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,035 | |||||
Dividends, shares (in shares) | 6,894 | |||||
Dividends, stock | $ 81 | |||||
First 10/28/2022 Dividend [Member] | ||||||
Record date | Feb. 17, 2023 | |||||
Payment date | Mar. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,040 | |||||
Dividends, shares (in shares) | 6,764 | |||||
Dividends, stock | $ 75 | |||||
Second 10/28/2022 Dividend [Member] | ||||||
Record date | Jan. 18, 2023 | |||||
Payment date | Feb. 15, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 3,021 | |||||
Dividends, shares (in shares) | 5,754 | |||||
Dividends, stock | $ 74 | |||||
Third 10/28/2022 Dividend [Member] | ||||||
Record date | Dec. 19, 2022 | |||||
Payment date | Jan. 13, 2023 | |||||
Distributions declared per share (in dollars per share) | $ 0.11 | |||||
Dividends, cash | $ 2,978 | |||||
Dividends, shares (in shares) | 5,618 | |||||
Dividends, stock | $ 69 | |||||
Fourth 10/28/2022 Dividend [Member] | ||||||
Record date | Nov. 17, 2022 | |||||
Payment date | Dec. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.05 | |||||
Dividends, cash | $ 1,319 | |||||
Dividends, shares (in shares) | 2,171 | |||||
Dividends, stock | $ 27 | |||||
First 7/29/2022 Dividend [Member] | ||||||
Record date | Nov. 17, 2022 | |||||
Payment date | Dec. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,638 | |||||
Dividends, shares (in shares) | 4,341 | |||||
Dividends, stock | $ 57 | |||||
Second 7/29/2022 Dividend [Member] | ||||||
Record date | Oct. 18, 2022 | |||||
Payment date | Nov. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,580 | |||||
Dividends, shares (in shares) | 4,621 | |||||
Dividends, stock | $ 60 | |||||
Third 7/29/2022 Dividend [Member] | ||||||
Record date | Sep. 19, 2022 | |||||
Payment date | Oct. 14, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,558 | |||||
Dividends, shares (in shares) | 7,703 | |||||
Dividends, stock | $ 81 | |||||
First 4/29/22 Dividend [Member] | ||||||
Record date | Aug. 18, 2022 | |||||
Payment date | Sep. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,528 | |||||
Dividends, shares (in shares) | 4,925 | |||||
Dividends, stock | $ 60 | |||||
Second 4/29/2022 Dividend [Member] | ||||||
Record date | Jul. 19, 2022 | |||||
Payment date | Aug. 16, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,484 | |||||
Dividends, shares (in shares) | 3,939 | |||||
Dividends, stock | $ 55 | |||||
Third 4/29/2022 Dividend [Member] | ||||||
Record date | Jun. 17, 2022 | |||||
Payment date | Jul. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,434 | |||||
Dividends, shares (in shares) | 4,286 | |||||
Dividends, stock | $ 51 | |||||
First 2/25/2022 Dividend [Member] | ||||||
Record date | May 18, 2022 | |||||
Payment date | Jun. 15, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,378 | |||||
Dividends, shares (in shares) | 4,428 | |||||
Dividends, stock | $ 50 | |||||
Second 2/25/2022 Dividend [Member] | ||||||
Record date | Apr. 19, 2022 | |||||
Payment date | May 16, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,349 | |||||
Dividends, shares (in shares) | 4,088 | |||||
Dividends, stock | $ 49 | |||||
Third 2/25/2022 Dividend [Member] | ||||||
Record date | Mar. 18, 2022 | |||||
Payment date | Apr. 14, 2022 | |||||
Distributions declared per share (in dollars per share) | $ 0.10 | |||||
Dividends, cash | $ 2,352 | |||||
Dividends, shares (in shares) | 3,221 | |||||
Dividends, stock | $ 46 |
Note 11 - Financial Highlight_2
Note 11 - Financial Highlights - Financial Highlights (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended | 6 Months Ended | ||||
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | Dec. 31, 2022 | ||
Net asset value at beginning of period (in dollars per share) | $ 11.47 | $ 11.56 | ||||
Net investment income (in dollars per share) | 1 | 0.62 | ||||
Realized loss (in dollars per share) | (0.58) | (0.04) | ||||
Unrealized depreciation on investments (in dollars per share) | (0.23) | (0.10) | ||||
Net increase in net assets resulting from operations (in dollars per share) | $ 0.01 | $ 0.31 | 0.19 | 0.48 | ||
Distributions declared (in dollars per share) | [1] | (0.66) | (0.60) | |||
From net investment income (in dollars per share) | (0.66) | (0.60) | ||||
From net realized gain on investments (in dollars per share) | 0 | 0 | 0 | 0 | ||
Return of capital (in dollars per share) | 0 | 0 | ||||
Other (in dollars per share) | [2] | 0.07 | 0.25 | |||
Net asset value at end of period (in dollars per share) | 11.07 | 11.69 | 11.07 | 11.69 | ||
Per share market value, beginning of period (in dollars per share) | 11.60 | 15.92 | ||||
Per share market value, end of period (in dollars per share) | $ 12.08 | $ 11.54 | $ 12.08 | $ 11.54 | ||
Total return based on a market value | [3] | 9.80% | (23.70%) | |||
Shares outstanding at end of period (in shares) | 32,096,259 | 24,857,104 | 32,096,259 | 24,857,104 | 27,753,373 | |
Expenses without incentive value | [4] | 14.20% | 10.80% | |||
Incentive fees | [4] | 1.90% | 2.60% | |||
Net expenses | [4] | 16.10% | 13.40% | |||
Net investment income with incentive fees | [4] | 17.50% | 10.50% | |||
Net assets at the end of the period | $ 355,419 | $ 290,605 | $ 355,419 | $ 290,605 | $ 318,448 | |
Average net asset value | $ 331,850 | $ 271,976 | $ 331,850 | $ 271,976 | ||
Average debt per share (in dollars per share) | $ 15.11 | $ 12.81 | ||||
Portfolio turnover ratio | [5] | 7.60% | 11.30% | |||
[1]Distributions are determined based on taxable income calculated in accordance with income tax regulations, which may differ from amounts determined under GAAP due to (i) changes in unrealized appreciation and depreciation, (ii) temporary and permanent differences in income and expense recognition, and (iii) the amount of spillover income carried over from a given tax year for distribution in the following tax year. The final determination of taxable income for each tax year, as well as the tax attributes for distributions in such tax year, will be made after the close of the tax year.[2]Includes the impact of the different share amounts as a result of calculating per share data based on the weighted average basic shares outstanding during the period and certain per share data based on the shares outstanding as of a period end or transaction date. The issuance of common stock on a per share basis reflects the incremental net asset value changes as a result of the issuance of common stock in the Company’s continuous public offering and pursuant to the Company’s distribution reinvestment plan. The issuance of common stock at an offering price, net of sales commissions and dealer manager fees, that is greater than the net asset value per share results in an increase in net asset value per share.[3]The total return equals the change in the ending market value over the beginning of period price per share plus distributions paid per share during the period, divided by the beginning price.[4]Annualized.[5]Calculated by dividing the lesser of purchases or the sum of (1) principal prepayments and (2) maturities by the monthly average debt investment balance. |
Note 12 - Subsequent Events (De
Note 12 - Subsequent Events (Details Textual) - Subsequent Event [Member] - USD ($) $ in Millions | Jul. 31, 2023 | Jul. 27, 2023 | Jul. 25, 2023 | Jul. 18, 2023 | Jul. 13, 2023 | Jul. 12, 2023 | Jul. 06, 2023 |
Conversion From Loan to Common Shares [Member] | |||||||
Debt Conversion, Original Debt, Amount | $ 2.7 | ||||||
Conversion From Loan to Preferred Stock [Member] | |||||||
Debt Conversion, Original Debt, Amount | 0.5 | ||||||
Venture Loan and Security Agreement [Member] | Conversion From Loan to Common Shares [Member] | |||||||
Debt Conversion, Original Debt, Amount | $ 5 | ||||||
Debt Conversion, Converted Instrument, Shares Issued (in shares) | 2,164,502 | ||||||
Venture Loan and Security Agreement [Member] | Evelo Biosciences, Inc. [Member] | |||||||
Repayments of Debt | $ 5 | ||||||
Debt Investments [Member] | Nexii Building Solutions, Inc1 [Member] | |||||||
Payments to Acquire Investments | $ 0.2 | $ 0.3 | $ 0.3 | ||||
Debt Investments [Member] | Aerobiotix, LLC [Member] | |||||||
Payments to Acquire Investments | $ 0.2 | ||||||
Debt Investments [Member] | Tallac Therapeutics, Inc [Member] | |||||||
Payments to Acquire Investments | $ 5 | ||||||
Equity Investment [Member] | Better Place Forests Co. [Member] | |||||||
Payments to Acquire Investments | $ 0.8 |